sentence	label
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The aim of this paper was to establish the interaction between @DRUG$ and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide , or @DRUG$ To the antinonciceptive effect of these peptides in mice after intracistern injection.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine, warfarin, tacrolimus, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur when it contains its derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), @DRUG$, azole antifungals.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/phenobarbital.	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
@DRUG$: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of @DRUG$, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-mechanism
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole ( @DRUG$ , cefoperazone , @DRUG$ , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Acetaminophen/theophylline, lidocaine/@DRUG$, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Other CONCOMITANT THERAPY : Although specific interaction studies have not been conducted in clinical trials, @DRUG$ When co-administered with angiotensin converting enzyme inhibitors ( ACE ), @DRUG$ , calcium-channel blockers , diuretics , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$ is a substrate for both @DRUG$ and CYP3A4.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$ , tricyclic antidepressants or @DRUG$ For this reason, severe, prolonged hypotension or hypertension may occur.	DDI-false
Tolbutamide : In diabetic patients receiving @DRUG$ and @DRUG$ , no significant effects were seen on tolbutamide plasma levels or fasting blood glucose .	DDI-false
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	DDI-false
Other Chemotherapy Agents In a separate study , concomitant administration of @DRUG$ with capecitabine did not meaningfully alter the pharmacokinetics of either agent ( or the metabolites of @DRUG$ ) .	DDI-false
* Anticoagulants including coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as: @DRUG$ ( NSAIDs ) , and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, @DRUG$, phenobarbital or St.	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Antiarrhythmia : Other antiarrhythmic drugs, such as quinidine, @DRUG$ , disopyramide , and @DRUG$ , have been used concurrently with amiodarone .	DDI-false
OBJECTIVES : Our goal was to develop the steady-state pharmacokinetics of @DRUG$ and cyclosporine ( INN , @DRUG$ ) when coadministered in de novo kidney allograft recipients during the first year after transplantation .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with efavirenz .	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib : Caution should be exercised when gleevec is administered with CYP3A4 inhibitors (e.g. ketoconazole, @DRUG$ , erythromycin , @DRUG$ ) .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with @DRUG$.	DDI-effect
Other concomitant therapies : In clinical trials, the safety profile in patients with @DRUG$ - together with anxiolytics, @DRUG$ and sedatives ( including benzodiazepines ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime, cefoperazone, cefotetan), @DRUG$ , @DRUG$ ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ Flupentixol and ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, @DRUG$, and methotrexate.	DDI-false
Therefore, when @DRUG$ is given to a patient receiving warfarin, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium @DRUG$ , @DRUG$ VIDEX chewable/buffer tablets or paediatric powders or products containing calcium, iron or zinc may significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-false
Pre-treatment of healthy volunteers with multiple doses @DRUG$ followed by a single dose of @DRUG$ , increased Gleevec oral-dose clearance by 3.8-fold , which significantly ( p 0.05 ) decreased mean cmax and AUC(0 - 8) .	DDI-mechanism
@DRUG$ and Tricyclic Antidepressants : FORADIL should be administered with extreme caution in patients being treated with @DRUG$ Or tricyclic antidepressants, because the effect of formoterol on the cardiovascular system can be enhanced by these active substances.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Oral @DRUG$ Co-administration of atorvastatin and oral contraceptives increased AUC values for @DRUG$ Ethinylestradiol by about 30% and 20%.	DDI-false
Drug interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - @DRUG$ Flupentixol increases the effect of tricyclic antidepressants	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and quinidine.	DDI-advise
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
When LEVSIN is co-administered with others @DRUG$ Amantadine, haloperidol, @DRUG$ , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher @DRUG$ and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and @DRUG$.	DDI-false
Co-medicines that induce CYP3A4 (e.g. dexamethasone, phenytoin, carbamazepine, @DRUG$ , @DRUG$ or St.	DDI-false
@DRUG$, but not @DRUG$, decreases heart rate at high doses.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ It is co-administered with other antimuscarinics, @DRUG$ , haloperidol , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-effect
@DRUG$, @DRUG$, and azoles are known to cause QTc prolongation.	DDI-false
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide and prednisone with vincristine plus. @DRUG$ ) without receiving @DRUG$ therapy .	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ Other antiarrhythmic drugs, such as quinidine, @DRUG$ , disopyramide , and phenytoin , have been used concurrently with amiodarone .	DDI-false
Co-medications that induce CYP3A4 ( e.g. , dexamethasone , @DRUG$ , carbamazepine , @DRUG$ , phenobarbital or St.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole @DRUG$ due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Probenecid: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	DDI-mechanism
The @DRUG$ You are a family of @DRUG$ and hypnotic drugs .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine , warfarin , @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ : Potentiation of @DRUG$-type ( CYP2C9 and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents ( @DRUG$ , nevirapine or @DRUG$ ) .	DDI-false
Colestipol-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Warfarin: @DRUG$ have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ : @DRUG$ , ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasms and ischaemia of extremities and other tissues.	DDI-false
Antacids: Concomitant administration of @DRUG$ may reduce plasma levels of @DRUG$.	DDI-mechanism
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Both @DRUG$ and 18-MC block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens ;	DDI-effect
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma ( HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , teniposide , and prednisone with vincristine plus bleomycin ) without receiving @DRUG$ therapy .	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
The coingestion of acetaminophen with theophylline, @DRUG$ with @DRUG$ , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-effect
@DRUG$ taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both zidovudine and @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The data suggest that @DRUG$ has a narrower spectrum of actions and will have a substantially greater therapeutic index than @DRUG$.	DDI-false
The blood pressure effect of @DRUG$ tended to be greater in patients on atenolol than in patients on no other @DRUG$ therapy.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with @DRUG$ for the following : sertraline and paroxetine .	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic clonidine . It is not known whether the concurrent use of these agents with @DRUG$ In humans, disturbances of the IOP-lowering effect may occur.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$: Quinolones have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
Anticoagulant inhibition was observed during the administration of phenobarbital , @DRUG$ and @DRUG$ ;	DDI-false
• Co-administration with compounds that are potent CYP3A4 inducers (e.g. phenobarbital, phenytoin, @DRUG$ , @DRUG$ ) may result in decreased plasma levels of saquinavir .	DDI-false
@DRUG$-@DRUG$ The absorption of vitamin K can be reduced.	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were used together with beta-adrenergic blockers, methyldopa, nitrates, @DRUG$ , hydralazine , @DRUG$ and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Digoxin: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Similarly dialyzed were @DRUG$ , quinidine, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ At three different serum concentrations.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, clarithromycin).	DDI-false
, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
@DRUG$ , an anionic-binding resin , has a considerable effect in lowering the rate and extent of @DRUG$ bioavailability .	DDI-mechanism
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, sedatives, @DRUG$).	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
Hemodynamic and electrophysiological interactions have also been reported after concomitant use of @DRUG$ , @DRUG$ ==References====External links==	DDI-false
@DRUG$ : Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum .	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma ( HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , teniposide, and @DRUG$ with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.	DDI-mechanism
No significant interactions were found between @DRUG$ and @DRUG$ or digoxin.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
Garlic capsules Garlic capsules should not be used while taking saquinavir ( @DRUG$ ) as the sole @DRUG$ Because of the risk of decreased saquinavir plasma concentration.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), EGF (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	DDI-false
These results suggest that both dexamethasone and retinyl acetate , and possibly other @DRUG$ and @DRUG$ Prostate epithelium proliferation can be controlled by dose-dependent changes in insulin and EGF activity.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , @DRUG$ , @DRUG$ , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Sedatives/Hypnotics : @DRUG$ , @DRUG$ CONTRAINDICATE because of the potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and @DRUG$.	DDI-false
Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/@DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and @DRUG$.	DDI-false
Sine bradycardia was treated with oral @DRUG$ in combination with lidocaine ( @DRUG$ substrate ) given for local anesthesia .	DDI-false
Coadministration of @DRUG$ decreased the maximum plasma concentration of @DRUG$ by 6 % , decreased clearance by 38 % , and increased half-life by 58 % .	DDI-mechanism
In EM individuals treated with @DRUG$ or fluoxetine , the AUC of @DRUG$ is approximately 6- to 8-fold and Css , max is about 3- to 4-fold greater than atomoxetine alone .	DDI-mechanism
The safety and efficacy of @DRUG$ in combination with any @DRUG$ have not been established.	DDI-false
Although neither @DRUG$ Neither retinyl acetate influences prostatic epithelium proliferation in RPMI1640 with transferrin alone, modifying the mitogenic effect of EGF and @DRUG$.	DDI-effect
* Drug interactions : Flupentixol may interact with some drugs, such as @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Possible drug interactions of HUMORSOL with @DRUG$ or with other @DRUG$.	DDI-false
@DRUG$ produced distinctive effects in each task : it substituted for the training dose in @DRUG$ - Discrimination and increased the number of responses with short ( < 3 s ) interresponse times and increased overall response rates in the DRL scheme.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ ( FORTOVASE ) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations .	DDI-false
Although @DRUG$ It has been shown that PROLEUKIN-induced adverse reactions such as fever, renal insufficiency, hyperbilirubinaemia, confusion and dyspnoea are reduced, the concomitant administration of these active substances with PROLEUKIN can reduce the efficacy of PROLEUKIN against the tumour and should therefore be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
Then , the effects of metabotropic glutamate receptor ( mGluR ) agonists , DCG-IV and @DRUG$ To the above behavioral changes induced by @DRUG$ were found .	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and @DRUG$ such as nonsteroidal anti-inflammatory drugs ( @DRUG$ Aspirin may increase the risk of bleeding when administered at the same time as ardeparin.	DDI-false
These results suggest that both @DRUG$ Retinyl acetate and possibly other glucocorticoids and @DRUG$ Prostate epithelium proliferation can be controlled by dose-dependent changes in insulin and EGF activity.	DDI-false
However, reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
Co-administration of @DRUG$ and cerivastatin did not alter the pharmacokinetics of @DRUG$.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was used in clinical trials with angiotensin converting enzyme inhibitors (ACE), @DRUG$ , calcium channel blockers, diuretics and nonsteroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions .	DDI-false
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
However, in the second study, administration of 12 g @DRUG$ One hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in cerivastatin AUC of less than 8% and a decrease in Cmax of about 30% compared to the dose. @DRUG$ alone .	DDI-false
@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
Sedatives/Hypnotics: @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin , @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and @DRUG$, on the above behavioral changes induced by PCP were found.	DDI-false
Oral Contraceptives: Coadministration of @DRUG$ and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-mechanism
Coingestion of @DRUG$ with theophylline, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
@DRUG$: The concomitant use of Bepridil with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	DDI-false
@DRUG$ The administration of diflunisal to normal volunteers, the @DRUG$ Elevated renal clearance and significantly increased plasma levels of indomethacin.	DDI-false
@DRUG$ It can interact with medicines known to interact with the conventional formulation of @DRUG$.	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Medicines that may alter the plasma concentration of imatinib Drugs that may increase the plasma concentration of imatinib @DRUG$ Plasma concentrations: Caution should be exercised when gleevec is administered with inhibitors of the CYP3A4 family (e.g. ketoconazole, itraconazole, erythromycin, @DRUG$ ) .	DDI-false
Non-selective MAO inhibitors including @DRUG$ , phenelzine sulfate , and pargyline HC1 : Concomitant use of @DRUG$ Non-selective MAO inhibitors can lead to hypertension.	DDI-false
These results suggest that the hepatoxicity of @DRUG$ In alcoholic beverages, interactions with its congeners and @DRUG$ ;	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
• Drug interactions: Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Antagonism between @DRUG$ and @DRUG$ in vitro has been demonstrated.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
The intensity, uniformity and time course of @DRUG$ The interference with phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone has been systematically studied in 16 patients who: @DRUG$ therapy .	DDI-false
The effects of DCG-IV and @DRUG$ upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Careful observation is required when @DRUG$ is administered concurrently with @DRUG$.	DDI-advise
Anticoagulants : Potentiation of warfarin-type ( CYP2C9 and @DRUG$ substrate ) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide , quinine , amiodarone , @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The effects of ruthenium red (@DRUG$) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after @DRUG$ withdrawal .	DDI-false
@DRUG$ Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$ , have been used concurrently with amiodarone .	DDI-false
Amiodarone may suppress certain CYP450 enzymes , including CYP1A2 , @DRUG$ , @DRUG$ , and CYP3A4.	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
CYP2D6 inhibitors - @DRUG$ is primarily metabolized by the CYP2D6 pathway to @DRUG$.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown .	DDI-false
The effects of DCG-IV and @DRUG$ After phencyclidine (@DRUG$)-induced movement and behavioural changes in mice.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-mechanism
@DRUG$ In normal subjects, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a benzodiazepine) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-mechanism
In addition, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data .	DDI-false
@DRUG$: The concomitant administration of @DRUG$ and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-false
Antiarrhythmics : Amiodarone , bepridil , flecainide , @DRUG$ , @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent @DRUG$ such as @DRUG$.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), @DRUG$ (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , @DRUG$ Acetylsalicylic acid, NSAIDs ( @DRUG$ ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
@DRUG$: Concurrent administration of @DRUG$ may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
@DRUG$ including @DRUG$ , Phenelzinsulfate, and Pargylin HC1: Concurrent use of L-tyrosine and non-selective MAO inhibitors can cause high blood pressure.	DDI-false
Fenfluramine may have the effect of @DRUG$ ==References====External links==* Official website	DDI-false
@DRUG$ had a similar effect in the presence of @DRUG$.	DDI-false
No data are available for the coadministration of @DRUG$/ritonavir or FORTOVASE/@DRUG$ and garlic capsules .	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Non-selective MAO inhibitors including @DRUG$ , Phenelzinsulfate, and Pargylin HC1: Concurrent use of L-tyrosine and non-selective @DRUG$ may cause hypertension .	DDI-false
@DRUG$ taken concomitantly with quinidine increases @DRUG$ The serum concentration by 33% after two days.	DDI-false
Methotrexate: Caution should be used if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
@DRUG$ : In normal volunteers , concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50 % increase in plasma levels of acetaminophen .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and @DRUG$ , specifically , dacarbazine , cis-platinum , tamoxifen and interferon-alfa .	DDI-effect
Warfarin-@DRUG$ can antagonize the effect of @DRUG$	DDI-effect
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin , with multivalent cation-containing products such as @DRUG$ Or aluminum antacids, sucralfat, VIDEX chew/buffer tablets or child powder, or products that contain calcium, iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-mechanism
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/@DRUG$ , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
Therefore , it would be expected that a dosing schedule of @DRUG$ , given at the time of sleep and @DRUG$ Administration prior to supper would not result in a significant decrease in the clinical effect of cerivastatin sodium.	DDI-false
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of @DRUG$ and @DRUG$, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.	DDI-effect
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( @DRUG$ ) , NSAIDs ( piroxicam ) , and @DRUG$ The pharmacokinetics/pharmacodynamics of fondaparinux sodium were not significantly affected.	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, @DRUG$.	DDI-false
@DRUG$-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, @DRUG$.	DDI-false
@DRUG$-Concomitant intake of colestipol and vitamin K may reduce the absorption of @DRUG$.	DDI-false
In addition, we have shown that @DRUG$ is a useful pharmacological tool with which to examine the @DRUG$-mediated responses of megakaryocytes.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Dosage adjustment of @DRUG$ When co-administered with CYP2D6 inhibitors, it may be necessary, e.g. @DRUG$ , fluoxetine , and quinidine .	DDI-advise
Interaction on the antinociceptive effect between @DRUG$ and enkephalins or @DRUG$.	DDI-effect
In clinical studies performed with @DRUG$ , the concomitant use of oral @DRUG$ The pharmacokinetics/pharmacodynamics of fondaparinux sodium are not significantly affected by warfarin, platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-mechanism
acetaminophen/theophylline, @DRUG$/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent @DRUG$ such as furosemide.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Seizure, associated with increased @DRUG$ concentrations, has been reported with concomitant administration of intravenous @DRUG$.	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells;	DDI-false
Theophylline : As with some other quinolones , concurrent administration of @DRUG$ with @DRUG$ It may lead to increased serum concentrations of theophylline and an extension of the elimination half-life.	DDI-mechanism
In addition to this pharmacological interaction , this report describes a novel chemical reaction between temazepam ( a @DRUG$ ) and @DRUG$ Under acidic conditions similar to found in vivo, resulting in a 3-ethoxylated product.	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a @DRUG$) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
@DRUG$ may interfere with the absorption of @DRUG$.	DDI-mechanism
Coingestion of acetaminophen with @DRUG$ , phenobarbital with acetaminophene and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug .	DDI-false
Similarly dialyzed were phenobarbital, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
In general, these drugs have one or more pharmacological activities, similar to bepridil hydrochloride, including @DRUG$ such as @DRUG$ and procainamide , cardiac glycosides and tricyclic anti-depressants .	DDI-false
@DRUG$ : The concomitant administration of diflunisal and @DRUG$ In normal subjects, this did not affect naproxene plasma levels, but significantly reduced renal excretion of naproxene and its glucuronide metabolite.	DDI-false
The effect of @DRUG$ As regards our patient's warfarin requirement, it seemed to be at most 5 to 7 days after the onset of treatment. @DRUG$ and extended a similar length of time after rifampin withdrawal .	DDI-false
Suppression by @DRUG$ of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats .	DDI-effect
Anti-arrhythmics and @DRUG$ The extension of the QT interval observed with @DRUG$ could exaggerate.	DDI-effect
@DRUG$ : In healthy individuals , plasma concentrations of atorvastatin increased approximately 40 % with coadministration of @DRUG$ Erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Agents Causing Renin Release : The antihypertensive effect of enalapril and @DRUG$ It is enhanced by antihypertensive agents that cause the release of renin (e.g. @DRUG$ ) .	DDI-effect
Therefore , it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and @DRUG$ Given before the Lord's Supper would not lead to a significant decrease in the clinical effect of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Primary and secondary @DRUG$ deficiencies constitute the sole indication of physiological oral @DRUG$ therapy.	DDI-false
♪ Drugs that can change ♪ @DRUG$ Plasma concentrations Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when gleevec is administered with CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, @DRUG$ ,,,,,,,,,,,	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/@DRUG$ Theophylline/acetaminophene and valproic acid/phenobarbital.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , @DRUG$ ), beta-blockers, calcium channel blockers, diuretics and non-steroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (@DRUG$), erythromycin, azole antifungals.	DDI-false
Cimetidine: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
@DRUG$ and @DRUG$ Patients receiving coumarin should not be taken.	DDI-false
@DRUG$: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
@DRUG$-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ , carbamazepine , @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors , @DRUG$ It has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors , sodium channels , and the 5-HT transporter .	DDI-false
• Drug interactions: Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ is the first @DRUG$ to be approved for clinical use, and has been studied extensively in humans since 1986.	DDI-false
only @DRUG$ enhances @DRUG$-induced increases in accumbal dopamine.	DDI-effect
Two groups ( SH/DA ; SH/FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol , @DRUG$ , higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages ;	DDI-false
In addition, fondaparinux did not affect the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$ , and @DRUG$ The pharmacokinetics of digoxin in steady state.	DDI-false
Pharmacokinetic or pharmacodynamic drug interactions between argatroban and co-administered aspirin (administered 162.5 mg orally 26 and 2 hours before starting therapy with argatroban) have not been established. @DRUG$ 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban 1.5 g/kg/min for 18 hours).	DDI-false
In clinical studies performed with @DRUG$ , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and @DRUG$ The pharmacokinetics/pharmacodynamics of fondaparinux sodium were not significantly affected.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$ , fibric acid derivatives , niacin ( nicotinic acid ) , @DRUG$ , azole antifungals .	DDI-false
In addition , Fondaparinux neither influenced the pharmacodynamics of @DRUG$ , @DRUG$ , piroxicam, and digoxin, and the pharmacokinetics of digoxin in steady state.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Hypotension : Patients on Diuretic Therapy : Patients on @DRUG$ Especially those who have recently started diuretic therapy may occasionally experience an excessive reduction in blood pressure after initiation of Enalapril or @DRUG$ therapy.	DDI-effect
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
No data are available for the coadministration of @DRUG$/ritonavir or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
Concomitant use of LEVSIN with other antimuscarinic agents, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors may lead to additive side effects due to cholinergic blockade, @DRUG$ or some @DRUG$.	DDI-false
@DRUG$ : The concomitant use of Bepridil with long- and short-acting @DRUG$ It was safely tolerated in patients with stable angina pectoris.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
There was no significant difference ( p > 0.05 ) in AUC ( 48.59 + /- 8.52 vs. 49.9 + /- 9.93), Cmax ( 7.73 + /- 2.6 vs. 6.6 + /- 2.0 ) and tmax ( 1.1 + /- 0.6 vs. 1.6 + /- 1.1 ) for @DRUG$ versus levofloxacin/@DRUG$ regimens .	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Antiarrhythmics: @DRUG$, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including @DRUG$ Like quinidine and procainamide, heart glycoside and @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir ( @DRUG$ ) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations .	DDI-false
Clinical implications of @DRUG$ interactions with five @DRUG$.	DDI-int
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Since amiodarone is a substrate for CYP3A4, there is a potential for St. John's Word to be used in patients who: @DRUG$ could result in reduced @DRUG$ levels .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, reserpine.	DDI-effect
@DRUG$, such as verapamil, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergotic derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
In addition to the interactions noted above , chronic (   2 weeks ) oral @DRUG$ administration impairs metabolism of phenytoin , @DRUG$ , and methotrexate .	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
Concomitant cyclophosphamide , @DRUG$ , vincristine , and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as @DRUG$ or @DRUG$ antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Tolbutamide: In diabetic patients receiving @DRUG$ and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Ergot Derivatives: @DRUG$, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Potassium-sparing diuretics (e.g. spironolactone, triamterene or @DRUG$ Potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as @DRUG$.	DDI-false
Although studies designed to examine drug interactions have not been done , it was noted that @DRUG$ The treatment of relapses has been performed for up to 28 days in patients ( N=180 ) with @DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions including fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant use of these active substances with @DRUG$ Beta-blockers and other antihypertensive agents may increase hypotension at @DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
Non-selective MAO inhibitors including @DRUG$ , @DRUG$ Pargylin HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
Co-administration: Concomitant use of Argatroban with @DRUG$, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Data from in vitro studies @DRUG$ other than alprazolam suggest a possible drug interaction for the following : ergotamine , @DRUG$ , amiodarone, nicardipine, and nifedipine.	DDI-int
@DRUG$/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of @DRUG$ 1.5   g/kg/min . over 18 hours ) .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ It is co-administered with other antimuscarinics, amantadine, haloperidol, @DRUG$ , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat .	DDI-effect
@DRUG$ : Amiodarone , bepridil , @DRUG$ , propafenone, quinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
Lithium : @DRUG$ Toxicity has been reported in patients receiving lithium concomitantly with medicinal products that cause sodium excretion, including @DRUG$.	DDI-false
Concurrent administration of oxyphenbutazone and @DRUG$ may result in elevated serum levels of @DRUG$.	DDI-false
@DRUG$ and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
In addition , Fondaparinux neither influenced the pharmacodynamics of warfarin , @DRUG$ , piroxicam , and digoxin , nor the pharmacokinetics of @DRUG$ at steady state .	DDI-false
The intensity , uniformity and time course of @DRUG$ interference by phenobarbital , secobarbital , @DRUG$ In 16 patients receiving coumarin therapy, chloral hydrate and methaqualone were systematically studied.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
These results suggest that acute dosing with @DRUG$ would not affect behaviors most closely associated with @DRUG$ intoxication.	DDI-false
Antiarrhythmia : Other antiarrhythmic drugs such as quinidine, procainamide, @DRUG$ , and phenytoin , have been used concurrently with @DRUG$.	DDI-false
@DRUG$ , lidocaine, phenobarbital, @DRUG$ , theophylline , and valproic acid were added to pooled human serum at therapeutic concentrations .	DDI-false
Both efavirenz and @DRUG$ It was compared to triple therapy with PI. @DRUG$ over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with efavirenz .	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Possible drug interactions of @DRUG$ with succinylcholine or with other @DRUG$.	DDI-int
Hydrochlorothiazide : In normal volunteers , concomitant administration of diflunisal and @DRUG$ The result was a significantly increased plasma level of @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other CONCOMITANT THERAPY : Although specific interaction studies have not been conducted in clinical trials, @DRUG$ was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , calcium-channel blockers , @DRUG$ , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$ Amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
injection of @DRUG$ ( @DRUG$ ) were observed by measuring locomotor activity and stereotyped behavior .	DDI-false
# pollination, associated with increased @DRUG$ Co-administration of intravenous @DRUG$ has been reported.	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$ Amantadine, haloperidol, phenothiazine, @DRUG$ , tricyclic antidepressants or some antihistamines .	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-@DRUG$ , dihydropyridine calcium channel blockers , certain HMG-CoA reductase inhibitors , etc . ) .	DDI-mechanism
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$ : FORADIL should be administered with extreme caution in patients being treated with @DRUG$ Or tricyclic antidepressants, because the effect of formoterol on the cardiovascular system can be enhanced by these active substances.	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors ( @DRUG$ ) , @DRUG$ Piroxicam and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when administering imatinib @DRUG$ with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , @DRUG$ , erythromycin , clarithromycin ) .	DDI-advise
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
However, LDL-C reduction was greater when @DRUG$ and @DRUG$ were coadministered than when either drug was given alone.	DDI-effect
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and fluvastatin.	DDI-false
Acetaminophen, @DRUG$, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was co-administered with @DRUG$ , @DRUG$ Calcium channel blockers, diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
The @DRUG$ study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The AUC and Cmax of both the ( R ) and ( S ) isomers of @DRUG$ were unaffected by concurrent dosing of 0.3 mg @DRUG$.	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by phenobarbital, @DRUG$ , glutethimide, chloral hydrate and methaqualone have been systematically studied in 16 patients who: @DRUG$ therapy .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and @DRUG$ CHOP chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or with a CHOP-like regimen (i.e. cyclophosphamide, doxorubicin, teniposide and prednisone with vincristine plus). @DRUG$ ) without antiretroviral therapy.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
There are 3 types of indications : specific ( for the treatment of some forms of @DRUG$ deficit i.e. acute ) , pharmacological ( i.e. without alterations of @DRUG$ status ) and mixed -- pharmacological and aetiopathogenic--(for example complications of chronic alcoholism ) .	DDI-false
It differs structurally from the other currently available @DRUG$ ( @DRUG$ , simvastatin , and pravastatin ) , leading to unique biopharmaceutical properties relative to the other agents of this class .	DDI-false
Antihistamines : @DRUG$ * , @DRUG$ * CONTRAINDICATED due to the potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, @DRUG$, niacin (nicotinic acid), erythromycin, azole antifungals.	DDI-false
In view of the long and variable half-life of @DRUG$ The potential for drug interactions is not only with concomitant medication, but also with medications given after discontinuation of @DRUG$.	DDI-false
@DRUG$ The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion .	DDI-false
Fenfluramine may slightly increase the effect of antihypertensive agents, e.g. guanethidine, @DRUG$ , @DRUG$.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ Theoretically, MAOI could influence flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Chloral hydrate and @DRUG$ interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus @DRUG$ ) without antiretroviral therapy.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , @DRUG$ , @DRUG$ ( nicotinic acid ) , erythromycin , azole antifungals .	DDI-false
• Delayed adverse reactions to iodised contrast media : A review of the literature revealed that 12.6% ( range 11 - 28% ) of the 501 patients who had various @DRUG$ Containing dosing regimens that were subsequently administered @DRUG$ experienced acute , atypical adverse reactions .	DDI-effect
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or enalaprilat.	DDI-effect
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , calcium-blocking agents , @DRUG$ , prazosin and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
Acetaminophene: Pharmacokinetic or pharmacodynamic drug-effect interactions between @DRUG$ and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of @DRUG$ 1.5   g/kg/min . over 18 hours ) .	DDI-false
@DRUG$ taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55 % and 33 % , respectively .	DDI-false
@DRUG$ may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, reserpine.	DDI-effect
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant use of methotrexate. @DRUG$ This may lead to increased plasma levels of @DRUG$.	DDI-false
@DRUG$ (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
@DRUG$: astemizole*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
ANTACID ( @DRUG$ Cerivastatin plasma concentrations were not affected by the concomitant use of @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , @DRUG$ , @DRUG$ , diuretics , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
The pharmacokinetics of naltrexone and its major metabolite @DRUG$ were unaffected following co-administration with @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, @DRUG$ , pimozide, carbamazepine, @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
There was not a significant difference ( p > 0.05 ) in AUC ( 48.59 + /- 8.52 vs. 49.9 + /- 9.93 ) , Cmax ( 7.73 + /- 2.6 vs. 6.6 + /- 2.0 ) , and tmax ( 1.1 + /- 0.6 vs. 1.6 + /- 1.1 ) for @DRUG$ Versus @DRUG$/Oxycodon regime.	DDI-false
Simultaneous use of other @DRUG$ may potentiate the undesirable effects of @DRUG$.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$-Concomitant intake of mineral oil and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Antihypertensives : @DRUG$ should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a @DRUG$ inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including @DRUG$ , with multivalent cation-containing products such as @DRUG$ or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including @DRUG$ , with multivalent cation-containing products such as magnesium or @DRUG$ Antacids, sucralfate, VIDEX chewable tablets or paediatric powders or products containing calcium, iron or zinc may significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and L-CCG-1, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Simultaneous use with @DRUG$s may result in a reduced absorption of @DRUG$.	DDI-false
Non-steroidal anti-inflammation drugs : The administration of diflunisal to normal volunteers who @DRUG$ Elevated renal clearance and significantly increased plasma levels of @DRUG$.	DDI-false
Therefore, the combined use of @DRUG$ with @DRUG$ should generally be avoided .	DDI-advise
acetaminophen/theophylline , @DRUG$/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, @DRUG$ or @DRUG$).	DDI-false
The concomitant use of naltrexone with @DRUG$ produced a 25 % increase in AUC and a 33 % increase in the Cmax of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl @DRUG$ 55% and 33% respectively.	DDI-false
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Coadministration of @DRUG$ decreased the maximum plasma concentration of @DRUG$ by 6%, decreased clearance by 38%, and increased half-life by 58%.	DDI-mechanism
@DRUG$ : astemizole * , @DRUG$ * CONTRAINDICATED due to the potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
Drugs That Inhibit @DRUG$ Metabolism Via Cytochrome P450 3A: The initial step in @DRUG$ metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-advise
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ ( CYP3A4 substrate ) given for local @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
FLEXERIL may increase the effect of alcohol, @DRUG$ , and other @DRUG$.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions including fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant use of these active substances with @DRUG$ The effectiveness of antitumours can be reduced. @DRUG$ Beta-blockers and other antihypertensive agents may increase the hypotension observed with PROLEUKIN.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and @DRUG$ with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
Other medicines: medicines such as quinidine, @DRUG$ Procainamide, phenothiazine, antihistamines and @DRUG$ It may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
The bioavailability of the capsule formulation of @DRUG$ was not affected when administered 5 minutes following an @DRUG$.	DDI-false
Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-false
Non-steroidal anti-inflammatory drugs : The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
BACKGROUND : The effects of the combined administration of bombsin and verapamil hydrochloride (Verapamil ), a @DRUG$ , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( @DRUG$ ) and the index of colorectal cancers were studied in male Wistar rats.	DDI-false
@DRUG$ In patients who: @DRUG$ , and renal function should be carefully monitored .	DDI-advise
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
In clinical studies with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors (acetylsalicylic acid) and NSAIDs ( @DRUG$ ) , and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
@DRUG$ or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$;	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Since @DRUG$ is a substrate for CYP3A4 and CYP2C8 , drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of @DRUG$.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes , including CYP1A2 , CYP2C9 , CYP2D6 , and @DRUG$.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ Before starting treatment with Enalapril or @DRUG$ increase or increase salt intake.	DDI-false
@DRUG$: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
Therefore , @DRUG$ and @DRUG$ Concomitant use should not be performed.	DDI-advise
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with @DRUG$ and prednisone.	DDI-false
Acetaminophen, lidocaine, @DRUG$, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
@DRUG$ These medicines in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies .	DDI-false
Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with @DRUG$ , @DRUG$ Diuretics may potentiate a possible hypocalemic effect of beta2-agonists.	DDI-false
Other cardiovascular agents: @DRUG$ Enalapril IV was co-administered with beta-adrenergic blockers, methyldopa, @DRUG$ , calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when administering imatinib @DRUG$ ketoconazole, itraconazole, erythromycin, @DRUG$ ) .	DDI-advise
Co-administration of colestipol and @DRUG$ The absorption of vitamin K can be reduced.	DDI-false
@DRUG$ : @DRUG$ CYP3A4 substrate in combination with amiodarone has been associated with myopathy/rhabdomyolysis reports.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergotic derivatives, @DRUG$ , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$ Amantadine, haloperidol, phenothiazine, monoamine oxidase (MAO) inhibitors, @DRUG$ Or some antihistamines.	DDI-false
Isocarboxazid should be administered with caution to patients receiving @DRUG$ (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-false
BACKGROUND : The effects of combined administration of bombesin and @DRUG$ ( verapamil ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
Nonsteroidal Anti-Inflammatory Drugs : The administration of @DRUG$ to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin .	DDI-mechanism
Plasma levels of @DRUG$ may become subtherapeutic during @DRUG$ therapy.	DDI-mechanism
@DRUG$ , Methylxanthines and Diuretics : Concomitant treatment with xanthine derivatives , steroids , or @DRUG$ may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Limited clinical data in angina patients @DRUG$ and @DRUG$ therapy indicate no discernible changes in serum digoxin levels .	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , @DRUG$ , @DRUG$ , sedatives , tranquilizers ) .	DDI-false
Dexamethasone and @DRUG$ similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
Further , no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and fluvastatin .	DDI-false
@DRUG$ : Plasma concentrations of atorvastatin decreased approximately 25 % when colestipol and @DRUG$ were coadministered .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and @DRUG$.	DDI-false
acetaminophen/@DRUG$, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and CYP3A4.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , @DRUG$ , hydralazine , prazosin and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
Lack of an effect of @DRUG$ on the disposition of @DRUG$ and dideoxyinosine in HIV-infected patients.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ Eproxindine - ethanol : @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Ergot Derivatives : Dihydroergotamine , ergonovine , ergotamine , @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ Toxicity characterized by peripheral vasospasm and ischemia of extremities and other tissues.	DDI-false
Five days of @DRUG$ treatment did not significantly affect steady-state pharmacokinetic variables of @DRUG$ compared with placebo ;	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
The AUC and Cmax of both the (R) and (S) isomers of @DRUG$ were unaffected by concurrent dosing of 0.3 mg @DRUG$.	DDI-false
Two groups ( SH/DA ; SH/FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$ , @DRUG$ , higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages ;	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Moreover , additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving @DRUG$ This study showed no difference in the extent of bioavailability of @DRUG$ Relative to the control data.	DDI-false
@DRUG$ : Concurrent administration of @DRUG$ Meclopenamate sodium plasma levels can be lowered, possibly through competition for protein-binding sites.	DDI-false
@DRUG$: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Acetaminophen , @DRUG$ , phenobarbital , quinidine , @DRUG$ , and valproic acid were added to pooled human serum at therapeutic concentrations .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Several drug interaction studies have been completed with both @DRUG$ and @DRUG$.	DDI-false
Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another @DRUG$ and @DRUG$ but may be seen after several months.	DDI-effect
Antihypertensive agents: amiodarone should be used with caution in patients receiving antihypertensive agents (e.g. @DRUG$ , a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), @DRUG$ ( @DRUG$ NSAIDs (piroxicam) and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Acetaminophen, lidocaine, phenobarbital, @DRUG$, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
No significant interactions were found between nisoldipine and @DRUG$ or @DRUG$.	DDI-false
@DRUG$ : Caution should be used if @DRUG$ It is co-administered with methotrexate.	DDI-false
The effects of @DRUG$ (@DRUG$) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and @DRUG$.	DDI-false
Accordingly, when @DRUG$ is administered with oral @DRUG$, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.	DDI-advise
Other Cardiovascular Agents : @DRUG$ ug and Enalapril IV together with @DRUG$ , methyldopa , nitrates , calcium-blocking agents , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Co-administration of @DRUG$ with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
Dosage adjustment of @DRUG$ It may be necessary when co-administered with CYP2D6 inhibitors such as paroxetine, fluoxetine and @DRUG$.	DDI-advise
The effects of DCG-IV and @DRUG$ upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	DDI-false
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or pimozide).	DDI-advise
Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between @DRUG$ and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ Methaqualone has been systematically studied in 16 patients who: @DRUG$ therapy .	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/@DRUG$.	DDI-false
The concomitant use of @DRUG$ tablets and other @DRUG$ is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.	DDI-effect
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$ : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
In clinical trials with: @DRUG$ co-administration of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
@DRUG$: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
@DRUG$ : As with some other quinolones , concurrent administration of @DRUG$ Theophylline can be used to increase serum concentrations of theophylline and prolong the elimination half-life.	DDI-false
Like ibogaine ( 40 mg/kg ) , 18-MC ( 40 mg/kg ) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of @DRUG$ nicotine in rats;	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as quinidine and @DRUG$ , @DRUG$ And tricyclic antidepressants.	DDI-false
Ketoconazole: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium @DRUG$ , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-false
Other Cardiovascular Agents : @DRUG$ , methyldopa, nitrates, calcium blockers, @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Drug Interactions : @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - Arecolin - eproxindine - ethanol: flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Potassium-sparing diuretics (e.g. spironolactone, @DRUG$ , or @DRUG$ ) , potassium supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Acute symptoms should be treated with a short-acting, inhaled  @DRUG$ such as @DRUG$ (the physician should provide the patient with such medication and instruct the patient in how it should be used).	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant administration of these agents with PROLEUKIN may reduce the efficacy of antitumours. @DRUG$ 12 and should therefore be avoided. @DRUG$ In PROLEUKIN, hypotension and other antihypertensive agents may be increased.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-effect
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, @DRUG$, rifampin, phenobarbital or St.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Although neither dexamethasone nor @DRUG$ Influenced the proliferation of prostate epithelium in RPMI1640 with transferrin alone, modifying the mitogenic effect of @DRUG$ and insulin .	DDI-effect
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 @DRUG$ and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN .	DDI-false
Methotrexate: Caution should be exercised if: @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
There have been case reports of increased steady-state levels of @DRUG$ , @DRUG$ , and phenytoin during concomitant therapy with amiodarone.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , @DRUG$ , @DRUG$ Effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
• Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, @DRUG$ , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days , systemic exposure ( AUC ) to @DRUG$ 72% decreased.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ , alprazoleam, and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Acetaminophen, lidocaine, @DRUG$, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , @DRUG$ chemotherapy), cardiotoxic (e. g., @DRUG$ Hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$ : Concomitant administration of @DRUG$ may reduce plasma levels of diflunisal .	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
@DRUG$: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	DDI-false
@DRUG$/theophylline , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
If @DRUG$ is administered with drugs that inhibit Pgp, increased concentrations of @DRUG$ are likely, and caution should be exercised.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
In clinical trials with: @DRUG$ , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( @DRUG$ ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
• Suppression by verapamil of @DRUG$-enhanced peritoneal metastases of intestinal adenocarcinoma induced by @DRUG$ in wistar rats .	DDI-false
Monoamine oxidase inhibitors and tricyclic antidepressants : @DRUG$ In patients treated with @DRUG$ Or tricyclic antidepressants, because the effect of formoterol on the cardiovascular system can be enhanced by these active substances.	DDI-advise
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ , amiodarone , @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
@DRUG$ : In hypercholesterolemic patients , steady-state @DRUG$ AUC and Cmax increased approximately 50 % and 24 % respectively after 10 days with co-administration of erythromycin , a known inhibitor of cytochrome P450 3A4 .	DDI-false
Coingestion of acetaminophen with @DRUG$, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Other concomitant therapies : In clinical studies, the safety profile in patients with acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ ( including benzodiazepines ) , or @DRUG$ It was similar in patients taking placebo with these concomitant medications as in patients receiving placebo.	DDI-false
In a clinical pharmacology study, @DRUG$ Sulindac was given to hypertensive patients receiving @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Glyburide: The concomitant administration of @DRUG$ with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ increases enterohepatic elimination of amiodarone and may reduce its serum levels and @DRUG$/2 .	DDI-false
Acetaminophene, lidocaine, phenobarbital, quinidine, @DRUG$ , and @DRUG$ The pooled human serum was added at therapeutic concentrations.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
- corticosteroids, methylxanthine and @DRUG$ : Accompanying treatment with @DRUG$ Steroids, or diuretics may potentiate a potential hypocalemic effect of beta2-agonists.	DDI-false
[ Quantitative approach to Incisive Treatment @DRUG$ The problems encountered during the long-term treatment of psychotic patients with @DRUG$ Six typical case reports show.	DDI-false
• Concomitant use of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
@DRUG$ and @DRUG$ could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.	DDI-false
@DRUG$ : The concomitant administration of ciprofloxacin with the @DRUG$ Glyburide has, in rare cases, led to severe hypoglycaemia.	DDI-false
@DRUG$ as potent @DRUG$ of glucocorticoid-induced mouse mammary tumor virus gene expression.	DDI-false
@DRUG$ (increases bioavailability by 50%), @DRUG$, and valproates.	DDI-false
The use of acetaminophene with acetaminophene @DRUG$ , @DRUG$ with acetaminophen , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
@DRUG$: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In general, these drugs have one or more pharmacological activities, similar to bepridil hydrochloride, including @DRUG$ Like quinidine and procainamide, @DRUG$ And tricyclic antidepressants.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	DDI-false
However, if Argatroban is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
Antacids : Concomitant administration of @DRUG$ The plasma levels of @DRUG$ can be reduced.	DDI-mechanism
The conversion of @DRUG$ to @DRUG$ is catalyzed by aldehyde oxidase .	DDI-false
Co-administration of @DRUG$ and @DRUG$ The pharmacokinetics of cerivastatin sodium have not changed.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$ may displace acidic drugs such as phenytoin or @DRUG$ from their binding sites.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Efavirenz and nevirapine were compared with triple therapy with PI. @DRUG$ over 48 weeks as initial therapy , with similar responses being observed with @DRUG$ Regimes and superiority observed with efavirenz.	DDI-false
The effects of @DRUG$ (RR) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Acid-catalyzed ethanolysis of @DRUG$ in anhydrous and aqueous @DRUG$ solutions .	DDI-mechanism
Amiodarone may suppress certain CYP450 enzymes, including: @DRUG$ , CYP2C9 , @DRUG$ , and CYP3A4.	DDI-false
However , the absolute number of @DRUG$-related deaths is far greater than the number of deaths in @DRUG$ or heroin users .	DDI-false
METHODS: Since the start of the experiment, the rats received 10 weekly subcutaneous injections of @DRUG$ ( 7.4 mg/kg body weight ) and subcutaneous injections of @DRUG$ ( 40 microg/kg body weight ) every other day , and from week 16 , intraperitoneal injections of verapamil ( 10 or 20 mg/kg body weight ) every other day until the end fo the experiment in week 45 .	DDI-false
@DRUG$ : In controlled studies in healthy volunteers , bepridil hydrochloride either had no effect ( one study ) or was associated with modest increases , about 30 % ( two studies ) in steady-state serum @DRUG$ concentrations .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ increases the effect of @DRUG$	DDI-effect
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
These increases should be considered when selecting an oral @DRUG$ for a woman taking @DRUG$.	DDI-advise
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of warfarin and @DRUG$.	DDI-false
Administration of @DRUG$ concomitantly with oral @DRUG$ The serum concentrations of amiodarone and desethylamiodaron have been shown to decrease.	DDI-false
@DRUG$: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
@DRUG$ Probenecid affects renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum .	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs , e.g. , guanethidine , methyldopa , @DRUG$.	DDI-effect
@DRUG$ , @DRUG$ , phenobarbital , quinidine , theophylline , and valproic acid were added to pooled human serum at therapeutic concentrations .	DDI-false
Anticoagulants including coumarin derivatives, indandion derivatives and @DRUG$ such as nonsteroidal anti-inflammatory drugs ( NSAIDs ) , and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
In clinical studies with fondaparinux, the concomitant use of oral anticoagulants ( @DRUG$ , platelet inhibitors (acetylsalicylic acid) and NSAIDs ( @DRUG$ Digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , @DRUG$ CYP3A4 inhibitors) or @DRUG$ antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
@DRUG$ Including coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as non-steroidal anti-inflammatory drugs ( @DRUG$ ) , and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and @DRUG$ were coadministered.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-int
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (@DRUG$ substrate) given for local anesthesia.	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of @DRUG$ (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of @DRUG$ (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
@DRUG$ Simultaneous administration of antacids may reduce the plasma levels of @DRUG$.	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ may result in elevated serum levels of oxyphenbutazone.	DDI-mechanism
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Theophylline : As with some other @DRUG$ , concurrent administration of @DRUG$ Theophylline can be used to increase serum concentrations of theophylline and prolong the elimination half-life.	DDI-false
Moreover , additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , @DRUG$ , haloperidol, phenothiazine, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines .	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , @DRUG$ , indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$ Hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of @DRUG$.	DDI-false
The effects of ruthenium red ( RR ) on @DRUG$ (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
Non-steroidal anti-inflammatory drugs (but not @DRUG$): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate , @DRUG$ , and @DRUG$ HC1 : Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-false
In clinical studies with fondaparinux, the concomitant use of oral anticoagulants ( @DRUG$ ) , @DRUG$ ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , @DRUG$ , @DRUG$ , tricyclic antidepressants or some antihistamines.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , @DRUG$ , indinavir , @DRUG$ , erythromycin, etc.) is indicated, reduction of budesonide dose should be considered.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Ergot Derivatives : @DRUG$ , ergonovine , @DRUG$ , Methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischaemia of extremities and other tissues.	DDI-false
Antiarrhythmics : Other @DRUG$ Medicines such as quinidine, procainamide, disopyramide and phenytoin were used concomitantly with @DRUG$.	DDI-false
Higher concentrations of @DRUG$ ( 10(-8 ) - 10(-6 ) M ) or @DRUG$ ( 3 X 10(-8 ) - 10(-7 ) M ) enhance the mitogenic activity of EGF .	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (@DRUG$), erythromycin, azole antifungals.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as @DRUG$ , procainamide , @DRUG$ , and phenytoin , have been used concurrently with amiodarone .	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
Acetaminophen, @DRUG$, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, @DRUG$ , VIDEX chewable/buffer tablets or pediatric powder, or products containing calcium, @DRUG$ , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
(ii) the effects of @DRUG$ The most important membrane sterols in human cells were more effectively inhibited by added cholesterol, while the effects of @DRUG$ The main membrane sterol in the yeast was more efficiently affected by ergosterol.	DDI-false
@DRUG$: Amiodarone, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
Co-administration : Concomitant use of Argatroban with antiplatelet agents , @DRUG$ , and other @DRUG$ may increase the risk of bleeding .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of the magnesium deficiency and to discriminate between magnesium deficiency due to insufficient @DRUG$ intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation .	DDI-false
@DRUG$: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	DDI-false
Concomitantly given @DRUG$ did not interfere with the absorption of a tablet of @DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
There have been reports of QTc prolongation , with or without TdP , in patients taking @DRUG$ when @DRUG$ , macrolide antibiotics , or azoles were administered concomitantly .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Aspirin/@DRUG$ : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ ( 162.5 mg orally administered 26 and 2 hours before the start of argatroban 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after the start of argatroban 1.5 g/kg/min for 18 hours).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat .	DDI-false
Cephalosporine-@DRUG$ containing N-methylthiotetrazole page chains ( @DRUG$ Cefoperazone, cefotetan, cefamandol, latamoxef) or methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/@DRUG$.	DDI-false
@DRUG$ Other antiarrhythmic drugs, such as @DRUG$ Procainamide, disopyramide and phenytoin were used concomitantly with amiodarone.	DDI-false
Haemodynamic effects of glucose and @DRUG$ were additive when @DRUG$ was co-administered but not under basal conditions.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ - Nitrates, calcium blockers, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-effect
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with @DRUG$ or potent diuretics such as furosemide.	DDI-effect
The concomitant use of cholestyramine and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , @DRUG$ , @DRUG$ In 16 patients receiving coumarin therapy, chloral hydrate and methaqualone were systematically studied.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide , quinine , amiodarone , quinidine , @DRUG$ Tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Caution should be exercised if an @DRUG$ It is administered at the same time as medications that can reduce the levels or activity of endogenous steroid hormones such as ketoconazole, spironolactone and @DRUG$.	DDI-advise
The availability of potent @DRUG$ • (@DRUG$)-based antiretroviral therapy and concerns about protease inhibitor (PI)-related metabolic disorders have led to significant shifts in treatment practices in HIV infection.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ ): @DRUG$ - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Acetaminophen , lidocaine , @DRUG$ , quinidine, theophylline, and @DRUG$ The pooled human serum was added at therapeutic concentrations.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
@DRUG$: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Naproxen: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-mechanism
Therefore, patients under @DRUG$ therapy should be carefully monitored when concomitant @DRUG$ therapy is indicated.	DDI-advise
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , @DRUG$ , cefotetan, cefamandole, @DRUG$ ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
@DRUG$: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
The aim of this paper was to establish the interaction between @DRUG$ and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , @DRUG$ , chloralhydrate and @DRUG$ The treatment was systematically studied in 16 patients receiving coumarin therapy.	DDI-false
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, @DRUG$ ), myelotoxic (e.g., @DRUG$ Chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Antimycobacterial Agents : @DRUG$ CONTRAINDICATE since co-administration of this medicinal product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir .	DDI-false
Aspirin : In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of @DRUG$ Aspirin and aspirin were co-administered.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
No data are available for the coadministration of INVIRASE/@DRUG$ or @DRUG$/ritonavir and garlic capsules .	DDI-false
Several drug interaction studies have been completed with both @DRUG$ and @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , @DRUG$ Tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
Withdrawal of @DRUG$ decreased the @DRUG$ requirement by 50%.	DDI-mechanism
Multivalent Cation-Containing products: Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, VIDEX chewable tablets or pediatric powder or products which: @DRUG$ , @DRUG$ Zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
@DRUG$ and Tricyclic Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents .	DDI-false
@DRUG$ and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with @DRUG$.	DDI-effect
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , disopyramide , quinine , @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antiarrhythmics: Amiodarone, bepridil, flecainide, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.	DDI-false
@DRUG$: Concurrent administration of aspirin may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-false
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , analgesics , antiemetics , @DRUG$ , @DRUG$ ) .	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-false
@DRUG$ A small decrease in diflunisal levels was observed in multiple doses of diflunisal and diflunisal in normal volunteers. @DRUG$ were administered concomitantly .	DDI-false
Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine derivatives , @DRUG$ , or @DRUG$ may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Both @DRUG$ and @DRUG$ • Improvement of locomotor and/or stereotypical effects of stimulants.	DDI-false
@DRUG$ showed the most potent inhibition ( 66 % inhibition at 10 microM ) , which was far more potent than that of crude @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Acetaminophen/@DRUG$, lidocaine/chinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with @DRUG$ Concomitant therapy with anxiolytics, hypnotic agents and sedatives (including @DRUG$ ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
The concomitant use of @DRUG$ tablets and other @DRUG$ Because of the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy is not recommended.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$-Concomitant intake of mineral oil and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Coingestion of acetaminophen with theophylline , @DRUG$ - with acetaminophene and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
Coingestion of @DRUG$ with theophylline , phenobarbital with acetaminophen , and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug .	DDI-false
The effects of @DRUG$ and L-CCG-1 upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice .	DDI-false
Special care should be taken when using Gleevec with CYP3A4 substrates with a narrow therapeutic window (e. g. @DRUG$ or @DRUG$ ) .	DDI-false
@DRUG$-Broad-spectrum antibiotics may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
@DRUG$ It was also used at the same time as @DRUG$ No evidence of clinically relevant adverse reactions.	DDI-false
Plasma levels of @DRUG$ It has been reported that the number of oral @DRUG$ ;	DDI-false
Glyburide: The concomitant administration of @DRUG$ with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
These results suggest that both dexamethasone and retinyl acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and @DRUG$.	DDI-false
Methotrexate Renal tubular transport of @DRUG$ The concomitant use of @DRUG$ This may lead to increased plasma levels of methotrexate.	DDI-mechanism
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum @DRUG$ , sucralfate , @DRUG$ The chewable/buffered tablets or paediatric powders, or products that contain calcium, iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
@DRUG$: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, @DRUG$ , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Atromid-S may displace acidic drugs such as @DRUG$ or @DRUG$ from their binding sites.	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ Alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ Indinavir was observed for 48 weeks as initial therapy, with similar response rates. @DRUG$ Regimes and superiority observed with efavirenz.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Sedatives/@DRUG$: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
• Co-administration with compounds that are potent CYP3A4 inducers (e. g. @DRUG$ , phenytoin, dexamethasone, carbamazepine) may lead to decreased plasma levels of @DRUG$.	DDI-mechanism
Antiarrhythmics : @DRUG$ , bepridil , flecainide , @DRUG$ , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ A possible interaction for the following medications is recommended: @DRUG$ , cyclosporine , amiodarone , nicardipine , and nifedipine .	DDI-int
Among the @DRUG$, many, like @DRUG$, cannot be used clinically because they are toxic;	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients who block -@DRUG$ (e.g. propranolol, CYP3A4 inhibitor) or @DRUG$ • antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window ( e.g. , @DRUG$ ==References====External links==	DDI-advise
Other Cardiovascular Agents : Enalapril and @DRUG$ For co-administration with beta-adrenergic blockers, @DRUG$ Nitrates, calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or @DRUG$ antacids , sucralfate , @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, @DRUG$, @DRUG$).	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of @DRUG$, dextromethorphan, and methotrexate.	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-int
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when @DRUG$, macrolide antibiotics, or azoles were administered concomitantly.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , @DRUG$ ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of zidovudine , although it significantly decreased the @DRUG$ Tmax increased by 44% and intracellular exposure to phosphorylated @DRUG$ by 110 % .	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin , potentially leading to increased plasma levels of @DRUG$.	DDI-false
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
@DRUG$ and @DRUG$ : a drug interaction.	DDI-int
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/@DRUG$ , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Antihistamines: @DRUG$*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
In addition to the above interactions, chronic (2 weeks) oral administration of Cordaron affects the metabolism of phenytoin, @DRUG$ , and @DRUG$.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
Acetaminophen, lidocaine, phenobarbital, @DRUG$, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$ The risk of seizures may be reduced in patients who: @DRUG$	DDI-effect
In addition, fondaparinux did not affect the pharmacodynamics of @DRUG$ , acetylsalicylic acid , piroxicam , and digoxin , nor the pharmacokinetics of @DRUG$ at steady state .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	DDI-false
Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
There is a significant increase in exposure to @DRUG$ when Gleevec is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-false
acetaminophen/theophylline, @DRUG$/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Co-administration : Concomitant use of @DRUG$ with @DRUG$ Thrombolytics and other anticoagulants may increase the risk of bleeding.	DDI-effect
- mineral oil compositional intake of mineral oil and @DRUG$ The absorption of @DRUG$ can be reduced.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Like @DRUG$ ( 40 mg/kg ) , 18-MC ( 40 mg/kg ) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats ;	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$ : The concomitant administration of ciprofloxacin with the sulfonylurea @DRUG$ Rare cases have led to severe hypoglycaemia.	DDI-false
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-int
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin, containing multivalent cation products such as magnesium or aluminium @DRUG$ , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
@DRUG$, lidocaine, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , fibric acid derivatives , niacin ( nicotinic acid ) , @DRUG$ , @DRUG$.	DDI-false
Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission ( e.g. , @DRUG$ ) should only be carried out with caution, since the effect of @DRUG$ may be potentiated .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Other medicines: medicines such as quinidine, disopyramide, procainamide, phenothiazine, @DRUG$ , and @DRUG$ It may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
1 hour after the beginning of the @DRUG$ or @DRUG$ 500 mg p.o.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
@DRUG$ A change in serum levels of phenytoin (increased and decreased) has been reported in patients receiving @DRUG$ at the same time.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Quetiapine fumarate ( ' @DRUG$ ' ) is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by phenobarbital, secobarbital, @DRUG$ , @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
To determine whether injection of @DRUG$ A fixed dose of 9.9 g/m2 @DRUG$ The intravenous administration was administered for three hours at the same time as cisplatin.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , @DRUG$ , latamoxef) or methylthiadiazole ( @DRUG$ ) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
There is a significant increase in exposure to imatinib when @DRUG$ is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-mechanism
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
"It is concluded that @DRUG$ Methaqualone can be used without additional caution in prothrombin test monitoring during oral administration. @DRUG$ therapy .	DDI-false
This study demonstrated that the potent cytochrome P450 enzyme-inducer @DRUG$ did indeed have a marked effect on the metabolism of @DRUG$, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.	DDI-mechanism
Therefore, interactions may occur after concomitant administration of psychotropic medicinal products (e. g. @DRUG$ , analgesics , @DRUG$ , sedatives, sedatives).	DDI-false
Other Drugs : Drugs such as quinidine , @DRUG$ , procainamide , phenothiazines , @DRUG$ , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and valproic acid/phenobarbital.	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, @DRUG$, reserpine.	DDI-false
Caution should be exercised when: @DRUG$ It is specified in connection with @DRUG$.	DDI-advise
@DRUG$ may suppress certain CYP450 enzymes , including CYP1A2 , CYP2C9 , @DRUG$ , and CYP3A4 .	DDI-false
@DRUG$: Simvastatin (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with @DRUG$ , beta blockers, calcium channel blockers, diuretics, and @DRUG$ ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
The effects of ruthenium red ( @DRUG$ ) on @DRUG$ ( InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
Antiarrhythmics : Other @DRUG$ drugs , such as @DRUG$ Procainamide, disopyramide and phenytoin were used concomitantly with amiodarone.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
The blood pressure effect of SULAR tended to be greater in patients on @DRUG$ than in patients on no other @DRUG$ therapy .	DDI-false
@DRUG$ : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir .	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$ : FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents .	DDI-false
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.	DDI-effect
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and cimetidine.	DDI-advise
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In EM individuals treated with paroxetine or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
Oral @DRUG$ : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and @DRUG$ - about 30% and 20%.	DDI-false
Caution should be exercised when: @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as @DRUG$ , spironolactone , and cimetidine .	DDI-advise
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$: Amiodarone, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
It was concluded that oral @DRUG$ and @DRUG$ can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.	DDI-false
For this reason, the dosage of @DRUG$ should be adjusted when these @DRUG$ are administered concomitantly .	DDI-false
• Co-administration with compounds that are potent CYP3A4 inducers (e.g. phenobarbital, @DRUG$ , dexamethasone , @DRUG$ ) may result in decreased plasma levels of saquinavir .	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent diuretics such as @DRUG$.	DDI-effect
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants : FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents .	DDI-false
Like @DRUG$ 40 mg/kg and 18-MC ( 40 mg/kg) reduce intravenous self-administration of morphine and @DRUG$ • oral self-administration of ethanol and nicotine in rats;	DDI-false
Effect of @DRUG$ on the pharmacokinetics of @DRUG$.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
The risk of myopathy during treatment with medicines in this class is increased when cyclosporin is co-administered. @DRUG$ , niacin ( @DRUG$ ) , erythromycin , azole antifungals .	DDI-false
In clinical studies with fondaparinux, co-administration of @DRUG$ ( @DRUG$ ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
On administration of oral @DRUG$, the need for @DRUG$ therapy should be reviewed and the dose reduced by approximately 50% or discontinued.	DDI-advise
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Mineral Oil-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Other concomitant therapies : In clinical trials, the safety profile in patients with acamprosate concomitantly with @DRUG$ , @DRUG$ and sedatives ( including benzodiazepines ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Medicines that may alter the plasma concentration of imatinib Drugs that may increase the plasma concentration of imatinib @DRUG$ Plasma concentrations : Caution should be exercised when gleevec is administered with inhibitors of the CYP3A4 family (e.g. @DRUG$ , itraconazole , erythromycin , clarithromycin ) .	DDI-false
This effect is small with occasional doses of @DRUG$, but may be clinically significant when @DRUG$ are used on a continuous schedule.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Both @DRUG$ and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
@DRUG$ and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Hydrochlorothiazide: In normal subjects, concomitant use of @DRUG$ and @DRUG$ This resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-mechanism
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma ( HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , teniposide , and prednisone with vincristine plus @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
Oral contraceptives: concomitant use of atorvastatin and oral contraceptives @DRUG$ increased AUC values for norethindrone and @DRUG$ - about 30% and 20%.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, @DRUG$.	DDI-false
Both @DRUG$ and 18-MC block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
@DRUG$ Amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. @DRUG$ , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
@DRUG$ ( increases bioavailability by 50 % ) , @DRUG$ , and valproates .	DDI-false
Concomitant oral administration of @DRUG$ (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral @DRUG$.	DDI-mechanism
@DRUG$ , but not @DRUG$ , decreases heart rate at high doses .	DDI-false
High-dose @DRUG$ with @DRUG$ protection .	DDI-effect
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, @DRUG$, sedatives, tranquilizers).	DDI-false
DIGOXIN: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).	DDI-false
Anticoagulants : Potentiation of warfarin-type ( @DRUG$ CYP3A4 substrate and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
@DRUG$ : In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs , the co-administration of @DRUG$ For this reason, further deterioration of renal function may result.	DDI-false
Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	DDI-false
Corticosteroids , Methylxanthines and @DRUG$ : Concomitant treatment with xanthine derivatives , @DRUG$ Diuretics may potentiate a possible hypocalemic effect of beta2-agonists.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$ : The concomitant administration of @DRUG$ with the sulfonylurea glyburide has , on rare occasions , resulted in severe hypoglycemia .	DDI-false
In order to evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL ), the authors retrospectively compared a group of 24 patients with HIV-NHL who had been treated with the @DRUG$ , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$ , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Amiodarone taken concomitantly with @DRUG$ increases @DRUG$ The serum concentration by 33% after two days.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, @DRUG$ , alfentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , @DRUG$ Piroxicam and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Acetaminophen , @DRUG$ , phenobarbital, quinidine, theophylline, and @DRUG$ The pooled human serum was added at therapeutic concentrations.	DDI-false
@DRUG$ Elevates the enerohepatic elimination of @DRUG$ There may be a reduction in serum levels and t1/2.	DDI-false
@DRUG$ taken concomitantly with @DRUG$ increases quinidine serum concentration by 33% after two days.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and @DRUG$ or erythromycin.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Since the concomitant use of warfarin with @DRUG$ The prothrombin time increases by 100% after 3 to 4 days, the dose of @DRUG$ should be reduced by one-third to one-half , and prothrombin times should be monitored closely .	DDI-false
Other drugs : Drugs like @DRUG$ , @DRUG$ , procainamide , phenothiazines , antihistamines , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$ , and @DRUG$ during concomitant therapy with amiodarone .	DDI-false
Acetaminophen/@DRUG$, lidocaine/chinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Co-medications that induce CYP3A4 ( e.g. , dexamethasone , @DRUG$ , @DRUG$ , rifampin , phenobarbital or St.	DDI-false
Therefore, interactions after concomitant use of @DRUG$ ( e.g. , narcotics , analgesics , @DRUG$ , sedatives, sedatives).	DDI-false
Antiarrhythmics : Amiodarone , bepridil , @DRUG$ , @DRUG$ , Chinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
@DRUG$ , methylxanthine and diuretics: concomitant treatment with @DRUG$ Steroids, or diuretics may potentiate a potential hypocalemic effect of beta2-agonists.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus, cyclosporin, ergot derivatives, pimozide, @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Concomitant @DRUG$, @DRUG$, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite @DRUG$ were unaffected following co-administration with Acamprosate.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-false
@DRUG$ : The concomitant administration of @DRUG$ and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third .	DDI-false
Although @DRUG$ It has been shown that PROLEUKIN-induced adverse reactions such as fever, renal insufficiency, hyperbilirubinaemia, confusion and dyspnoea are reduced, the concomitant administration of these active substances with PROLEUKIN can reduce the antitumour effectiveness of PROLEUKIN and should therefore be avoided. 12 beta-blockers and other antihypertensives may increase hypotension in @DRUG$.	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ - Nitrates, calcium blockers, @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , @DRUG$ * Calcium blockers, hydralacin, @DRUG$ And digoxin without evidence of clinically significant adverse interactions.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
@DRUG$: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of @DRUG$ 1.5   g/kg/min . over 18 hours ) .	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. @DRUG$ , a @DRUG$ Substrate, and diltiazem, an inhibitor of CYP3A4) due to the potential for bradycardia, sinus arrest, and AV block;	DDI-false
Anticoagulants : Potentiation of warfarin-type ( CYP2C9 and @DRUG$ substrate ) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding .	DDI-false
The intensity , uniformity and time course of anticoagulant interference by @DRUG$ , sekobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
@DRUG$ : Plasma concentrations of @DRUG$ When co-administered with colestipol and atorvastatin, the dose decreased by approximately 25%.	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as quinidine and procainamide , @DRUG$ and @DRUG$.	DDI-false
@DRUG$ should be administered with caution to patients receiving @DRUG$ (disulfiram, Wyeth-Ayerst Laboratories).	DDI-advise
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Medicines that inhibit or induce cytochrome P450 3A4 enzymes @DRUG$ CYP3A4 and concomitant administration of potent inhibitors or inducers of CYP3A4 @DRUG$ concentrations significantly .	DDI-false
only @DRUG$ enhances @DRUG$-induced increases in accumbal dopamine .	DDI-effect
These results suggest that the hepatoxicity of @DRUG$ in alcoholic beverages is enhanced by interaction with its congeners and @DRUG$;	DDI-effect
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$ , Diltiazem, and @DRUG$.	DDI-false
Although studies designed to examine drug interactions have not been done , it was noted that @DRUG$ or @DRUG$ The treatment of relapses for up to 28 days was administered to patients ( N=180 ) with betaseron.	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Potassium-sparing diuretics (e.g. @DRUG$ , @DRUG$ Potassium supplements or salt substitutes containing potassium may lead to significant increases in serum potassium.	DDI-false
Other CONCOMITANT THERAPY : Although specific interaction studies have not been conducted in clinical trials, @DRUG$ was used concomitantly with @DRUG$ Beta-blockers, calcium channel blockers, diuretics and non-steroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
BACKGROUND : Effects of combined administration of bombsin and verapamil hydrochloride ( @DRUG$ ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
@DRUG$/Hypnotics: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent diuretics such as @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other Drugs : Drugs such as quinidine , disopyramide , procainamide , @DRUG$ , antihistamines, and @DRUG$ It may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a @DRUG$ substrate , and diltiazem , a @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Drug interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
Treatment with CYP3A4 inhibitors (such as ketoconazole, @DRUG$ , @DRUG$ , indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of budesonide dose should be considered.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ Incorporating coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as: @DRUG$ ( NSAIDs ) , and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 Beta-blockers and other @DRUG$ Hypotension observed with PROLEUKIN may be increased.	DDI-false
Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ Treatment and concerns about protease inhibitor (@DRUG$)-related metabolic disorders have led to significant shifts in treatment practices in HIV infection.	DDI-false
Drugs that may alter @DRUG$ Medicines that may increase the plasma concentration of imatinib: Caution is recommended when administering imatinib @DRUG$ with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , erythromycin , clarithromycin ) .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Co-medicines that induce CYP3A4 (e.g. @DRUG$ , @DRUG$ , carbamazepine, rifampin, phenobarbital or St.	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ This may lead to increased serum levels of oxyphenbutazone.	DDI-mechanism
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( @DRUG$ ), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and digoxin did not significantly affect @DRUG$ pharmacokinetics/pharmacodynamics.	DDI-false
@DRUG$ : Dihydroergotamine , ergonovine , @DRUG$ , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
Other Cardiovascular Agents : @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ Nitrates, calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and @DRUG$.	DDI-advise
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$    @DRUG$ antagonism	DDI-false
Co-administration of naltrexone with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
@DRUG$ had no effect on plasma levels of @DRUG$.	DDI-false
The immediate release , but not the coat-core formulation of @DRUG$ increased plasma @DRUG$ concentrations by about 20 % .	DDI-mechanism
@DRUG$ : Other @DRUG$ Medicines such as quinidine, procainamide, disopyramide and phenytoin have been used concomitantly with amiodarone.	DDI-false
Oral @DRUG$ Co-administration of atorvastatin and oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30 % and 20 % .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
@DRUG$ : Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium , including ACE inhibitors .	DDI-false
The aim of this paper was to investigate the interaction between neurotensin and both. @DRUG$ or its synthetic analogue @DRUG$ , or tuftsin, the anti-non-ciceptive effect of these peptides in mice after intracistern injection.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and digoxin or @DRUG$.	DDI-false
@DRUG$/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Probenecid: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of @DRUG$ in serum.	DDI-false
@DRUG$ and @DRUG$ exert additive ocular and renal vasodilator effects on healthy humans.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur when it contains its derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Digoxin : When multiple doses of atorvastatin and @DRUG$ were coadministered , steady-state plasma @DRUG$ Concentrations increased by about 20%.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , @DRUG$ , a CYP3A4 substrate and diltiazem @DRUG$ Inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , dapsone , disopyramide , @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
There is a significant increase in exposure to imatinib when @DRUG$ is coadministered with @DRUG$ ( CYP3A4 inhibitor ) .	DDI-mechanism
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
If cholinergic blockades occur, additive undesirable effects may occur if: @DRUG$ is administered concomitantly with other antimuscarinics , amantadine , @DRUG$ , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-effect
Agents Causing Renin Release : The antihypertensive effect of @DRUG$ Enalapril IV is enhanced by antihypertensive agents that cause the release of renin (e.g. @DRUG$ ) .	DDI-effect
However, the concomitant use of @DRUG$ and @DRUG$ The oral starting dose of 5 - 7.5 mg, followed by 2.5 - 6 mg/day orally for 6 - 10 days, leads to an increase in prothrombin time ( PT ) and International Normalised Ratio ( INR ).	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
@DRUG$: Quinolones have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-false
In addition to the above mentioned interactions, chronic ( 2 weeks ) oral @DRUG$ Administration affects the metabolism of phenytoin, dextromethorphan and @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
HMG-CoA Reductase Inhibitors: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$ , doxorubicin , teniposide , and prednisone with vincristine plus @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , dacarbazine , @DRUG$ , @DRUG$ and interferon-alfa .	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ after their prolonged administration.	DDI-false
Then, the effects of the metabotropic glutamate receptor (mGluR ) agonists, @DRUG$ and @DRUG$ To the above behavioral changes induced by PCP were found.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$ Amantadine, haloperidol, phenothiazine, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs ( NSAIDs ) , and @DRUG$ may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Colestipol : Plasma concentrations of @DRUG$ 25 % if Colestipol and @DRUG$ were coadministered .	DDI-false
• Co-administration with compounds that are potent CYP3A4 inducers (e. g. phenobarbital, phenytoin, dexamethasone, @DRUG$ @DRUG$ may decrease plasma levels.	DDI-mechanism
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Antipyrine : Because atorvastatin does not affect the pharmacokinetics of @DRUG$ Interactions with others @DRUG$ metabolized via the same cytochrome isozymes are not expected .	DDI-false
Co-medicines that induce CYP3A4 (e.g. @DRUG$ , phenytoin , @DRUG$ , rifampin, phenobarbital or St.	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and @DRUG$ Chemotherapy plus HAART with a group of 80 patients treated with CHOP chemotherapy or with a CHOP-like regimen (e.g. cyclophosphamide, doxorubicin, teniposide and prednisone) @DRUG$ Bleomycin) without antiretroviral therapy.	DDI-false
Although @DRUG$ It has been shown that PROLEUKIN-induced adverse reactions such as fever, renal insufficiency, hyperbilirubinaemia, confusion and dyspnoea are reduced, the concomitant administration of these active substances with PROLEUKIN can reduce the antitumour effectiveness of PROLEUKIN and should therefore be avoided. @DRUG$ Hypotension observed with PROLEUKIN may be increased.	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
@DRUG$: Amiodarone, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
It is important that patients understand how to use @DRUG$  (@DRUG$) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.	DDI-false
In general, these drugs have one or more pharmacological activities, similar to @DRUG$ , including antiarrhythmics such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
The data from alprazoleam in vitro studies indicate a possible interaction with alprazoleam for the following medicinal products: @DRUG$ and @DRUG$.	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal .	DDI-false
Multivalent Cation-Containing Products : Simultaneous Application of a @DRUG$ , including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfat, VIDEX chew/buffer tablets or child powder, or products that contain calcium, iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Other Cardiovascular Agents : Enalapril and @DRUG$ In addition to beta-adrenergic blockers, methyldopa, nitrates, calcium blockers, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
• Higher concentrations of dexamethasone ( 10(-8 ) - 10(-6 ) M or @DRUG$ ( 3 X 10(-8 ) - 10(-7 ) M ) increase the mitogenic activity of @DRUG$.	DDI-effect
@DRUG$ should be used with caution in patients taking @DRUG$, and renal function should be carefully monitored.	DDI-advise
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Potassium-sparing diuretics ( e.g. , @DRUG$ , Triamteren or Amilorid), @DRUG$ Supplements or salt substitutes containing potassium may lead to significant increases in serum potassium.	DDI-false
Other Drugs:Drugs such as @DRUG$, @DRUG$, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous opiate such as @DRUG$.	DDI-mechanism
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 Beta-blockers and other @DRUG$ Hypotension observed with PROLEUKIN may be increased.	DDI-false
In a clinical pharmacology study , indomethacin or @DRUG$ There were hypertensive patients given @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , @DRUG$ ), beta blockers, calcium channel blockers, diuretics, and @DRUG$ NSAIDs without evidence of clinically significant adverse interactions.	DDI-false
Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
Cyclosporine: Administration of @DRUG$ concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-mechanism
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Data from in vitro studies of @DRUG$ other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of @DRUG$ and @DRUG$ , including crescentic IgA glomerulonephritis , oculo-bulbar myasthenia gravis , inflammatory arthritis , thyroiditis , bullous pemphigoid , and Stevens-Johnson syndrome .	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
Like ibogain ( 40 mg/kg), @DRUG$ ( 40 mg/kg ) decreases the intravenous self-administration of morphine and @DRUG$ • oral self-administration of ethanol and nicotine in rats;	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , @DRUG$ , ritonavir , indinavir , saquinavir , @DRUG$ A reduction in the dose of budesonide should be considered.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and quinidine.	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib : Caution should be exercised when gleevec is administered with CYP3A4 inhibitors (e.g. ketoconazole, @DRUG$ , @DRUG$ , clarithromycin ) .	DDI-false
No data are available for the coadministration of INVIRASE/ritonavir or @DRUG$/@DRUG$ and garlic capsules.	DDI-false
Concurrent use with @DRUG$ or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of @DRUG$.	DDI-mechanism
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , @DRUG$ (e. g. cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$ - is a neutralising means for @DRUG$ It protects against kidney damage.	DDI-effect
Since @DRUG$ is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of @DRUG$.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , @DRUG$/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Drugs that may alter @DRUG$ Plasma concentrations Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when gleevec is administered with CYP3A4 inhibitors (e.g. ketoconazole, @DRUG$ Erythromycin, clarithromycin, erythromycin, erythromycin, erythromycin.	DDI-false
While 18-MC and @DRUG$ 18-MC has much lower affinities than @DRUG$ For NMDA and Sigma-2 receptors, sodium channels and the 5-HT transporter.	DDI-false
@DRUG$ had a similar effect in the presence of @DRUG$.	DDI-false
@DRUG$: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and atorvastatin were coadministered.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ The depletion associated with a dysregulation of the control mechanisms of magnesium status, which requires more or less specific regulation of its causal dysregulation.	DDI-false
Additional drugs that are not recommended for coadministration with @DRUG$ and @DRUG$ are included below.	DDI-false
Acetaminophen/theophylline, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/Phenobarbital.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ @DRUG$ over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with efavirenz .	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-effect
@DRUG$/Hypnotics : @DRUG$ , Midazolam CONTRAINDICATES due to the potential for serious and/ or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and CYP3A4.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Although @DRUG$ have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-effect
Other reported interactions with amiodarone: @DRUG$ (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as @DRUG$ and procainamide , @DRUG$ And tricyclic antidepressants.	DDI-false
Physiological oral @DRUG$ load constitutes the best tool for diagnosis of @DRUG$ deficiency and the first step of its treatment.	DDI-false
@DRUG$ In diabetic patients who: @DRUG$ No significant effects on tolbutamide plasma levels or fasting blood glucose were observed.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Multivalent Cation-Containing products: co-administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ Antacids, sucralfate, VIDEX chewable tablets or pediatric powders or products which: @DRUG$ Iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-false
@DRUG$ Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.	DDI-false
Therefore, when meclofenamate sodium is given to a patient receiving @DRUG$, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
The authors investigated the possibility of a similar interaction between @DRUG$ and @DRUG$.	DDI-false
@DRUG$ : In healthy individuals , plasma concentrations of atorvastatin increased approximately 40 % with coadministration of atorvastatin and @DRUG$ A known inhibitor of cytochrome P450 3A4.	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-benzodiazepines , @DRUG$ , certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients receiving receptor blockers (e.g. propranolol, CYP3A4 inhibitor), or @DRUG$ • Antagonists (e.g. verapamil, a) @DRUG$ substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The availability of potent @DRUG$ (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
While @DRUG$ and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1   g/kg/min . over 4 hours ) or @DRUG$ ( 1000 mg orally administered 12, 6 and 0 hours before, and 6 and 12 hours after, start of argatroban 1.5 g/kg/min. over 18 hours).	DDI-false
Coingestion of acetaminophen with theophylline , @DRUG$ with acetaminophene and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , @DRUG$ , @DRUG$ , nicardipine, and nifedipine.	DDI-false
It is structurally distinct from the other currently available @DRUG$ (@DRUG$, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
Probenecid : Probenecid interferes with renal tubular secretion of @DRUG$ and generates an increase in the level of @DRUG$ in serum .	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , @DRUG$ , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a @DRUG$ substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , @DRUG$ , indomethacin), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$ Effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
In patients receiving digoxin therapy, oral administration of @DRUG$ Regularly, this leads to an increase in serum levels. @DRUG$ Concentration that can achieve toxic values with resulting clinical toxicity.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
However , if @DRUG$ is to be initiated after cessation of @DRUG$ therapy , allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy .	DDI-false
@DRUG$ : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/phenobarbital.	DDI-false
Like ibogaine ( 40 mg/kg ) , 18-MC ( 40 mg/kg ) decreases the intravenous self-administration of morphine and @DRUG$ The oral self-administration of @DRUG$ and nicotine in rats ;	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , @DRUG$ , indinavir , saquinavir , erythromycin , etc . ) is indicated , reduction of the @DRUG$ The dose should be considered.	DDI-advise
@DRUG$ diminished binding of @DRUG$ Net change of 9.9 % ( percentage increase for FDF, 21.2% ) at 1732 micromol/L.	DDI-mechanism
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
In addition, additional interaction studies with niacin and propranolol have no effect on @DRUG$ plasma levels , and administration to a patient population chronically receiving @DRUG$ The bioavailability of digoxin compared to control data was not different.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
This can occur because @DRUG$ competitively displaces @DRUG$ From protein binding sites.	DDI-mechanism
Moreover , additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving @DRUG$ The bioavailability of digoxin compared to control data was not different.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine, amiodarone, @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
Probenecid : @DRUG$ Influences renal tubular secretion of @DRUG$ This leads to an increase in serum ciprofloxacin levels.	DDI-mechanism
In EM patients treated with paroxetine, or @DRUG$ , the AUC of @DRUG$ is approximately 6- to 8-fold and Css , max is about 3- to 4-fold greater than atomoxetine alone .	DDI-mechanism
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
@DRUG$: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-false
Since the concomitant administration of warfarin with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
@DRUG$ - plasma digoxin levels and @DRUG$ The steady-state clearance was not affected by co-administration of cerivastatin sodium 0.2 mg.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, @DRUG$ , @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
The effects of @DRUG$ were very strong and completely depressed the @DRUG$-induced hyperlocomotion .	DDI-effect
Quetiapine fumarate ('@DRUG$') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , @DRUG$ , @DRUG$ And nifedipine.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as @DRUG$ Antacids or antacids of aluminium, sucralfat, VIDEX tablets, chewable/buffered tablets or pediatric powders or products which: @DRUG$ , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
@DRUG$: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
• WARFARIN: @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Caution should be exercised when @DRUG$ are given in conjunction with @DRUG$.	DDI-advise
Dexamethasone and retinyl acetate similarly inhibit and stimulate @DRUG$- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-false
DIGOXIN : Plasma @DRUG$ levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Concomitant administration of @DRUG$ doubled the AUC for @DRUG$.	DDI-mechanism
Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-mechanism
Ergot Derivatives : @DRUG$ , @DRUG$ , ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasms and ischaemia of extremities and other tissues.	DDI-false
Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with @DRUG$ , steroids , or diuretics may potentiate a possible hypokalemic effect of   @DRUG$	DDI-effect
Dexamethasone and @DRUG$ Similarly, EGF or @DRUG$-induced proliferation of the prostate epithelium inhibits and stimulates.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$ including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Agents Causing Renin Release : The antihypertensive effect of enalapril and @DRUG$ IV is extended by: @DRUG$ , which cause renin release (e.g., diuretics).	DDI-effect
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent @DRUG$ such as @DRUG$.	DDI-false
@DRUG$ Not used as a replacement for oral or inhaled @DRUG$.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
@DRUG$ ( Magnesium-Aluminum Hydroxide ): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , @DRUG$ , phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ Or some antihistamines.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Data from in vitro studies @DRUG$ suggest a possible drug interaction with alprazolam for the following : @DRUG$ and paroxetine .	DDI-false
Concomitant cyclophosphamide, @DRUG$, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as @DRUG$ , procainamide, disopyramide, and phenytoin were used at the same time as @DRUG$.	DDI-false
Both ibogaine and 18-MC block @DRUG$-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or with a CHOP-like regimen (i.e. cyclophosphamide, @DRUG$ , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-false
Monitoring for @DRUG$ The toxicity and serial measurement of the amiodarone serum concentration during the concomitant @DRUG$ therapy should be considered .	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime), @DRUG$ , @DRUG$ , cefamandol, latamoxef) or methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , @DRUG$ Erythromycin, clarithromycin, erythromycin, erythromycin, erythromycin.	DDI-false
* Anticoagulants including coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as: @DRUG$ ( NSAIDs ) and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
@DRUG$ : @DRUG$ It does not appear to have a significant effect on the bioavailability of ciprofloxacin.	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$ Including coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as non-steroidal anti-inflammatory drugs (NSAIDs) and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-advise
Digoxin : In controlled studies in healthy volunteers , @DRUG$ either had no effect ( one study ) or was associated with modest increases , about 30 % ( two studies ) in steady-state serum @DRUG$ concentrations .	DDI-mechanism
Acetaminophene: Pharmacokinetic or pharmacodynamic drug-effect interactions between @DRUG$ and concomitantly administered @DRUG$ ( 162.5 mg orally administered 26 and 2 hours before the start of argatroban 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after the start of argatroban 1.5 g/kg/min for 18 hours).	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , @DRUG$ ) or hepatotoxic ( e.g. , @DRUG$ , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems .	DDI-false
Pretreatment of megakaryocytes with extracellular @DRUG$ (50 microM) also inhibited @DRUG$-induced responses.	DDI-effect
Antipyrine: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
@DRUG$ In healthy volunteers, ketoconazole, a CYP3A4 inhibitor, with 200 mg twice daily for 7 days, systemic exposure ( AUC ) @DRUG$ The half-life increased to 1.7 times the control.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin , @DRUG$ , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
Since @DRUG$ does not markedly inhibit CYP450s ( CYP1A2 , CYP2A6 , CYP2C9 , CYP2C19 , CYP2D6 , CYP2E1 , or CYP3A4 ) in vitro , @DRUG$ is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes .	DDI-false
Similarly dialyzed were @DRUG$, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , @DRUG$ , cyclosporin, ergot derivatives, pimozide, carbamazepine, @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or @DRUG$ • antagonists (e.g. verapamil, a CYP3A4 substrate and @DRUG$ , a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest, and AV block;	DDI-false
During transfer to oral @DRUG$, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral @DRUG$.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , @DRUG$ - Calcium blockers, hydralazine, prazosin and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
Acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/@DRUG$.	DDI-false
Similarly dialyzed were @DRUG$, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
The pharmacokinetics of naltrexone and its major metabolite @DRUG$ After co-administration with @DRUG$, treatment was unaffected.	DDI-false
because of this, the dosage of @DRUG$ should be adjusted when these @DRUG$ are administered concomitantly.	DDI-false
Therefore , when @DRUG$ is given to a patient receiving warfarin , the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Corticosteroids , @DRUG$ Abs and diuretics: Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a possible hypocalemic effect @DRUG$	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, @DRUG$, and nifedipine.	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Although neither @DRUG$ nor @DRUG$ Influences the proliferation of prostate epithelium in RPMI1640 with transferrin alone, altering the mitogenic effect of EGF and insulin.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
Interaction on the anticoagulant effect between neurotensin and @DRUG$ or @DRUG$.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
METHODS: Since the start of the experiment, the rats received 10 weekly subcutaneous injections of @DRUG$ 7.4 mg/kg body weight) and subcutaneous injections of bombsin ( 40 μg/kg body weight ) every other day and from week 16 intraperitoneal injections of @DRUG$ ( 10 or 20 mg/kg body weight ) every other day until the end fo the experiment in week 45 .	DDI-false
Suppression by @DRUG$ of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.	DDI-effect
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , @DRUG$ , or @DRUG$ may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Further , no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and @DRUG$.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitors (NNRTI)-based antiretroviral therapy and concerns about @DRUG$ Metabolism disorders (@DRUG$) have led to significant shifts in treatment practices in HIV infection.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Some @DRUG$/substances are known to accelerate metabolism @DRUG$ by stimulating the synthesis of CYP3A4 ( enzyme induction ) .	DDI-false
Since @DRUG$ does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, @DRUG$ is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (CYP3A4 substrate) given for local @DRUG$.	DDI-false
The results increase the possibility that the ethanocyte reaction can occur in the stomach of people who consume @DRUG$ and @DRUG$ Regularly.	DDI-mechanism
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or @DRUG$ antagonists ( e.g. , @DRUG$ , a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , @DRUG$ , disopyramide, and phenytoin, were used simultaneously with @DRUG$.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
Acetaminophene/theophylline, lidocaine/chinidine, @DRUG$/@DRUG$ , phenobarbital/ valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
Haemodynamic effects of @DRUG$ Insulins were additive if: @DRUG$ The administration was performed simultaneously, but not under basal conditions.	DDI-false
Molecular basis for the selective toxicity of @DRUG$ for yeast and @DRUG$ for animal cells.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$, such as @DRUG$, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
DIGOXIN : Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ may enhance the effects of alcohol, barbiturates, and other @DRUG$.	DDI-effect
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Anticoagulant inhibition was observed during the administration of @DRUG$, secobarbital and @DRUG$;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with @DRUG$ Beta-blockers and other antihypertensive agents may increase hypotension in PROLEUKIN.	DDI-false
Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of @DRUG$, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
Although @DRUG$ @DRUG$-induced side effects such as fever, renal insufficiency, hyperbilirubinaemia, confusion and dyspnoea have been shown to be reduced, concomitant administration of these agents with PROLEUKIN may reduce the efficacy of PROLEUKIN against the tumour and should therefore be avoided. 12 beta-blockers and other antihypertensive agents may increase hypotension in PROLEUKIN.	DDI-effect
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Cyclosporin : administration of non-sterioal anti-inflammatory medicinal products at the same time as @DRUG$ has been associated with an increase in @DRUG$-induced toxicity , possibly due to decreased synthesis of renal prostacyclin .	DDI-false
However , the absolute number of @DRUG$-related deaths is far greater than the number of deaths in amphetamine or @DRUG$ users .	DDI-false
These results suggest that both @DRUG$ and retinyl acetate , and possibly other @DRUG$ and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF .	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
; Naproxen : Simultaneous use of @DRUG$ In normal subjects, naproxene and naproxene did not affect naproxene plasma levels, but significantly reduced the urinary excretion of naproxene. @DRUG$ and its glucuronide metabolite .	DDI-false
* Drug interactions : Flupentixol may interact with some drugs, such as @DRUG$ MAOI (MAOI): MAOI could theoretically influence @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a @DRUG$) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
Glyburide : The concomitant administration of @DRUG$ with the @DRUG$ Glyburide has, in rare cases, led to severe hypoglycaemia.	DDI-effect
omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent if @DRUG$ ==References====External links== @DRUG$ At the dose that suppresses gastric acid secretion maximum.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or @DRUG$.	DDI-effect
@DRUG$ had no significant effect on @DRUG$ pharmacokinetics .	DDI-false
@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
@DRUG$ : When multiple doses of atorvastatin and @DRUG$ Plasma digoxin concentrations at steady-state increased by about 20%.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
Combinations of @DRUG$ and @DRUG$ Rash: Effects on drug discrimination and behavioural inhibition in rats.	DDI-false
@DRUG$ Incorporating coumarin derivatives, indandion derivatives and @DRUG$ such as nonsteroidal anti-inflammatory drugs ( NSAIDs ) , and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
It is structurally distinct from the other currently available @DRUG$ (lovastatin, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Combination of amiodarone with other @DRUG$ Treatment should be reserved for patients with life-threatening ventricular arrhythmias who respond incompletely to a single active substance or who do not respond to @DRUG$.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (@DRUG$) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.	DDI-false
@DRUG$ may displace acidic drugs such as @DRUG$ or tolbutamide from their binding sites.	DDI-mechanism
Like @DRUG$ 18-MC ( 40 mg/kg ) reduces intravenous self-injection of @DRUG$ • cocaine and oral self-administration of ethanol and nicotine in rats;	DDI-false
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and @DRUG$.	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$ : Chinolone have been reported to reduce the effects of oral @DRUG$ Warfarin or its derivatives.	DDI-false
acetaminophen/@DRUG$, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
The effects of @DRUG$ ( RR ) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
The application of local anaesthetic solutions that @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors , @DRUG$ or phenothiazines may produce severe , prolonged hypotension or hypertension .	DDI-effect
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - @DRUG$ Flupentixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupentixol increases the effect of tricyclic antidepressants	DDI-false
In EM patients treated with paroxetine, or @DRUG$ , the AUC of atomoxetine is approximately 6- to 8-fold and Css , max is about 3- to 4-fold greater than @DRUG$ alone .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Withdrawal of @DRUG$ decreased the @DRUG$ - 50 % requirement.	DDI-mechanism
Multivalent Cation-Containing products: Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, VIDEX chew/buffer tablets or child powder, or products containing calcium, @DRUG$ Zinc, or zinc can significantly reduce the absorption of @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-false
Coadministration of @DRUG$ with 40 mg SULAR tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain @DRUG$, etc.).	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, @DRUG$).	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
Although neither @DRUG$ The proliferation of the prostate epithelium in RPMI1640, which contains transferrin alone, was not influenced by retinyl acetate, they modify the mitogenic effect of @DRUG$ and insulin .	DDI-effect
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
To determine whether injection of thiosulfate would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Acetaminophene/theophylline, lidocaine/chinidine, phenobarbital/acetaminophene, @DRUG$/@DRUG$ , quinidine/lidocaine, theophylline/acetaminophene and valproic acid/phenobarbital.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and @DRUG$.	DDI-false
@DRUG$ could exaggerate the depression of AV nodal conduction observed with @DRUG$.	DDI-effect
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ , nitrates , @DRUG$ , hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , @DRUG$ , @DRUG$ , saquinavir, erythromycin, etc.) is indicated, reduction of budesonide dose should be considered.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( @DRUG$ , @DRUG$ , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
@DRUG$ Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$ , and phenytoin , have been used concurrently with amiodarone .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
This study demonstrates that concurrent administration of @DRUG$ The dose and total exposure of @DRUG$ can be increased at least twice.	DDI-mechanism
@DRUG$ may increase slightly the effect of antihypertensive drugs , e.g. , guanethidine , @DRUG$ , reserpine .	DDI-effect
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
@DRUG$: Meclofenamate sodium enhances the effect of @DRUG$.	DDI-false
@DRUG$: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , @DRUG$ , asparaginase) effects with @DRUG$ The toxicity in these organ systems can be increased.	DDI-effect
Concomitant use with @DRUG$s may result in the reduced absorption of @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
@DRUG$-Concomitant intake of colestipol and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ Deficit and discrimination between magnesium deficiency due to insufficient magnesium intake, which requires only oral physiological supplement and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation .	DDI-false
@DRUG$ The simultaneous use of diflunisal and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third .	DDI-false
BACKGROUND : The effects of combined administration of @DRUG$ Hydrochloride and verapamil ( @DRUG$ ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or @DRUG$.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$: The concomitant use of Bepridil and @DRUG$ has been well tolerated in patients with stable angina.	DDI-false
Both efavirenz and @DRUG$ It was used with triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with efavirenz .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$ and tricyclic antidepressants : @DRUG$ In patients treated with monoamine oxidase inhibitors or tricyclic antidepressants, the use should be carried out with extreme caution as the effect of formoterol on the cardiovascular system may be enhanced by these agents.	DDI-false
Monoamine oxidase inhibitors and tricyclic antidepressants: FORADIL should be used in patients treated with @DRUG$ or @DRUG$ Because the effect of formoterol on the cardiovascular system can be enhanced by these active substances.	DDI-false
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was co-administered with @DRUG$ , beta blockers, calcium channel blockers, @DRUG$ , and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Five days of @DRUG$ treatment did not significantly affect steady-state pharmacokinetic variables of @DRUG$ compared with placebo;	DDI-false
Multivalent Cation-Containing products: co-administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ @DRUG$ , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
The continued need for the other @DRUG$ agent should be reviewed after the effects of @DRUG$ have been established, and discontinuation ordinarily should be attempted.	DDI-false
BACKGROUND : The effects of combined administration of bombesin and @DRUG$ (Verapamil), a calcium channel blocker induced by azoxymethane by the incidence of peritoneal metastases of intestinal adenocarcinoma ( @DRUG$ ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
Two groups (SH/DA; SH/FA) were treated daily with synthetic hydroalcoholic solutions containing ethanol. @DRUG$ , higher alcohols and @DRUG$ — in the same proportions as in the most frequently distilled and fermented alcoholic beverages;	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/phenobarbital.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , @DRUG$ , and @DRUG$.	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, @DRUG$.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
Acetaminophen/@DRUG$, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, @DRUG$, and @DRUG$.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors , tricyclic antidepressants or @DRUG$ For this reason, severe, prolonged hypotension or hypertension may occur.	DDI-effect
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Although this effect was noted even when @DRUG$ was given 4 hours prior to @DRUG$, this regimen did not result in diminished efficacy.	DDI-effect
Other Cardiovascular Agents : Enalapril and @DRUG$ IV was co-administered with beta-adrenerg blockers, methyldopa, nitrates, @DRUG$ , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., @DRUG$, analgesics, antiemetics, sedatives, tranquilizers).	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole ( @DRUG$ Cefoperazone, cefotetan, cefamandol, latamoxef) or methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
However , reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 ( eg , @DRUG$ , @DRUG$ Dexamethasone, carbamazepine) may lead to decreased plasma levels of saquinavir.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, @DRUG$ Elevated plasma concentrations may occur when alprazom is co-administered with triazolam. @DRUG$ ;	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$-@DRUG$ may decrease the absorption of vitamin K.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$ including tranylcypromine sulfate , phenelzine sulfate , and pargyline HC1 : Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension .	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-false
The steady state plasma concentrations of @DRUG$ and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.	DDI-false
METHODS : From the beginning of the experiment , rats were given 10 weekly subcutaneous injections of AOM ( 7.4 mg/kg body weight ) and subcutaneous injections of @DRUG$ ( 40 microg/kg body weight ) every other day , and from week 16 , intraperitoneal injections of @DRUG$ 10 or 20 mg/kg body weight every other day until the end of the test at week 45.	DDI-false
@DRUG$: @DRUG$ appear to have no significant effect on the bioavailability of ciprofloxacin.	DDI-false
The immediate release, but not the coat-core formulation of @DRUG$ increased plasma @DRUG$ concentrations by about 20%.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and prednisone with vincristine plus bleomycin) without reception @DRUG$ therapy .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , @DRUG$ , @DRUG$ ) .	DDI-false
ANTACID (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
Simultaneous cyclophosphamide, doxorubicin, vincristine and @DRUG$ chemotherapy plus @DRUG$ Treatment in patients with human immunodeficiency virus-associated non-Hodgkin lymphoma.	DDI-false
@DRUG$ and @DRUG$ Similarly, EGF or insulin-induced proliferation of prostate epithelium is inhibited and stimulated.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-effect
@DRUG$ : When multiple doses of @DRUG$ and digoxin were coadministered , steady-state plasma digoxin concentrations increased by approximately 20 % .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Acetaminophen/theophylline, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/phenobarbital.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Molecular basis for selective toxicity of @DRUG$ for yeast and @DRUG$ For animal cells.	DDI-false
Based on the results of these studies, it is concluded that: @DRUG$ It can be safely used together with both. @DRUG$ and dideoxyinosine .	DDI-false
@DRUG$: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-false
@DRUG$/@DRUG$ , lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Concomitant @DRUG$ , doxorubicin , vincristine , and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
For treatment with CYP3A4 inhibitors (such as ketoconazole, intraconazole, @DRUG$ , indinavir, saquinavir, @DRUG$ A reduction in the dose of budesonide should be considered.	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, @DRUG$ , @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
There have been reports of QTc prolongation , with or without TdP , in patients taking @DRUG$ when fluoroquinolones , @DRUG$ , or azoles were administered concomitantly .	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat .	DDI-false
@DRUG$ : Altered serum levels of @DRUG$ Treatment (increased and decreased) has been reported in patients receiving ciprofloxacin concomitantly.	DDI-false
Co-administration of BOTOX and @DRUG$ The effect of neuromuscular transmission (e.g. curare-like compounds) should be done with caution. @DRUG$ It can be potentiated.	DDI-false
Acetaminophen/@DRUG$, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/@DRUG$.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ 12 beta blockers and others @DRUG$ may potentiate the hypotension seen with PROLEUKIN .	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/@DRUG$.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-effect
Plasma levels of @DRUG$ The treatment may be subtherapeutic @DRUG$ therapy .	DDI-mechanism
Suppression by @DRUG$ of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ in wistar rats.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum @DRUG$ , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, @DRUG$, and CYP3A4.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Other concomitant therapies : In clinical trials, the safety profile in patients with @DRUG$ • Accompanied by anxiolytics, hypnotic agents and @DRUG$ The use of placebo with these concomitant medications was similar to that of volunteers (including benzodiazepines), or non-opioid analgesics.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , @DRUG$ , ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, @DRUG$ dose should be considered .	DDI-advise
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$ , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$: @DRUG$ have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.	DDI-false
Primary and secondary @DRUG$ Weaknesses represent the only indication for physiological oral @DRUG$ therapy .	DDI-false
The hypoglycemic effect of @DRUG$ has been reported to increase when @DRUG$ is given concurrently.	DDI-effect
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Although glucocorticoids @DRUG$-induced side effects such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea have been shown to reduce, concomitant administration of these agents with PROLEUKIN may reduce the efficacy of antitumours. @DRUG$ Beta-blockers and other antihypertensive agents may increase the hypotension observed with PROLEUKIN.	DDI-false
The administration of local @DRUG$ • Epinephrine or norepinephrine for patients who have monoamine oxidase inhibitors, tricyclic antidepressants, or @DRUG$ For this reason, severe, prolonged hypotension or hypertension may occur.	DDI-effect
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ • Reduction of dysregulation of control mechanisms @DRUG$ status which requires more or less specific regulation of its causal dysregulation .	DDI-false
Drugs that may alter @DRUG$ Plasma concentrations Drugs that may increase @DRUG$ plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , erythromycin , clarithromycin ) .	DDI-false
In addition , @DRUG$ neither influenced the pharmacodynamics of @DRUG$ Acetylsalicylic acid, piroxicam and digoxin, and the pharmacokinetics of digoxin in steady state.	DDI-false
In the present study, the @DRUG$ clozapine was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, @DRUG$, erythromycin, clarithromycin).	DDI-false
The steady state plasma concentrations of imipramine and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
If cholinergic blockades occur, additive undesirable effects may occur if: @DRUG$ It is used at the same time as others. @DRUG$ Amantadine, haloperidol, phenothiazine, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Oral @DRUG$: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, @DRUG$ , pimozide , carbamazepine , fentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
The effects of @DRUG$ were very strong and completely depressed the @DRUG$-induced hyperlocomotion.	DDI-effect
Possible drug interactions of @DRUG$ with @DRUG$ or with other anticholinesterase agents.	DDI-int
The bioavailability of the capsule formulation of @DRUG$ was not affected when administered 5 minutes following an @DRUG$.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Other Cardiovascular Agents : Enalapril and @DRUG$ IV have been used concomitantly with @DRUG$ , methyldopa, nitrates, calcium blockers, hydralacin, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Multivalent Cation-Containing products: co-administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ Antacids, sucralfate, VIDEX chewing/buffering tablets or paediatric powders, or products containing calcium, @DRUG$ , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
@DRUG$ As with some other quinolones, co-administration of ciprofloxacin with theophylline may lead to increased serum concentrations. @DRUG$ Elongation of elimination half-life.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ Deficit and to discriminate between magnesium deficiency due to insufficient magnesium uptake, which requires only oral physiological supplement and magnesium degradation, which with a dysregulation of the control mechanisms of @DRUG$ Status that requires more or less specific regulation of its causal dysregulation.	DDI-false
Sedatives/@DRUG$ : triazolam , @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .	DDI-false
@DRUG$: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , @DRUG$ , Amiodaron, Nicardipine, and @DRUG$.	DDI-false
@DRUG$, such as verapamil, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Colestipol-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with @DRUG$ concomitantly with @DRUG$ , hypnotics and sedatives ( including benzodiazepines ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
Dexamethasone and @DRUG$ similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Drug/Laboratory Test Interactions @DRUG$, including @DRUG$, are known to occasionally induce a positive direct Coombs test.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
- Non-selective MAO inhibitors including tranylcypromin sulfate, @DRUG$ , and Pargylin HC1: Simultaneous use of @DRUG$ and non-selective MAO inhibitors may cause hypertension .	DDI-false
@DRUG$ , lidocaine , @DRUG$ , quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/@DRUG$ , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin , potentially leading to increased plasma levels of @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
• Drug interactions: Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/phenobarbital.	DDI-false
The co-administration of alcohol and @DRUG$ • Does not affect the pharmacokinetics of @DRUG$ or acamprosate .	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including @DRUG$ With multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Other medicines: medicines such as quinidine, disopyramide, @DRUG$ , phenothiazines , @DRUG$ , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
BACKGROUND : The effects of combined administration of bombesin and @DRUG$ ( verapamil ) , a @DRUG$ The incidence of peritoneal metastasis of intestinal adenocarcinoma induced by azoxymethane (AOM) and the index of colorectal cancers were studied in male Wistar rats.	DDI-false
@DRUG$ including tranylcypromine sulfate , @DRUG$ Pargylin HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The blood pressure effect of @DRUG$ tended to be greater in patients on @DRUG$ than in patients on no other antihypertensive therapy.	DDI-effect
It was concluded that oral @DRUG$ and @DRUG$ Concomitant administration may take place without a significant decrease in AUC, Cmax or tmax.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect @DRUG$ pharmacodynamics - arecoline - eproxindine - ethanol : flupentixol and ethanol lead to additive CNS depression - tricyclic antidepressants : flupentixol increases the effect of @DRUG$	DDI-false
Glyburide: The concomitant administration of ciprofloxacin with the @DRUG$ @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
In addition to this pharmacological interaction , this report describes a novel chemical reaction between @DRUG$ (a benzodiazepine) and @DRUG$ under acidic conditions similar to those found in vivo , resulting in a 3-ethoxylated product .	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
In addition to the interactions noted above , chronic (   2 weeks ) oral Cordarone administration impairs metabolism of @DRUG$ , Dextromethorphan, and @DRUG$.	DDI-false
@DRUG$ , such as verapamil , @DRUG$ and nifedipine , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and sedatives ( including @DRUG$ ) , or @DRUG$ It was similar in patients taking placebo with these concomitant medications as in patients receiving placebo.	DDI-false
@DRUG$ is metabolized to @DRUG$ by the cytochrome P450 ( CYP450 ) enzyme group , specifically cytochromes P450 3A4 ( CYP3A4 ) and CYP2C8 .	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and @DRUG$.	DDI-false
The effects of concomitant @DRUG$ administration on the steady-state pharmacokinetics of @DRUG$.	DDI-false
However , LDL-C reduction was greater when @DRUG$ and @DRUG$ were coadministered than when either drug was given alone .	DDI-effect
@DRUG$/theophylline , @DRUG$/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Some @DRUG$/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
@DRUG$ : In some patients with compromised renal function who are being treated with @DRUG$ Concomitant use of Enalapril may lead to further deterioration of renal function.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or @DRUG$.	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-false
Therefore , when @DRUG$ It is given to a patient who: @DRUG$ The dose of warfarin should be reduced to prevent excessive prolongation of prothrombin time.	DDI-advise
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ The doses of procainamide and procainamide should be reduced by one third when co-administered with @DRUG$.	DDI-false
@DRUG$ The recording of @DRUG$ may be affected.	DDI-mechanism
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
@DRUG$ : Dihydroergotamine , ergonovine , ergotamine , @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
Fenfluramine may slightly increase the effect of antihypertensive agents, e.g. @DRUG$ , methyldopa , @DRUG$.	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, diltiazem, and @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide, @DRUG$ , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
The initiation of @DRUG$ or @DRUG$ use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.	DDI-false
There have been case reports of increased steady-state levels of @DRUG$ , procainamide , and @DRUG$ • during concomitant therapy with amiodarone.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
- corticosteroids, methylxanthine and @DRUG$ Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a possible hypokalemic effect @DRUG$	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl, alfentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Lithium : @DRUG$ Toxicity has been reported in patients who: @DRUG$ Accompanied by medicines that cause the excretion of sodium, including ACE inhibitors.	DDI-false
As Ibogain ( 40 mg/kg ) reduces 18-MC ( 40 mg/kg ) intravenous self-administration of morphine and cocaine and oral self-administration of @DRUG$ and @DRUG$ in rats ;	DDI-false
When LEVSIN is co-administered with others @DRUG$ , @DRUG$ , haloperidol , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (@DRUG$, @DRUG$ or delavirdine).	DDI-false
In addition, fondaparinux did not affect the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$ , and digoxin , nor the pharmacokinetics of @DRUG$ At Steady State.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine ( @DRUG$ ==References====External links==	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergotic derivatives, pimozide, carbamazepine, @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , @DRUG$ ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients with receptor blockers (e.g. propranolol, @DRUG$ inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a @DRUG$ Substrate, and diltiazem, an inhibitor of CYP3A4) due to the potential for bradycardia, sinus arrest, and AV block;	DDI-false
Non-steroidal anti-inflammatory drugs ( but not @DRUG$ ): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies .	DDI-false
@DRUG$ : @DRUG$ Bepridil, flecainide, propafenone, quinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
The possibility of hypotensive effects with @DRUG$ or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat .	DDI-false
Like ibogain ( 40 mg/kg), @DRUG$ ( 40 mg/kg ) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats ;	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
@DRUG$: The concomitant administration of ciprofloxacin with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
Other concomitant therapies : In clinical trials, the safety profile in patients with acamprosate concomitantly with @DRUG$ , hypnotics and @DRUG$ The use of placebo with these concomitant medications was similar to that of volunteers (including benzodiazepines), or non-opioid analgesics.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
In addition, additional interaction studies with: @DRUG$ Administration to a patient population receiving chronic digoxin did not cause any difference in the extent of bioavailability of digoxin. @DRUG$ relative to control data .	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
The intensity, uniformity and time course of @DRUG$ - disorders caused by phenobarbital, @DRUG$ , glutethimide , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
While @DRUG$ and @DRUG$ 18-MC has much lower affinities than ibogain for NMDA and Sigma-2 receptors, sodium channels and 5-HT transporters.	DDI-false
Monitoring the amiodarone toxicity and serial measurement of @DRUG$ serum concentration during concomitant @DRUG$ therapy should be considered .	DDI-advise
@DRUG$: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	DDI-false
Acetaminophen: Pharmacokinetic or pharmacodynamic drug-effect interactions between argatroban and concomitant use of argatroban have not been established. @DRUG$ ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or @DRUG$ ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of Argatroban 1.5   g/kg/min . over 18 hours ) .	DDI-false
The @DRUG$ study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.	DDI-false
The co-administration of medicinal products which are nephrotoxic (e. g. @DRUG$ , indomethacin ), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin ) or hepatotoxic (e.g., methotrexate, asparaginase ) effects with: @DRUG$ The toxicity in these organ systems can be increased.	DDI-effect
Warfarin: @DRUG$ enhances the effect of @DRUG$.	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-mechanism
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Antihypertensives : @DRUG$ Propranolol, an inhibitor of CYP3A4 or calcium channel antagonists (e.g. verapamil, @DRUG$ Substrate, and diltiazem, an inhibitor of CYP3A4) due to the potential for bradycardia, sinus arrest, and AV block;	DDI-false
Effects of @DRUG$ on Drug Metabolizing Enzymes and Drug Transport Systems @DRUG$ inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin, vincristine, and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Sedatives/@DRUG$: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Co-administration : Concomitant use of @DRUG$ - with antiplatelet agents, @DRUG$ And other anticoagulants can increase the risk of bleeding.	DDI-effect
BACKGROUND : The effects of combined administration of @DRUG$ and verapamil hydrochloride ( verapamil ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( @DRUG$ ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
@DRUG$: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and @DRUG$ in rats;	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Anticoagulants : Potentiation of @DRUG$-type ( @DRUG$ and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
Acetaminophen/@DRUG$, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Colestipol-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Other Drugs : Drugs such as @DRUG$ , disopyramide , @DRUG$ , phenothiazines , antihistamines , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Two groups ( SH/DA ; SH/FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$ , methanol , higher @DRUG$ acetaldehyde and acetaldehyde in the same proportions as in the most common distilled and fermented alcoholic beverages;	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when fluoroquinolones, @DRUG$, or azoles were administered concomitantly.	DDI-false
Medicines that cause the release of renin : The antihypertensive effect of @DRUG$ Ug and enalapril IV is supplemented by @DRUG$ that cause renin release ( e.g. , diuretics ) .	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Further , no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of warfarin and @DRUG$.	DDI-false
Co-administration : Concomitant use of Argatroban with @DRUG$ , @DRUG$ And other anticoagulants can increase the risk of bleeding.	DDI-false
In clinical studies with fondaparinux, co-administration of @DRUG$ ( Warfarin ), @DRUG$ ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin , with multivalent cation-containing products such as magnesium or @DRUG$ antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
• Non-selective MAO inhibitors including @DRUG$ , Phenelzinsulfate, and @DRUG$ HC1 : Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension .	DDI-false
However, the concomitant use of @DRUG$ and @DRUG$ (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).	DDI-effect
Dextromethorphan is a substrate for both @DRUG$ and @DRUG$.	DDI-false
Antihypertensives : @DRUG$ Propranolol, a CYP3A4 inhibitor ) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Earlier studies showed a significant reduction in oral bioavailability of @DRUG$ and @DRUG$ when administered concomitantly with an intravenous opiate such as morphine .	DDI-false
The pharmacokinetic or pharmacodynamic drug-effect interactions between: @DRUG$ 1 g/kg/min) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after the start of argatroban 1.5 g/kg/min. for 18 hours.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide , @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
@DRUG$ ( but not @DRUG$ ): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , @DRUG$ , and @DRUG$ , were used simultaneously with amiodarone.	DDI-false
@DRUG$ : @DRUG$ The plasma concentration of saquinavir is reduced due to the concomitant use of this medicine with saquinavir in an antiretroviral regimen.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without treatment @DRUG$ therapy .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
No data are available for the coadministration of @DRUG$/@DRUG$ or FORTOVASE/ritonavir and garlic capsules.	DDI-false
Oral Contraceptives : Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30 % and 20 % .	DDI-mechanism
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of the magnesium deficiency and to discriminate between magnesium deficiency due to insufficient @DRUG$ Ingestion that requires only oral physiological supplement and magnesium deficiency, which is accompanied by a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and @DRUG$.	DDI-false
The effect of the blood pressure of @DRUG$ tended to be greater in patients on atenolol than in patients on no other @DRUG$ therapy .	DDI-false
Little has been said about the adverse effects of liver exposure to the interaction of @DRUG$ "with his congeners and @DRUG$ , coexisted in the content of alcoholic beverages.	DDI-false
acetaminophen/@DRUG$ , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
* Pharmacokinetic or pharmacodynamic drug interactions between argatroban and co-administered aspirin ( 162.5 mg orally 26 and 2 hours before starting treatment with argatroban 1 g/ kg/ min for 4 hours), or @DRUG$ ( 1000 mg orally administered 12, 6 and 0 hours before, and 6 and 12 hours after, beginning of the @DRUG$ 1.5   g/kg/min . over 18 hours ) .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Isocarboxazid should be used with caution in patients who: @DRUG$ ( @DRUG$ ==References====External links==	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
@DRUG$ (e.g. spironolactone, triamterene or @DRUG$ Potassium supplements or salt substitutes containing potassium may lead to significant increases in serum potassium.	DDI-false
Blood sampling for the pharmacokinetics of @DRUG$ and @DRUG$ was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Slow-channel calcium blockers, such as verapamil, @DRUG$ and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
Glyburide : The concomitant administration of ciprofloxacin with the @DRUG$ @DRUG$ has , on rare occasions , resulted in severe hypoglycemia .	DDI-false
@DRUG$ is a substrate for both @DRUG$ and CYP3A4 .	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
@DRUG$ : Potentiation of warfarin-type ( CYP2C9 and @DRUG$ The substrate) Anticoagulant response is almost always seen in patients receiving amiodarone and can lead to severe or fatal bleeding.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Since amiodarone is a substrate for @DRUG$ , there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels .	DDI-false
Other drugs : Drugs like @DRUG$ , disopyramide, procainamide, phenothiazine, antihistamines and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high-dose PROLEUKIN and antineoplastic agents, in particular: @DRUG$ , @DRUG$ , tamoxifen and interferon-alfa .	DDI-false
However , @DRUG$ stimulated , but did not significantly inhibit , proliferation in the presence of @DRUG$.	DDI-effect
Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
@DRUG$ : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , @DRUG$ , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
In general, these drugs have one or more pharmacological activities, similar to bepridil hydrochloride, including @DRUG$ ♪ Like quinidine and @DRUG$ , cardiac glycosides and tricyclic anti-depressants .	DDI-false
A dose adjustment of STRATTERA may be required when co-administered with CYP2D6 inhibitors, e.g. @DRUG$ , @DRUG$ ==References====External links==	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , calcium-channel blockers , diuretics , and @DRUG$ ( @DRUG$ ) without evidence of clinically significant adverse interactions.	DDI-false
- Non-selective MAO inhibitors including tranylcypromin sulfate, phenylzinsulfate and @DRUG$ HC1 : Concurrent use of L-tyrosine and nonselective @DRUG$ may cause hypertension .	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (CYP3A4 substrate) given for local @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
When LEVSIN is co-administered with other antimuscarinic agents, amantadine, haloperidol, phenothiazines, @DRUG$ , tricyclic antidepressants or something @DRUG$.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following : ergotamine , cyclosporine , @DRUG$ , nicardipine , and nifedipine .	DDI-int
" medicinal products identified as CYP3A inhibitors of potential clinical significance based on clinical trials involving alprazoleam (when co-administered with: @DRUG$ Concomitant use of fluoxetine with @DRUG$ The maximum plasma concentration of alprazoleam increased by 46%, clearance by 21%, half-life by 17% and measured psychomotor performance.	DDI-false
In the present study, the @DRUG$ Clozapine was used in combination with an active dose of @DRUG$ In dual drug discrimination and mixed procedures, signals-unsigned differential enforcement of low rates (DRLs).	DDI-false
Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
The blood pressure effect of SULAR tended to be greater in patients on @DRUG$ than in patients on no other @DRUG$ therapy.	DDI-false
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	DDI-mechanism
Based on the results of these studies, it is concluded that: @DRUG$ may be safely coadministered with both zidovudine and @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Some @DRUG$/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of CYP3A4 (enzyme induction).	DDI-false
@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	DDI-effect
Limited clinical data in angina patients receiving concomitant @DRUG$ and @DRUG$ therapy indicate no discernible changes in serum digoxin levels.	DDI-false
ERYTHROMYCIN : In hypercholesterolemic patients at steady-state @DRUG$ AUC and Cmax increased after 10 days when co-administered with @DRUG$ A known inhibitor of cytochrome P450 3A4.	DDI-mechanism
@DRUG$ In controlled studies of healthy volunteers, @DRUG$ They either had no effect (one study) or were associated with modest increases, approximately 30% (two studies) at steady-state serum digoxin concentrations.	DDI-false
Both ibogaine and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Cardiovasculars : @DRUG$ In patients who: @DRUG$ therapy , administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity .	DDI-false
@DRUG$ The simultaneous use of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite .	DDI-false
@DRUG$ The rate and extent of absorption of ciprofloxacin were bioequivalent if: @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Phenytoin: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	DDI-mechanism
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( warfarin ) , platelet inhibitors ( @DRUG$ ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by @DRUG$ , secobarbital, glutethimide, chloralhydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Two groups (SH/DA; SH/FA) were treated daily with synthetic hydroalcoholic solutions containing ethanol, methanol, higher. @DRUG$ and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages ;	DDI-false
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of @DRUG$.	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations : ( i ) these @DRUG$ showed differential effects on cells ;	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ Increases the effect of tricyclic antidepressants	DDI-false
Because chronic dosage for the therapeutic efficacy of @DRUG$ Future studies should focus on investigating the chronic dose effects of these drugs in combination with @DRUG$.	DDI-false
Oral @DRUG$: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-false
@DRUG$ should be administered with caution to patients receiving Antabuse ( @DRUG$ , Wyeth-Ayerst Laboratories ) .	DDI-advise
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ Prostate epithelium proliferation can be regulated by dose-dependent changes in insulin and @DRUG$ activity.	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$ The efficacy of the warfarin type ( CYP2C9 and CYP3A4 substrate) is almost always observed in patients who: @DRUG$ and can result in serious or fatal bleeding .	DDI-false
There is a significant increase in exposure to @DRUG$ When Gleevec is co-administered with @DRUG$ ( CYP3A4 inhibitor ) .	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Concomitant @DRUG$ , doxorubicin , @DRUG$ , and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
Antiarrhythmics : Amiodarone , @DRUG$ , flecainide , propafenone , @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Oral @DRUG$ : Pharmacokinetic drug-drug interactions between Argatroban and @DRUG$ ( 7.5 mg single oral dose ) have not been demonstrated .	DDI-false
@DRUG$ or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$ ;	DDI-false
@DRUG$-@DRUG$ can antagonize the effect of warfarin	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
The co-administration of medicinal products which are nephrotoxic (e. g. @DRUG$ , indomethacin ) , myelotoxic ( e.g. , @DRUG$ chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems .	DDI-false
Other medicines: medicines such as quinidine, disopyramide, @DRUG$ , @DRUG$ , antihistamines , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
Anticoagulants including coumarin derivatives, indandion derivatives and @DRUG$ - Non-steroidal anti-inflammatory medicinal products (NSAIDs) and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
@DRUG$-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The effects of ruthenium red (@DRUG$) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-effect
@DRUG$: Caution should be used if @DRUG$ is administered concomitantly with methotrexate.	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
Nephrotoxicity following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent @DRUG$ such as furosemide .	DDI-effect
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Similarly dialyzed were phenobarbital, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
@DRUG$/@DRUG$ Triazolam, midazolam CONTRAINDICATES due to the potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-int
The conversion of @DRUG$ to @DRUG$ is catalyzed by aldehyde oxidase.	DDI-false
, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/phenobarbital.	DDI-false
To determine whether injection of thiosulfate would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
; Naproxen : Simultaneous use of @DRUG$ Naproxen in normal subjects had no effect on plasma levels of @DRUG$ However, urinary excretion of naproxene and its glucuronide metabolite was significantly reduced.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., @DRUG$).	DDI-false
Acetaminophen : In normal volunteers , concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50 % increase in plasma levels of @DRUG$.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or CHOP-like regimen (i.e., cyclophosphamide, doxorubicin), @DRUG$ , and Prednisone with @DRUG$ Bleomycin) without antiretroviral therapy.	DDI-false
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
@DRUG$ : @DRUG$ enhances the effect of warfarin .	DDI-effect
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, @DRUG$, tranquilizers).	DDI-false
Ergot Derivatives : Dihydroergotamine , ergonovine , @DRUG$ , @DRUG$ CONTRAINDICATE because of the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasms and ischaemia of extremities and other tissues.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine , and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , @DRUG$ , chloral hydrate and methaqualone have been systematically studied in 16 patients who: @DRUG$ therapy .	DDI-false
@DRUG$-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
@DRUG$ , Methylxanthines and Diuretics : Concomitant treatment with xanthine derivatives , @DRUG$ Diuretics may potentiate a possible hypocalemic effect of beta2-agonists.	DDI-false
Dexamethasone and retinyl acetate also inhibit and stimulate @DRUG$ or @DRUG$-induced proliferation of the prostate epithelium.	DDI-false
@DRUG$-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): @DRUG$ - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some @DRUG$.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ : Potentiation of warfarin-type ( @DRUG$ and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
@DRUG$ - Before taking diphenidol, the emetic response to @DRUG$ in the treatment of poisoning .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine , @DRUG$ Tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ ( MAOI ): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Tolbutamide : In diabetic patients receiving diflunisal and @DRUG$ , no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose .	DDI-false
" medicinal products identified as CYP3A inhibitors of potential clinical significance based on clinical trials involving alprazoleam (when co-administered with: @DRUG$ ): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-false
Anticoagulants : Potentiation of @DRUG$-type ( CYP2C9 and @DRUG$ The substrate) Anticoagulant response is almost always seen in patients receiving amiodarone and can lead to severe or fatal bleeding.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-int
Nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.	DDI-effect
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , @DRUG$ , @DRUG$ , antiemetics, sedatives, sedatives).	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipoid, and @DRUG$ with @DRUG$ Bleomycin) without antiretroviral therapy.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , @DRUG$ , tricyclic antidepressants or some antihistamines.	DDI-effect
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Although studies designed to examine drug interactions have not been done , it was noted that corticosteroid or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients ( N=180 ) receiving @DRUG$.	DDI-false
Ergot Derivatives : @DRUG$ , ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and @DRUG$ (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both @DRUG$ and @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Administration of @DRUG$ concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.	DDI-false
Glyburide : Concomitant use of @DRUG$ with the sulfonylurea @DRUG$ Rare cases have led to severe hypoglycaemia.	DDI-effect
When LEVSIN is co-administered with other antimuscarinic agents, amantadine, haloperidol, @DRUG$ - monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines .	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , @DRUG$ , ritonavir , indinavir , @DRUG$ , erythromycin , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
Garlic capsules Garlic capsules should not be used while taking saquinavir (Fortovase) alone @DRUG$ Because of the risk of decline @DRUG$ plasma concentrations .	DDI-false
@DRUG$ In healthy subjects, the @DRUG$ Systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold control at 200 mg twice daily for 7 days and half-life increased to 1.7-fold control.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban 1.5 g/kg/min for 18 hours).	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Acetaminophen, @DRUG$, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
The toxicity of Filipin as well as the therapeutic value of @DRUG$ (i) these factors can be rationalised at both cellular and molecular level by the following observations: @DRUG$ · showed differential effects on the cells ;	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.	DDI-false
Potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), @DRUG$ supplements , or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
@DRUG$ : Simvastatin ( @DRUG$ The substrate) in combination with amiodarone has been associated with myopathy/rhabdomyolysis reports.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
[Quantitative approach to treatment with incisive @DRUG$ by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with @DRUG$ are illustrated by six typical case reports.	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents ( efavirenz , @DRUG$ or @DRUG$ ) .	DDI-false
@DRUG$ ==References====External links== @DRUG$ Potassium supplements or salt substitutes containing potassium may lead to significant increases in serum potassium.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), erythromycin, @DRUG$.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ Therapeutic therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
Antiarrhythmics : Amiodarone , @DRUG$ , flecainide , @DRUG$ , Chinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and @DRUG$ were coadministered.	DDI-mechanism
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine, and @DRUG$ chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. @DRUG$ , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and digoxin or @DRUG$.	DDI-false
Cholestyramine increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and @DRUG$/2.	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
The steady state plasma concentrations of @DRUG$ and @DRUG$ have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of alprazolam tablets in doses up to 4 mg/day .	DDI-false
These results suggest that both @DRUG$ and @DRUG$ , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF .	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$, and phenytoin during concomitant therapy with @DRUG$.	DDI-false
Suppression by verapamil of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ in wistar rats.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Potassium-sparing diuretics ( e.g. , @DRUG$ , Triamteren or @DRUG$ Potassium supplements or salt substitutes containing potassium may lead to significant increases in serum potassium.	DDI-false
For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with @DRUG$ and a @DRUG$ do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.	DDI-effect
@DRUG$-Concomitant intake of @DRUG$ The absorption of vitamin K can be reduced.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Co-administration : Concomitant use of @DRUG$ Thrombolytics, thrombolytics and others @DRUG$ The risk of bleeding can be increased.	DDI-effect
Amiodarone may suppress certain CYP450 enzymes , including CYP1A2 , @DRUG$ , CYP2D6 and @DRUG$.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by @DRUG$ , secobarbital , @DRUG$ In 16 patients receiving coumarin therapy, chloral hydrate and methaqualone were systematically studied.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and @DRUG$ chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
@DRUG$ should be taken as directed and @DRUG$ should be taken with a main meal of the day, preferably the evening meal..	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
@DRUG$ : The concomitant use of Bepridil and @DRUG$ The treatment was well tolerated in patients with stable angina pectoris.	DDI-false
@DRUG$ ( e.g. , @DRUG$ Potassium supplements or salt substitutes containing potassium may lead to significant increases in serum potassium.	DDI-false
In addition , Fondaparinux neither influenced the pharmacodynamics of @DRUG$ - acetylsalicylic acid, piroxicam and @DRUG$ , nor the pharmacokinetics of digoxin at steady state .	DDI-false
@DRUG$ : @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine .	DDI-false
Physiological oral @DRUG$ The supplementation ( 5 mg/kg/day ) is simple and can be done in the diet or with @DRUG$s, with practically only one contraindication: open kidney failure.	DDI-false
@DRUG$: The concomitant administration of @DRUG$ with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, @DRUG$, and nifedipine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Other Drugs : Drugs such as @DRUG$ , disopyramide , procainamide , @DRUG$ , antihistamines , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ Elevated plasma concentrations may occur when alprazom is co-administered with triazolam. @DRUG$ ;	DDI-mechanism
Both @DRUG$ and @DRUG$ enhance the locomotor and/or stereotypic effects of stimulants.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
In order to evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL ), the authors retrospectively compared a group of 24 patients with HIV-NHL who had been treated with the @DRUG$ , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with @DRUG$ plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
However , if @DRUG$ Treatment with heparin should be initiated after discontinuation of heparin therapy, so that sufficient time is given for the effect of heparin on the aPTT to decrease before starting treatment. @DRUG$ therapy .	DDI-false
Concomitant @DRUG$ , doxorubicin, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-associated non-Hodgkin lymphoma.	DDI-false
@DRUG$ ( e.g. , spironolactone , triamterene , or amiloride ) , potassium supplements , or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Anticoagulants including coumarin derivatives, indandion derivatives and @DRUG$ such as @DRUG$ NSAIDs and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , @DRUG$ , VIDEX chewable/buffer tablets or paediatric powders or products containing calcium, iron or zinc may cause absorption of @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/@DRUG$.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
The benzodiazepines are a family of @DRUG$ and @DRUG$.	DDI-false
The effects of DCG-IV and L-CCG-1 upon @DRUG$ (@DRUG$)-induced movement and behavioural changes in mice.	DDI-false
Interaction on the anticoagulant effect between @DRUG$ and @DRUG$ or tuftsin .	DDI-effect
Data from in vitro studies with benzodiazepines other than: @DRUG$ • suggest a possible interaction with the following medicines: ergotamine, @DRUG$ , amiodarone, nicardipine, and nifedipine.	DDI-int
Guardians of children who have been prescribed @DRUG$ should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of @DRUG$.	DDI-false
Acetaminophen/@DRUG$, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Patients taking @DRUG$ concomitantly with @DRUG$ more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.	DDI-effect
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-false
Naproxen : Concomitant administration of diflunisal and naproxen in normal subjects had no effect on plasma levels of @DRUG$ However, significantly reduces urinary excretion of @DRUG$ and its glucuronide metabolite .	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ ( @DRUG$ Digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Oral @DRUG$ : Coadministration of @DRUG$ AUC values for norethindron and ethinylestradiol were increased by approximately 30% and 20% by oral contraceptives.	DDI-false
Potassium-sparing diuretics ( e.g. , @DRUG$ , triamterene , or amiloride ) , potassium supplements , or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Other Cardiovascular Agents : @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , calcium-blocking agents , hydralazine , @DRUG$ And digoxin without evidence of clinically significant adverse interactions.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The effects of DCG-IV and L-CCG-1 upon @DRUG$ (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
Haemodynamic effects of glucose and @DRUG$ were additive when @DRUG$ was co-administered but not under basal conditions .	DDI-false
Anti-arrhythmics and @DRUG$ could exaggerate the prolongation of the QT interval observed with @DRUG$.	DDI-effect
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
Concomitant @DRUG$, doxorubicin, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/phenobarbital.	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
Co-medications that induce CYP3A4 ( e.g. , dexamethasone , @DRUG$ , carbamazepine , rifampin , @DRUG$ or St.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin, containing multivalent cation products such as magnesium or aluminium antazida, @DRUG$ VIDEX chewable/buffer tablets or paediatric powders or products containing calcium, iron or zinc may significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
BACKGROUND : The effects of combined administration of bombesin and verapamil hydrochloride ( @DRUG$ ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( @DRUG$ ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , @DRUG$ and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
The data from in vitro studies with benzodiazepines other than alprazolam indicate a possible interaction with the following medicinal products: ergotamine, cyclosporin, @DRUG$ , nicardipine, and @DRUG$.	DDI-false
Histamine H2-receptor antagonists: @DRUG$ appear to have no significant effect on the bioavailability of @DRUG$.	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ For the following : sertralin and @DRUG$.	DDI-int
Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
The concomitant intake of @DRUG$ and @DRUG$ does not affect the pharmacokinetics of either alcohol or acamprosate.	DDI-false
Lithium : Lithium toxicity has been reported in patients receiving @DRUG$ Simultaneously with medications that cause the excretion of sodium, including @DRUG$.	DDI-effect
OBJECTIVE : Our goal was to promote the steady-state pharmacokinetics of everolimus and @DRUG$ ( INN , @DRUG$ ) when coadministered in de novo kidney allograft recipients during the first year after transplantation .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The monoamine oxidase inhibits the effect of @DRUG$ This should be taken into account if another medicine is prescribed after @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , @DRUG$ , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$ Including coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin may increase the risk of bleeding when administered at the same time as @DRUG$.	DDI-effect
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ , @DRUG$ , calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as @DRUG$.	DDI-false
Warfarin : @DRUG$ have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives .	DDI-effect
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus, cyclosporin, @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Monitoring for @DRUG$ toxicity and serial measurement of @DRUG$ Serum concentration should be considered during concomitant therapy with protease inhibitors.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , nicardipine , and @DRUG$.	DDI-int
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
♪ Drugs that can change ♪ @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , @DRUG$ , itraconazole , erythromycin , clarithromycin ) .	DDI-false
@DRUG$ (@DRUG$) produces psychotomimetic effects in humans that resemble schizophrenia symptoms.	DDI-false
==References====External links== @DRUG$ , @DRUG$ In vitro inhibition of platelet activation and decrease of platelet adhesion intravascular.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , @DRUG$ , quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ : Amiodarone , bepridil , flecainide , propafenone , @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
However, if @DRUG$ is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.	DDI-false
Therefore , interactions could occur following concomitant administration of @DRUG$ ( e.g. , @DRUG$ , analgesics, antiemetics, sedatives, sedatives.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-int
The risk of myopathy during treatment with medicines in this class is associated with the use of @DRUG$ , fibrous acid derivatives, niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone , they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
@DRUG$ - prior ingestion of @DRUG$ may decrease the emetic response to apomorphine in the treatment of poisoning.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ : @DRUG$ Impairs renal tubular secretion of ciprofloxacin and leads to an increase in serum ciprofloxacin levels.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
In clinical studies performed with @DRUG$ , the concomitant use of oral anticoagulants ( @DRUG$ ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
@DRUG$-@DRUG$ The intestine can sterilize and reduce the vitamin K contribution to the body through the intestinal microflora.	DDI-false
Cardiovasculars: @DRUG$: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Physiological oral @DRUG$ Load provides the best tool for diagnosing @DRUG$ deficiency and the first step of its treatment .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The use of local anesthetics containing epinephrine, or @DRUG$ Patients receiving monoamine oxidase inhibitors, @DRUG$ Or phenothiazines can cause severe, prolonged hypotension or hypertension.	DDI-effect
The data suggest that: @DRUG$ It has a narrower range of effects and will have a much larger therapeutic index than @DRUG$.	DDI-false
In EM individuals treated with paroxetine or @DRUG$, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
Acetaminophen , @DRUG$ , @DRUG$ , quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Anticoagulants such as coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as non-steroidal anti-inflammatory drugs ( @DRUG$ ) , and @DRUG$ The risk of bleeding may be increased when co-administered with ardeparin.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and @DRUG$.	DDI-false
Patients taking @DRUG$ concomitantly with @DRUG$ More commonly reported both weight gain and weight loss, compared to patients taking either medication alone.	DDI-effect
@DRUG$-Concomitant intake of mineral oil and @DRUG$ The absorption of vitamin K can be reduced.	DDI-false
@DRUG$: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	DDI-false
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , @DRUG$ , antiemetics , @DRUG$ , tranquilizers ) .	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ , nitrates, calcium blockers, hydralacin, @DRUG$ and digoxin without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$ Lithium toxicity has been reported in patients receiving lithium concomitantly with medicines that cause sodium excretion, including @DRUG$.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
Concomitant oral administration of @DRUG$ A known inhibitor of CYP3A4 activity in the liver and intestinal mucosa caused an eightfold increase in systemic exposure to oral @DRUG$.	DDI-mechanism
@DRUG$, @DRUG$, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
- Mineral oil compositional intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
How ibogain ( 40 mg/kg ) reduces intravenous self-injection of 18-MC ( 40 mg/kg ) @DRUG$ and cocaine and the oral self-administration of ethanol and @DRUG$ in rats ;	DDI-false
] METHOD : This study was a multicentre randomized double-blind study in 101 patients randomly receiving 1:1:1. @DRUG$ Tablets at doses of 0.5 mg, 1 mg or 2 mg twice daily with cyclosporin and @DRUG$.	DDI-false
Erythromycin : In healthy individuals , plasma concentrations of @DRUG$ increased approximately 40 % with coadministration of @DRUG$ Erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ ( 162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban 1.5 g/kg/min for 18 hours).	DDI-false
Both the toxicity of filipin and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
Since @DRUG$ is a substrate for CYP3A4 , there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
In addition , Fondaparinux neither influenced the pharmacodynamics of @DRUG$ , acetylsalicylic acid , @DRUG$ The pharmacokinetics of digoxin in steady state.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without reception @DRUG$ therapy .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/@DRUG$.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as @DRUG$ , @DRUG$ ==References====External links==	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin, containing multivalent cationic products such as magnesium or aluminium antacids, sucralfate, VIDEX chewable/buffer tablets or paediatric powders, or products containing calcium, iron or zinc may be used to absorb: @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-false
The aim of this paper was to investigate the interaction between neurotensin and both enkephalins or its synthetic analogues. @DRUG$ , or @DRUG$ To the antinonciceptive effect of these peptides in mice after intracistern injection.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, @DRUG$ - chewable/buffered tablets or pediatric powders or products which: @DRUG$ , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Effect of @DRUG$ on the pharmacokinetics of @DRUG$.	DDI-false
Amiodarone may suppress certain CYP450 enzymes , including @DRUG$ , CYP2C9 , CYP2D6 , and @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ have been reported to decrease the tubular secretion of @DRUG$ and to potentiate its toxicity.	DDI-mechanism
Concomitant administration of alcohol and acamprosate does not affect the pharmacokinetics of @DRUG$ or @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients with receptor blockers (e.g. propranolol, @DRUG$ Inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Limited comparative data in patients with high viral loads treated with @DRUG$- or @DRUG$-based regimens currently exist.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporine , ergot derivatives , @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
No data are available for the coadministration of INVIRASE/@DRUG$ or @DRUG$/ritonavir and garlic capsules.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other CONCOMITANT THERAPY: Although specific interaction studies have not been performed, in clinical studies cerivastatin sodium was used together with angiotensin converting enzyme ( ACE) inhibitors, beta-blockers, @DRUG$ , @DRUG$ , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$ Retinyl acetate also inhibits and stimulates EGF or @DRUG$-induced prostatic epithelium proliferation.	DDI-effect
The effect of @DRUG$ on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal .	DDI-effect
acetaminophen/theophylline , lidocaine/@DRUG$ , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
The superiority of @DRUG$ over @DRUG$-based regimens has been observed in comparative data in a subset of patients with high viral loads.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide , quinine , @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Drug interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupentixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : @DRUG$ Increases the effect of tricyclic antidepressants	DDI-false
As Ibogain ( 40 mg/kg ), 18-MC ( 40 mg/kg ) reduces intravenous self-administration of morphine and @DRUG$ The oral self-administration of ethanol and @DRUG$ in rats ;	DDI-false
FLEXERIL may enhance the effects of @DRUG$, barbiturates, and other @DRUG$.	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and @DRUG$.	DDI-false
Concomitant administration of other @DRUG$ may potentiate the undesirable effects of @DRUG$.	DDI-effect
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Acetaminophen, @DRUG$, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Lithium: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-effect
Antiarrhythmia: amiodarone, @DRUG$ , @DRUG$ , propafenone, quinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, @DRUG$ , VIDEX chewable/buffered tablets or pediatric powder , or products containing @DRUG$ Iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-false
Cyclosporine : Administration of @DRUG$ concomitantly with @DRUG$ The effect of cyclosporin has been associated with an increase in the toxicity caused by cyclosporin, possibly due to decreased synthesis of renal prostacycline.	DDI-mechanism
acetaminophen/theophylline , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ • Lack due to insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation .	DDI-false
Concomitant @DRUG$, doxorubicin, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-false
Drug Interactions : @DRUG$ This may be associated with some medicines such as monoamine oxidase inhibitors ( @DRUG$ MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-int
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Sinus bradycardia has been reported with oral @DRUG$ in combination with @DRUG$ (CYP3A4 substrate) given for local anesthesia.	DDI-false
@DRUG$ as potent @DRUG$ "Excretion of the glucocorticoid-induced mouse mammary tumor virus gene.	DDI-false
@DRUG$ Patients receiving @DRUG$ should not receive glutethimide treatment.	DDI-advise
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
@DRUG$ : The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite .	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Other reported interactions with @DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Earlier studies showed a significant reduction in oral bioavailability of @DRUG$ Ciprofloxacin is co-administered with an intravenous opiate such as @DRUG$.	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , fibric acid derivatives , @DRUG$ ( nicotinic acid ) , @DRUG$ , azole antifungals .	DDI-false
Sine bradycardia was treated with oral @DRUG$ In combination with lidocaine ( CYP3A4 substrate ) for local @DRUG$.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
HMG-CoA reductase inhibitors: @DRUG$ ( CYP3A4 substrate ) in combination with @DRUG$ It has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
@DRUG$ .Renal tube transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin , potentially leading to increased plasma levels of methotrexate .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
The @DRUG$ are a family of @DRUG$ and hypnotic drugs.	DDI-false
In vitro studies have shown that precipitation occurs when eye drops containing @DRUG$ The mixture is done with @DRUG$.	DDI-false
Therefore, if Meclofenamate sodium is given to a patient who: @DRUG$ , the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( @DRUG$ ), NSAIDs ( @DRUG$ ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
• Concomitant use of @DRUG$ The pharmacokinetics of acamprosate and acamprosate have no effect on the pharmacokinetics of @DRUG$ or acamprosate .	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
@DRUG$ Incorporating tranylcypromin sulfate, phenolic acid sulfate and @DRUG$ HC1 : Concurrent use of L-tyrosine and non-selective MAO inhibitors may lead to high blood pressure.	DDI-false
, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Oral @DRUG$ : Pharmacokinetic drug-drug interactions between @DRUG$ and warfarin ( 7.5 mg single oral dose ) have not been demonstrated .	DDI-false
Corticosteroids , @DRUG$ and @DRUG$ : Concomitant treatment with xanthine derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
Administration of rifampin with oral @DRUG$ has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone .	DDI-false
There was no significant difference ( p > 0.05 ) in AUC ( 48.59 + /- 8.52 vs. 49.9 + /- 9.93), Cmax ( 7.73 + /- 2.6 vs. 6.6 + /- 2.0 ) and tmax ( 1.1 + /- 0.6 vs. 1.6 + /- 1.1 ) for levofloxacin compared to @DRUG$/@DRUG$ regimens .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens with sequentially high-dose PROLEUKIN and antineoplastic agents, especially dacarbazine, cis-platinum. @DRUG$ and @DRUG$.	DDI-false
@DRUG$ : Caution should be used if diflunisal is administered concomitantly with @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Slow-channel calcium blockers , such as verapamil , @DRUG$ and @DRUG$ , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Agents Causing Renin Release : The antihypertensive effect of @DRUG$ and @DRUG$ IV is augmented by antihypertensive agents that cause renin release ( e.g. , diuretics ) .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ MAOI may theoretically influence flupentixol pharmacodynamics - @DRUG$ Eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupenthixol increases the effect of tricyclic antidepressants	DDI-false
Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$ showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , @DRUG$ , haloperidol , phenothiazines , @DRUG$ , tricyclic antidepressants or some antihistamines .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , alfentanyl, alprazoleam, and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of enalapril may result in a further deterioration of renal function.	DDI-false
@DRUG$ diminished the binding of @DRUG$ to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.	DDI-mechanism
Coingestion of acetaminophen with theophylline, @DRUG$ with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$ has been shown to be antagonistic to beta-lactam antibiotics , including @DRUG$ , based on in vitro studies and time kill curves with enteric gram-negative bacilli .	DDI-effect
@DRUG$ In diabetics, the diflunisal and @DRUG$ , no significant effects were seen on tolbutamide plasma levels or fasting blood glucose .	DDI-false
Since the concomitant use of @DRUG$ with amiodarone increases the prothrombin time by 100 % after 3 to 4 days , the dose of the @DRUG$ should be reduced by one-third to one-half , and prothrombin times should be monitored closely .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime, cefoperazone), @DRUG$ , cefamandole , @DRUG$ ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
@DRUG$ is the first @DRUG$ To be approved for clinical use, and has been studied extensively in humans since 1986.	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ ( a @DRUG$ ) and ethanol found under acidic conditions similar to in vivo, resulting in a 3-ethoxylated product.	DDI-false
Potassium-sparing diuretics ( e.g. , spironolactone , triamterene , or @DRUG$ ) , @DRUG$ supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
@DRUG$: The concomitant use of @DRUG$ and beta-blocking agents has been well tolerated in patients with stable angina.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
• Concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, indomethacin), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. @DRUG$ ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with @DRUG$ may increase toxicity in these organ systems .	DDI-effect
Therefore, interactions after concomitant use of @DRUG$ - narcotics, analgesics, antiemetics, sedatives, @DRUG$ ) .	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before dinner and 0.3 mg @DRUG$ About 4 hours after the same evening meal, cerivastatin AUC decreased by less than 8% and Cmax decreased by about 30% compared to the dose of cerivastatin sodium alone.	DDI-mechanism
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving @DRUG$ therapy.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and @DRUG$.	DDI-advise
@DRUG$ , @DRUG$ Azole is known to cause QTc prolongation.	DDI-false
Particular caution is recommended when administering @DRUG$ CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporin or @DRUG$ ) .	DDI-advise
These results suggest that both @DRUG$ and retinyl acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF .	DDI-effect
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission ( e.g. , curare-like compounds ) should only be performed with caution as the effect of the @DRUG$ It can be potentiated.	DDI-false
Medicines detected as CYP3A inhibitors of a possible clinical significance based on clinical trials involving alprazoleam ( Caution is recommended when co-administered with alprazoleam): @DRUG$ with @DRUG$ increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-mechanism
@DRUG$ and procainamide doses should be reduced by one-third when either is administered with @DRUG$.	DDI-false
It differs structurally from the other currently available @DRUG$ ( lovastatin , @DRUG$ , and pravastatin), resulting in unique biopharmaceutical properties compared to the other active substances of this class.	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as @DRUG$ , Spironolacton, and @DRUG$.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , @DRUG$ , glutethimide, chloralhydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Lack of an effect of @DRUG$ on the disposition of zidovudine and @DRUG$ in HIV-infected patients.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-int
It is assumed that increased interaction between @DRUG$ The antipsychotic effect of dopamine2 and serotonin2 receptors and high affinity binding sites for apomorphine @DRUG$ after their prolonged administration .	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$ , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
The effects of @DRUG$ (RR) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both @DRUG$ and dideoxyinosine.	DDI-false
Omeprazole : The rate and extent of absorption of @DRUG$ was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion .	DDI-false
@DRUG$ The simultaneous use of @DRUG$ with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
METHOD : This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg , 1 mg , or 2 mg twice daily with @DRUG$ and prednisone .	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as @DRUG$ Procainamide, cardiac glycosides and @DRUG$.	DDI-false
@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55 % and 33 % , respectively .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$ This is inhibited by @DRUG$.	DDI-mechanism
The risk of myopathy during treatment with medicines in this class is increased when cyclosporin is co-administered. @DRUG$ Niacin (nicotinic acid), @DRUG$ Azol Antimycotics.	DDI-false
Oral contraceptives: concomitant use of @DRUG$ and an oral @DRUG$ AUC values for norethindron and ethinylestradiol were increased by approximately 30% and 20%.	DDI-mechanism
Omeprazole : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion .	DDI-false
Colestipol-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Medicines that may alter the plasma concentration of imatinib Drugs that may increase the plasma concentration of imatinib @DRUG$ Plasma concentrations : Caution recommended for use @DRUG$ with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , erythromycin , clarithromycin ) .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
It was shown that @DRUG$ antagonized evidently the antinociceptive effect of @DRUG$ and their analogue.	DDI-effect
@DRUG$ and @DRUG$ : FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents .	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
Slow-channel calcium blockers, such as @DRUG$, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , @DRUG$ Sedativa and Sedativa (incl. @DRUG$ ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
@DRUG$ is a neutralizing agent for @DRUG$ that protects against renal damage.	DDI-effect
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Multivalent Cation-Containing Products : Simultaneous Application of a @DRUG$ , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
In view of the long and variable half-life of @DRUG$, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of @DRUG$.	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were used together with beta-adrenergic blockers, methyldopa, nitrates, @DRUG$ , @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (@DRUG$), erythromycin, azole antifungals.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , @DRUG$ Cefotetan, cefamandol, latamoxef) or methylthiadiazole ( @DRUG$ ) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Longitudinal assessment of @DRUG$ in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Acetaminophen , @DRUG$ , phenobarbital , @DRUG$ Theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Both ibogaine and @DRUG$ block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
However , in the second study , administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8 % , and a decrease in Cmax of about 30 % when compared to dosing @DRUG$ alone .	DDI-false
@DRUG$: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for @DRUG$ versus levofloxacin/@DRUG$ regimens.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ (e. g. cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors , 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors , sodium channels , and the 5-HT transporter .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/@DRUG$, and valproic acid/phenobarbital.	DDI-false
@DRUG$: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , @DRUG$ , teniposide, and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
@DRUG$ produced distinctive effects in each task: it substituted for the training dose in @DRUG$ discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.	DDI-false
Similarly dialyzed were @DRUG$, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, sedatives, @DRUG$).	DDI-false
@DRUG$ including tranylcypromine sulfate , phenelzine sulfate , and pargyline HC1 : Concomitant use of @DRUG$ Non-selective MAO inhibitors can lead to hypertension.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Since the concomitant administration of @DRUG$ with @DRUG$ increases the prothrombin time by 100 % after 3 to 4 days , the dose of the anticoagulant should be reduced by one-third to one-half , and prothrombin times should be monitored closely .	DDI-false
@DRUG$-@DRUG$ may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.	DDI-false
Among the @DRUG$ , many , like @DRUG$ , can not be used clinically because they are toxic ;	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors ( @DRUG$ ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion .	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$ Hypnotics and sedatives (including @DRUG$ The use of placebo with these concomitant drugs was similar to that of subjects who used placebo (e. g., non-opioid analgesics).	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Concomitant cyclophosphamide , @DRUG$ , vincristine , and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced @DRUG$ levels.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/@DRUG$, phenobarbital/ valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$ The effect of antihypertensive agents may increase slightly, e.g., @DRUG$ , methyldopa , reserpine .	DDI-effect
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Aspirin : In normal volunteers , a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
C-cephalosporins containing side chains of N-methylthiotetrazole (Cefmenoxime), @DRUG$ , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
@DRUG$: Amiodarone, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
@DRUG$ and methaqualone interact pharmacologically with orally administered @DRUG$ , but the effect is not clinically significant .	DDI-int
Digoxin: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
Therefore, when @DRUG$ is given to a patient receiving @DRUG$, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-advise
@DRUG$ diminished binding of @DRUG$ by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.	DDI-mechanism
Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Concomitant cyclophosphamide, @DRUG$, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or @DRUG$).	DDI-false
This effect can be mediated by the ability to @DRUG$ It is used to induce microsomal enzymes and thus the catabolism of @DRUG$.	DDI-mechanism
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Potassium-sparing diuretics ( e.g. , spironolactone , @DRUG$ Potassium supplements or salt substitutes containing @DRUG$ may lead to significant increases in serum potassium.	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and cimetidine.	DDI-advise
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
Chloramphenicol has been shown to be antagonistic to @DRUG$, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-false
@DRUG$ In healthy subjects receiving the CYP3A4 inducer, @DRUG$ , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days , systemic exposure ( AUC ) to lapatinib was decreased approximately 72 % .	DDI-false
Other medicines: medicines such as quinidine, @DRUG$ , procainamide , @DRUG$ , antihistamines , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
FLEXERIL may enhance the effects of alcohol, @DRUG$, and other @DRUG$.	DDI-false
Observations from drug interaction studies with @DRUG$ may not be predictive for @DRUG$.	DDI-false
The effects of ruthenium red (RR) on @DRUG$ (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Some drugs/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Orlistat-@DRUG$ may decrease the absorption of @DRUG$.	DDI-mechanism
Blood sampling for the pharmacokinetics of @DRUG$ and @DRUG$ was performed on day 1 , on weeks 1 , 2 , 3 , and 4 , and on months 2 , 3 , 6 , 9 , and 12 .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , @DRUG$ ), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. @DRUG$ Asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
BACKGROUND : The effects of combined administration of bombesin and verapamil hydrochloride ( @DRUG$ ) , a @DRUG$ , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$ , specifically , @DRUG$ , cis-platinum, tamoxifen and interferon alpha.	DDI-false
@DRUG$: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Since chronic dosing is required for therapeutic efficacy of @DRUG$, future studies should focus on investigation of chronic dosing effects of these drugs in combination with @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ and @DRUG$ similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	DDI-false
@DRUG$: Caution should be used if diflunisal is administered concomitantly with @DRUG$.	DDI-false
Co-medicines that induce CYP3A4 (e.g. dexamethasone, phenytoin, @DRUG$ , @DRUG$ , phenobarbital or St.	DDI-false
@DRUG$ : In normal volunteers , a small decrease in @DRUG$ Concentrations were observed when multiple doses of diflunisal and aspirin were administered concomitantly.	DDI-false
Observations from drug interaction studies with @DRUG$ may not be predictive for @DRUG$.	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Co-administration: Concomitant use of @DRUG$ with @DRUG$, thrombolytics, and other anticoagulants may increase the risk of bleeding.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Caution should be exercised if an @DRUG$ • co-administered with medicinal products that may reduce the concentration or activity of endogenous steroid hormones such as ketoconazole, @DRUG$ , and cimetidine .	DDI-advise
Other reported interactions with @DRUG$: Fentanyl (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
"Ergot derivatives: dihydroergotamine, @DRUG$ , @DRUG$ , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$ and @DRUG$.	DDI-false
It is structurally distinct from the other currently available @DRUG$ (lovastatin, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
The authors investigated the possibility of a similar interaction between @DRUG$ and @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ (but not aspirin): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	DDI-false
@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-false
@DRUG$ : Quinolones have been reported to enhance the effects of the oral anticoagulant @DRUG$ ==References==<br>	DDI-false
@DRUG$: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$-Concomitant intake of @DRUG$ The absorption of vitamin K can be reduced.	DDI-false
In the present study , the atypical antipsychotic @DRUG$ was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates ( DRL ) procedures .	DDI-false
Treatment with CYP3A4 inhibitors (e.g. @DRUG$ , intraconazole, ritonavir, indinavir, @DRUG$ , erythromycin, etc.) is indicated, reduction of budesonide dose should be considered.	DDI-false
Co-administration: Concomitant use of Argatroban with antiplatelet agents, @DRUG$, and other @DRUG$ may increase the risk of bleeding.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Prostatic epithelial proliferate in a defined medium, consisting of basal medium RPMI1640, containing: @DRUG$ ( 1 micrograms/ ml ), EGF ( 10 ng/ ml ) and @DRUG$ [ 3.7 micrograms/ ml or 0.1 IU/ ml].	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ , amiodarone , quinidine , @DRUG$ Tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
The administration of local anesthetic solutions containing @DRUG$ - Nonepinephrine in patients who: @DRUG$ , tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Data from in vitro studies of @DRUG$ other than @DRUG$ suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-advise
Aspirin/@DRUG$ : Pharmacokinetic or pharmacodynamic drug interactions between argatroban and co-administered aspirin (162.5 mg orally administered 26 and 2 hours before starting argatroban 1 g/kg/min over 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before starting and 6 and 12 hours after starting argatroban @DRUG$ 1.5   g/kg/min . over 18 hours ) .	DDI-false
Like @DRUG$ ( 40 mg/kg ) , @DRUG$ 40 mg/kg) decreases intravenous self-administration of morphine and cocaine and oral self-administration of ethanol and nicotine in rats;	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants : @DRUG$ In patients treated with monoamine oxidase inhibitors or tricyclic antidepressants, the use should be carried out with extreme caution as the effect of @DRUG$ On the cardiovascular system can be potentiated by these active substances.	DDI-false
Concurrent administration of @DRUG$ (for the treatment of hypotension related to obstetric blocks) and @DRUG$ may cause severe, persistent hypertension or cerebrovascular accidents.	DDI-effect
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ Antacids or aluminium antacids, sucralfate, VIDEX chewable/buffer tablets or pediatric powder or products containing calcium, iron or zinc may be used to absorb: @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
There have been case reports of increased steady-state levels of @DRUG$ , procainamide , and phenytoin during concomitant therapy with @DRUG$.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
It is assumed that increased interaction between @DRUG$ And high affinity binding places for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( @DRUG$ Digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
In addition, we have shown that @DRUG$ is a useful pharmacological tool with which to examine the @DRUG$-mediated responses of megakaryocytes .	DDI-false
Drug interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
In general, these drugs have one or more pharmacological activities, similar to bepridil hydrochloride, including antiarrhythmics such as quinidine and @DRUG$ , cardiac glycosides and @DRUG$.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The initiation of @DRUG$ or @DRUG$ The use can be triggered by similar personality traits of the user, such as impulsiveness and search for sensations.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
injection of @DRUG$ (@DRUG$) were observed by measuring locomotor activity and stereotyped behavior.	DDI-false
@DRUG$/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Gleevec increases plasma concentrations of other CYP3A4 metabolised medicinal products (e.g. triazolobenzodiazepines, @DRUG$ , certain @DRUG$ , etc . ) .	DDI-false
Ibogain as well as 18-MC block @DRUG$-induced and @DRUG$-induced dopamine release in nucleus accumbens;	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Similarly dialyzed were @DRUG$ , @DRUG$ , and theophylline , both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum .	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , @DRUG$ , niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Concomitant cyclophosphamide , @DRUG$ , @DRUG$ , and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ And prednisone with vincristine plus @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$ , etc . ) is indicated , reduction of the @DRUG$ dose should be considered .	DDI-advise
♪ Drugs that can change ♪ @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , erythromycin , @DRUG$ ) .	DDI-false
No significant interactions were found between nisoldipine and @DRUG$ or @DRUG$.	DDI-false
Slow-channel calcium blockers, such as @DRUG$, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Similarly dialyzed were @DRUG$ , quinidine , and @DRUG$ , both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum .	DDI-false
• Corticosteroids, methylxanthine and diuretics: concomitant treatment with xanthine derivatives, steroids or @DRUG$ A possible hypocalemic effect of @DRUG$	DDI-effect
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of Gleevec, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazoam and triazolam may have increased plasma concentrations if combined with @DRUG$ ;	DDI-mechanism
Omeprazole : The rate and extent of absorption of @DRUG$ • Proquin XR was administered alone or if Proquin XR was administered 2 hours after @DRUG$ At the dose that suppresses gastric acid secretion maximum.	DDI-false
ANTACID (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$ may increase sensitivity to the @DRUG$.	DDI-effect
Concurrent use with @DRUG$ Significant elimination by active renal tubular secretion may lead to increased plasma concentrations of @DRUG$.	DDI-mechanism
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-mechanism
Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , calcium-channel blockers , @DRUG$ , and @DRUG$ ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ * Ergotamine, cyclosporin, amiodarone, nicardipine and @DRUG$.	DDI-int
Hypersensitivity reactions have been reported in patients receiving combination regimens containing a high sequential dose. @DRUG$ and antineoplastic agents , specifically , @DRUG$ , cis-platinum , tamoxifen and interferon-alfa .	DDI-effect
In addition, fondaparinux did not affect the pharmacodynamics of warfarin, @DRUG$ , piroxicam, and @DRUG$ , nor the pharmacokinetics of digoxin at steady state .	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ Patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazine may experience severe, prolonged hypotension or hypertension.	DDI-false
No data are available for the coadministration of INVIRASE/@DRUG$ or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, @DRUG$, clarithromycin).	DDI-false
Beta-blocking Agents : The concomitant use of @DRUG$ and @DRUG$ The treatment was well tolerated in patients with stable angina pectoris.	DDI-false
In addition to the above interactions, the chronic (2 weeks) oral administration of Cordaron affects the metabolism of @DRUG$ , @DRUG$ , and methotrexate .	DDI-false
acetaminophen/theophylline , @DRUG$/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
In the first study, the co-administration of 0.2 mg @DRUG$ and 12 g @DRUG$ This resulted in a decrease in AUC of more than 22% and Cmax of 40% compared to the dose of cerivastatin sodium alone.	DDI-mechanism
Acetaminophen/@DRUG$, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate , phenelzine sulfate , and @DRUG$ HC1 : Simultaneous application of @DRUG$ and non-selective MAO inhibitors may cause hypertension .	DDI-false
Antagonism between @DRUG$ and @DRUG$ In vitro has been shown.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Orlistat-@DRUG$ may decrease the absorption of @DRUG$.	DDI-mechanism
In addition , @DRUG$ Neither influences the pharmacodynamics of warfarin, @DRUG$ , piroxicam, and digoxin, and the pharmacokinetics of digoxin in steady state.	DDI-false
Monitoring for amiodarone toxicity and serial measurement of @DRUG$ serum concentration during concomitant @DRUG$ therapy should be considered.	DDI-advise
Possible drug interactions of: @DRUG$ With succinylcholine or with other @DRUG$.	DDI-int
However , if Argatroban is to be initiated after cessation of @DRUG$ Treatment, sufficient time for heparin effect on the aPTT to @DRUG$ therapy .	DDI-false
@DRUG$ should not be used as a substitute for oral or inhaled @DRUG$.	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of @DRUG$ (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of @DRUG$ (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
Oral @DRUG$: Pharmacokinetic drug-drug interactions between Argatroban and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or @DRUG$.	DDI-false
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-effect
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/Phenobarbital.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients with receptor blockers (e.g. propranolol, @DRUG$ Inhibitor) or calcium channel antagonists (e.g. @DRUG$ , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and @DRUG$ were coadministered.	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and @DRUG$ with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
The effects of the simultaneous @DRUG$ administration on the steady-state pharmacokinetics of @DRUG$.	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ ( Piroxicam ) and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Both @DRUG$ The extracellular dopamine levels in the nucleus accumbens and 18-MC decrease, but only @DRUG$ Elevates extracellular serotonin levels in the nucleus accumbens.	DDI-false
CYP2D6 inhibitors - @DRUG$ is primarily metabolized by the CYP2D6 pathway to @DRUG$.	DDI-false
Pharmacokinetic or pharmacodynamic drug interactions between argatroban and co-administered aspirin (162.5 mg orally administered 26 and 2 hours prior to treatment) have not been demonstrated. @DRUG$ 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban 1.5 g/kg/min for 18 hours).	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
Therefore, it would be expected that a dosage regimen of @DRUG$ Given before the Lord's Supper and given cholestyramine would not lead to a significant decrease in the clinical effect of @DRUG$.	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
omeprazole : The rate and extent of absorption of @DRUG$ If Proquin XR was given alone or if: @DRUG$ 2 hours after administration of omeprazole at the dose that suppresses gastric acid secretion maximum.	DDI-false
Oral @DRUG$: Pharmacokinetic drug-drug interactions between @DRUG$ and warfarin (7.5 mg single oral dose) have not been demonstrated.	DDI-false
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume @DRUG$ and @DRUG$ on a regular basis.	DDI-mechanism
Drug interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): @DRUG$ - Arecolin - eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : @DRUG$ Increases the effect of tricyclic antidepressants	DDI-false
Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving @DRUG$ and @DRUG$ concurrently.	DDI-effect
@DRUG$-@DRUG$ in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-mechanism
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and @DRUG$, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
The risk of myopathy during treatment with medicines in this class is increased with concomitant administration of cyclosporin, fibric acid derivatives, @DRUG$ ( nicotinic acid ) , erythromycin , @DRUG$.	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Phenytoin : altered serum levels of @DRUG$ ( increased and decreased ) have been reported in patients receiving concomitant @DRUG$.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with @DRUG$ , methyldopa, nitrates, calcium blockers, hydralacin, prazosin and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-false
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, indomethacin) is myelotoxic (e.g. @DRUG$ chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. methotrexate, @DRUG$ Effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The @DRUG$ are a family of anxiolytic and @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Then, the effects of the metabotropic glutamate receptor (mGluR ) agonists, @DRUG$ and L-CCG-1 , on the above behavioral changes induced by @DRUG$ were found .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Treatment with CYP3A4 inhibitors (such as ketoconazole, @DRUG$ , ritonavir , @DRUG$ , saquinavir , erythromycin , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
@DRUG$: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
While @DRUG$ Ibogain has similar affinities for kappa opioid and possibly nicotinic acid receptors, @DRUG$ The affinities for NMDA and Sigma-2 receptors, sodium channels and 5-HT transporters are significantly lower than ibogain.	DDI-false
BACKGROUND : The effects of combined administration of @DRUG$ Verapamil hydrochloride (Verapamil), a calcium channel blocker, about the incidence of peritoneal metastases of intestinal adenocarcinoma induced by @DRUG$ ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Oral Contraceptives : Coadministration of atorvastatin and an oral @DRUG$ Elevated AUC values for @DRUG$ and ethinyl estradiol by approximately 30 % and 20 % .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
@DRUG$ increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and t1/2.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), @DRUG$ (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (@DRUG$ substrate) given for local anesthesia.	DDI-false
Potential differences in @DRUG$ dosing and pharmacokinetics at different levels of @DRUG$ exposure were assessed in the context of ANOVA.	DDI-false
The zidovudine study dosed subjects with 1200 mg/day of @DRUG$ ( n = 7 ) ( later changed to 600 mg/day [ n = 5 ] ) for Days 8 to 21 of a 21-day course of 100 mg , five times/day of @DRUG$.	DDI-false
@DRUG$ , lidocaine , phenobarbital , quinidine , @DRUG$ , and valproic acid were added to pooled human serum at therapeutic concentrations .	DDI-false
BACKGROUND : The effects of combined administration of @DRUG$ and @DRUG$ ( verapamil ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
@DRUG$ ( @DRUG$ Cerivastatin plasma concentrations were not affected by concomitant administration of antacids.	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine, and @DRUG$ chemotherapy therapy plus HAART with a group of 80 patients treated with CHOP chemotherapy or with a CHOP-like regimen (e.g. cyclophosphamide, doxorubicin, tenipide), and @DRUG$ • with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
It is important that patients understand how to @DRUG$   ( @DRUG$ ) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking .	DDI-false
Data from in vitro studies of @DRUG$ Other than alprazolem, a possible interaction may be proposed for the following medicinal products: ergotamine, cyclosporin, amiodarone, @DRUG$ , and nifedipine .	DDI-int
@DRUG$ had no significant effect on @DRUG$ pharmacokinetics.	DDI-false
The co-administration of medicinal products which are nephrotoxic (e. g. @DRUG$ , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , @DRUG$ Asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone , they modify the mitogenic effect of @DRUG$ and insulin .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ ; co-management of @DRUG$ Compared to the concomitant use of warfarin and placebo, the administration of cerivastatin in healthy volunteers did not lead to changes in prothrombin time or coagulation factor VII.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , @DRUG$ , @DRUG$ , and phenytoin , have been used concurrently with amiodarone .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
ANTACID (magnesium-aluminium hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
@DRUG$ also significantly decreased the incidence of lymphatic invasion of adenocarcinomas , which was enhanced by @DRUG$.	DDI-effect
It has been reported that tricyclic antidepressants dull the blood pressure lowering effect of systemic @DRUG$. @DRUG$ in humans can lead to resulting interference with the IOP lowering effect .	DDI-false
Plasma levels of @DRUG$ have been reported to increase in the presence of oral @DRUG$;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Other reported interactions with @DRUG$ Fentanyl ( CYP3A4 substrate) in combination with @DRUG$ For this reason, hypotension, bradycardia, and reduced cardiac output may occur.	DDI-false
@DRUG$ The hyperuric effect of @DRUG$ decreased.	DDI-effect
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( @DRUG$ ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
• Lack of an effect of @DRUG$ For the disposition of zidovudine and @DRUG$ In HIV-infected patients.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffer tablets or child powder, or products that can significantly reduce calcium, iron or zinc absorption of @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with @DRUG$ , methyldopa , nitrates , @DRUG$ , hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Atromide-S can be acidic medicines such as @DRUG$ or @DRUG$ From their binding sites.	DDI-false
@DRUG$ : Because atorvastatin does not affect the pharmacokinetics of antipyrine , interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected .	DDI-false
@DRUG$ does not affect serum @DRUG$ levels.	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with @DRUG$ , @DRUG$ , nitrates , calcium-blocking agents , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
When LEVSIN is co-administered with other antimuscarinic agents, amantadine, haloperidol, @DRUG$ , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some @DRUG$.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , @DRUG$ ), beta blockers, @DRUG$ , diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$).	DDI-false
Co-administration of phenytoin with 40 mg @DRUG$ tablets in epileptic patients lowered the @DRUG$ Plasma concentrations up to undetectable concentrations.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide and prednisone with vincristine plus). @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium .	DDI-effect
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Therefore, interactions following concomitant administration of psychotropic medicinal products (e.g. narcotics, analgesics, @DRUG$ , @DRUG$ , tranquilizers ) .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
In addition , @DRUG$ neither influenced the pharmacodynamics of warfarin , acetylsalicylic acid , piroxicam , and digoxin , nor the pharmacokinetics of @DRUG$ at steady state .	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
@DRUG$ Co-administration of procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55 % and 33 % , respectively .	DDI-false
Cyclosporine: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, @DRUG$ and interferon-alfa.	DDI-false
Probenecid : @DRUG$ • Impairs renal tubular secretion of ciprofloxacin and leads to an increase in renal tubular secretion of ciprofloxacin. @DRUG$ in serum .	DDI-mechanism
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Drugs Interactions : Flupentixol may interact with some drugs, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
Antihypertensives : @DRUG$ Propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
@DRUG$: The concomitant administration of ciprofloxacin with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ , @DRUG$ (e. g., fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-mechanism
The effect of rifampin on the @DRUG$ The need of our patient seemed to be a maximum of 5 to 7 days after the start of treatment. @DRUG$ A similar length of time after rifampin withdrawal is prolonged and prolonged.	DDI-false
This study showed that the potent cytochrome P450 enzyme inducer @DRUG$ In fact, had a significant effect on the metabolism of @DRUG$ , resulting in a 5-fold increase in clearance in patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder or bipolar disorder.	DDI-mechanism
The administration of local anesthetic solutions containing epinephrine or @DRUG$ Patients taking monoamine oxidase inhibitors, tricyclic antidepressants, or @DRUG$ For this reason, severe, prolonged hypotension or hypertension may occur.	DDI-effect
Medicines that may alter the plasma concentration of imatinib Drugs that may increase the plasma concentration of imatinib @DRUG$ Plasma concentrations: Caution should be exercised when gleevec is administered with inhibitors of the CYP3A4 family (e.g. ketoconazole, itraconazole, @DRUG$ ,,,,,,,,,,,	DDI-false
Therefore, interactions may occur after concomitant administration of psychotropic medicinal products (e. g. @DRUG$ , analgesics, antiemetics, sedatives, @DRUG$ ) .	DDI-false
Possible drug interactions of @DRUG$ with @DRUG$ or with other anticholinesterases.	DDI-int
@DRUG$ The lowering of the AV node line observed with @DRUG$ could exaggerate.	DDI-effect
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$ , although it significantly decreased the @DRUG$ tmax by 44 % and increased the intracellular exposure to phosphorylated zidovudine by 110 % .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
hypersensitivity reactions have been reported in patients receiving combination regimens with sequentially high-dose PROLEUKIN and @DRUG$ , in particular, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa .	DDI-false
It differs structurally from the other currently available @DRUG$ (Lovastatin, simvastatin, and @DRUG$ ) , leading to unique biopharmaceutical properties relative to the other agents of this class .	DDI-false
The management of the local @DRUG$ containing @DRUG$ Patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazine may experience severe, prolonged hypotension or hypertension.	DDI-false
@DRUG$-based regimens may have several advantages over @DRUG$-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$ : Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity , possibly due to decreased synthesis of renal prostacyclin .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ ♪ Don't affect the serum ♪ @DRUG$ levels .	DDI-false
There is a significant increase in exposure to @DRUG$ when @DRUG$ It is co-administered with ketoconazole ( CYP3A4 inhibitor).	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$ : @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents .	DDI-false
Concomitant cyclophosphamide , doxorubicin , @DRUG$ , and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-associated non-Hodgkin lymphoma.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Other medicines: medicines such as quinidine, disopyramide, @DRUG$ , phenothiazines , antihistamines , and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
• The intake of acetaminophene with theophylline, phenobarbital with @DRUG$ , and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( @DRUG$ ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Haemodynamic effects of @DRUG$ and @DRUG$ were additive when somatostatin was co-administered but not under basal conditions.	DDI-false
Hydrochlorothiazide: In normal subjects, concomitant use of @DRUG$ Hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, dextromethorphan, and @DRUG$.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
If @DRUG$ medicines that inhibit Pgp, increased concentrations of @DRUG$ are likely , and caution should be exercised .	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with @DRUG$ , beta blockers, calcium channel blockers, diuretics and nonsteroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions .	DDI-false
Cardiovasculars : @DRUG$ In patients receiving digoxin therapy, @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity .	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors , tricyclic antidepressants or phenothiazines may produce severe , prolonged hypotension or hypertension .	DDI-false
Other Cardiovascular Agents: @DRUG$ and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors ( @DRUG$ , @DRUG$ , and pravastatin ) , leading to unique biopharmaceutical properties relative to the other agents of this class .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the @DRUG$ response to apomorphine in the treatment of poisoning .	DDI-false
Other reported interactions with amiodarone: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
The steady-state plasma concentrations of @DRUG$ It has been reported that desipramine is co-administered with @DRUG$ Tablets at doses up to 4 mg/ day.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl, alfentanyl, alprazolem, and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, @DRUG$.	DDI-false
Digoxin : When multiple doses of @DRUG$ Digoxin and digoxin were co-administered, steady-state plasma @DRUG$ concentrations increased by approximately 20 % .	DDI-false
Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and @DRUG$.	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
- Mineral oil compositional intake of @DRUG$ The intake of @DRUG$ can be reduced by vitamin K.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Co-medications that induce CYP3A4 ( e.g. , @DRUG$ , phenytoin, carbamazepine, @DRUG$ , phenobarbital or St.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and @DRUG$.	DDI-false
These results suggest that both dexamethasone and @DRUG$ , and possibly other @DRUG$ Prostate epithelium proliferation can be regulated by dose-dependent changes in insulin and EGF activity.	DDI-false
rifampin pre-treatment of healthy volunteers with multiple doses followed by a single dose @DRUG$ , increased @DRUG$ oral-dose clearance by 3.8-fold , which significantly ( p 0.05 ) decreased mean cmax and AUC(0 - 8) .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs ( @DRUG$ Aspirin may increase the risk of bleeding if it is administered at the same time as @DRUG$.	DDI-effect
Response to @DRUG$ may be enhanced by @DRUG$.	DDI-effect
Antiarrhythmics: @DRUG$, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
The use of local anesthetics containing epinephrine, or @DRUG$ to patients receiving @DRUG$ , tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
For these reasons, it is the feeling, in most subjects, that an unsatisfactory lipid response to either drug alone, the potential benefits of combined therapy with @DRUG$ and a @DRUG$ Not outweigh the risks of severe myopathy, rhabdomyolysis and acute renal failure.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In some patients the combined use of @DRUG$ and @DRUG$ has been associated with fatal gastrointestinal hemorrhage.	DDI-effect
The possibility of hypotensive effects with enalapril or @DRUG$ It can be minimized by stopping the diuretic or increasing salt intake before starting Enalapril or @DRUG$ treatment.	DDI-false
@DRUG$ (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
Moreover, additional interaction studies with @DRUG$ and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
@DRUG$ (but not @DRUG$): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including @DRUG$ With multivalent cation-containing products such as magnesium or aluminium antacids, sucralfat, VIDEX chewable/buffer tablets or children's powder, or products containing calcium, @DRUG$ Zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-mechanism
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
No significant interactions were found between @DRUG$ and warfarin or @DRUG$.	DDI-false
However, @DRUG$ stimulated, but did not significantly inhibit, proliferation in the presence of @DRUG$.	DDI-effect
@DRUG$-@DRUG$ Adequate side chains of N-methylthiotetrazole (Cefmenoxime, cefooperazone, cefotetan, cefamandol, latamoxef) or methylthiadiazole (Cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
@DRUG$ has been shown to be antagonistic to beta-lactam antibiotics, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with beta-adrenergic blockers, methyldopa, @DRUG$ - Calcium blockers, @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - @DRUG$ Flupentixol increases the effect of tricyclic antidepressants	DDI-false
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
The effects of ruthenium red ( @DRUG$ ) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
@DRUG$ and methaqualone interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur when it contains its derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam.	DDI-false
Both @DRUG$ Indinavir was compared with PI for 48 weeks as initial therapy, with similar response rates observed in chronic renal failure patients. @DRUG$ Regimes and superiority observed with efavirenz.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Combination of @DRUG$ with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$ : Because @DRUG$ does not affect the pharmacokinetics of antipyrine , interactions with other drugs metabolized via the same cytochrome isozymes are not expected .	DDI-false
Drug interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: The concomitant use of @DRUG$ with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ Administration of non-sterioal anti-inflammatory medicinal products together with @DRUG$ The effect of cyclosporin has been associated with an increase in the toxicity caused by cyclosporin, possibly due to decreased synthesis of renal prostacycline.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , calcium-channel blockers , @DRUG$ , and nonsteroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions .	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Therefore, the combined use of @DRUG$ with @DRUG$ should generally be avoided.	DDI-advise
Acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Antiarrhythmics: @DRUG$, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or @DRUG$ antacids , @DRUG$ , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ 150 mg twice daily did not interact significantly with @DRUG$ (AUC was decreased by 15-20 %).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone , they modify the mitogenic effect of EGF and insulin .	DDI-false
In EM individuals treated with paroxetine or fluoxetine , the AUC of @DRUG$ This is about 6- to 8-fold and Css, max is about 3- to 4-fold larger than @DRUG$ alone .	DDI-false
No data are available for the concomitant use of @DRUG$/ritonavir or @DRUG$/ritonavir with garlic capsules.	DDI-false
Corticosteroids , @DRUG$ and Diuretics : Concomitant treatment with xanthine derivatives , @DRUG$ Diuretics may potentiate a possible hypocalemic effect of beta2-agonists.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Concomitant cyclophosphamide, @DRUG$, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
In the present study, the atypical antipsychotic @DRUG$ was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
Possible drug interactions of HUMORSOL with @DRUG$ Or with other @DRUG$.	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by @DRUG$ , @DRUG$ In 16 patients receiving coumarin therapy, glutethimide, chloral hydrate and methaqualone were systematically studied.	DDI-false
Coingestion of @DRUG$ with @DRUG$, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
@DRUG$ may block the antihypertensive action of @DRUG$ And similar-looking connections.	DDI-effect
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , @DRUG$ , @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
@DRUG$: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.	DDI-false
@DRUG$: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
Cyclosporin : Management of @DRUG$ Co-administration of cyclosporin has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacycline.	DDI-false
Antimycobacterial agents : rifampin, which has been used since the concomitant use of this medicinal product with @DRUG$ In an antiretroviral regimen, this reduces the plasma concentrations of @DRUG$.	DDI-false
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in @DRUG$ or @DRUG$ users.	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations : ( i ) these polyene antibiotics showed differential effects on cells ;	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$ or St.	DDI-false
Here we show that a combination of @DRUG$ or 3,7-dihydroxyflavone with @DRUG$ may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains.	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
Cephalosporine-@DRUG$ containing side chains of N-methylthiotetrazole (Cefmenoxime, Cefoperazone, Cefotetan), @DRUG$ Methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Higher concentrations of @DRUG$ The mitogenic effects of @DRUG$ are enhanced by the use of 10(-8 ) - 10(-6 ) M or retinyl acetate ( 3 X 10(-8 ) - 10(-7 ) M.	DDI-effect
@DRUG$ The management of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin .	DDI-false
Since @DRUG$ There is the potential that the use of St. John's word in patients who @DRUG$ could result in reduced amiodarone levels .	DDI-false
@DRUG$ " should be taken as being judged, and @DRUG$ The meal should be taken with a main meal of the day, preferably the Lord's Supper.	DDI-false
Other substances : Grapefruit juice given to healthy volunteers increased @DRUG$ The AUC by 50% and the Cmax by 84%, resulting in an increase in @DRUG$ plasma levels.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : @DRUG$ , @DRUG$ , amiodarone, nicardipine, and nifedipine.	DDI-false
Treatment with CYP3A4 inhibitors (e.g. @DRUG$ , intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, @DRUG$ dose should be considered .	DDI-advise
Based on the results of these studies , it is concluded that azithromycin may be safely coadministered with both @DRUG$ and @DRUG$.	DDI-false
Both ibogaine and @DRUG$ • Reduction of extracellular dopamine levels in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Non-steroidal anti-inflammatory agents : In some patients with renal impairment who have had @DRUG$ , the concomitant use of @DRUG$ For this reason, further deterioration of renal function may result.	DDI-effect
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$ Amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, @DRUG$ Substrate, and diltiazem, an inhibitor of CYP3A4) due to the potential for bradycardia, sinus arrest, and AV block;	DDI-false
• Co-administration with compounds that are potent CYP3A4 inducers (e. g. @DRUG$ , phenytoin, dexamethasone, @DRUG$ This may lead to decreased plasma levels of saquinavir.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Although glucocorticoids have shown @DRUG$-induced adverse reactions including fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea to reduce, concomitant administration of these agents with PROLEUKIN may reduce the efficacy of PROLEUKIN against tumour and should therefore be avoided. 12 beta-blockers and other antihypertensives may increase hypotension in @DRUG$.	DDI-false
apomorphine - prior ingestion of diphenidol may decrease the @DRUG$ response to @DRUG$ in the treatment of poisoning.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
• Non-selective MAO inhibitors including tranylcypromin sulfate, phenylzinsulfate and pargylin HC1: Concomitant use of @DRUG$ and non-selective @DRUG$ - May cause high blood pressure.	DDI-effect
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
@DRUG$     @DRUG$ antagonism	DDI-false
Co-administration: Concomitant use of Argatroban with @DRUG$, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Corticosteroids , @DRUG$ and Diuretics : Concomitant treatment with @DRUG$ Steroids, or diuretics may potentiate a potential hypocalemic effect of beta2-agonists.	DDI-false
Antiarrhythmics : Other @DRUG$ medicines such as quinidine, procainamide, @DRUG$ , and phenytoin, were used at the same time as amiodarone.	DDI-false
In EM individuals treated with paroxetine or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , @DRUG$ , @DRUG$ Myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$ : @DRUG$ The effects of oral anticoagulant warfarin or its derivatives have been reported to be intensified.	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents ( @DRUG$ , @DRUG$ or delavirdine ) .	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
In order to evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL ), the authors retrospectively compared a group of 24 patients with HIV-NHL who had been treated with the @DRUG$ , @DRUG$ , vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Both @DRUG$ and @DRUG$ block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens ;	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The safety and effectiveness of @DRUG$ In combination with any @DRUG$ It wasn't detected.	DDI-false
In order to evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL ), the authors retrospectively compared a group of 24 patients with HIV-NHL who had been treated with the @DRUG$ , doxorubicin , @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and triazolam) may have increased plasma concentrations if combined with @DRUG$ ;	DDI-mechanism
The following eight target drug/add drug combinations have been investigated: @DRUG$/@DRUG$.	DDI-false
Although @DRUG$ It has been shown that PROLEUKIN-induced side effects such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant use of these agents with @DRUG$ Beta-blockers and other antihypertensive agents may increase hypotension in PROLEUKIN.	DDI-false
Theophylline : As with some other quinolones , concurrent administration of ciprofloxacin with @DRUG$ It can lead to increased serum concentrations. @DRUG$ Elongation of elimination half-life.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: @DRUG$ enhances the effect of warfarin.	DDI-effect
Digoxin: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Co-administration of @DRUG$ and cerivastatin did not alter the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole ( @DRUG$ Cefoperazon, cefotetan, @DRUG$ Methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ Caution is recommended when co-administered with alprazolem: @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , disopyramide , and @DRUG$ , used at the same time as @DRUG$.	DDI-false
Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents , specifically , dacarbazine , cis-platinum , @DRUG$ and interferon-alfa .	DDI-effect
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, @DRUG$ - chewable/buffered tablets or paediatric powders, or products that can significantly reduce the absorption of calcium, iron or zinc @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent @DRUG$ such as furosemide.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving @DRUG$ therapy .	DDI-false
Therefore, @DRUG$ and @DRUG$ should not be used concomitantly.	DDI-advise
Since @DRUG$ is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , @DRUG$/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
@DRUG$ • the effect of @DRUG$ ==References====External links==* Official website	DDI-effect
Antiarrhythmics: Amiodarone, @DRUG$, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , @DRUG$ Sedatives (including benzodiazepines) or @DRUG$ It was similar in patients taking placebo with these concomitant medications as in patients receiving placebo.	DDI-false
@DRUG$, an anionic-binding resin, has a considerable effect in lowering the rate and extent of @DRUG$ bioavailability.	DDI-mechanism
OBJECTIVE : Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and @DRUG$ ( INN , ciclosporin ) when coadministered in de novo kidney allograft recipients during the first year after transplantation .	DDI-false
Chloramphenicol has been shown to be antagonistic to @DRUG$ , including @DRUG$ , based on in vitro studies and time kill curves with enteric gram-negative bacilli .	DDI-false
@DRUG$: Concomitant administration of antacids may reduce plasma levels of @DRUG$.	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-mechanism
Acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and valproic acid/phenobarbital.	DDI-false
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or @DRUG$).	DDI-advise
Moreover, the mechanisms underlying the development of dependence may be similar for @DRUG$ and @DRUG$.	DDI-false
@DRUG$ may enhance the effects of alcohol , barbiturates , and other @DRUG$.	DDI-effect
Anticoagulants: Potentiation of @DRUG$-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Both efavirenz and @DRUG$ have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , @DRUG$ , cis-platinum , @DRUG$ and interferon-alfa .	DDI-false
@DRUG$: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
- cholestyramine increase in cholestyramine and @DRUG$ The absorption of @DRUG$ can be reduced.	DDI-false
Co-administration of @DRUG$ and @DRUG$ The effect of the toxin should only be increased with caution if neuromuscular transmission (e.g. curare-like compounds) is impaired.	DDI-advise
Warfarin-@DRUG$ can antagonize the effect of @DRUG$	DDI-effect
No drug interactions between argatroban and argatroban have been observed. @DRUG$ or @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Guardians of children who have been prescribed @DRUG$ should be alerted to the general concern regarding asthma therapy compliance , especially neglect of anti-inflammatory therapy and overuse of @DRUG$.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , @DRUG$ , a CYP3A4 substrate and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Warfarin: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	DDI-false
Other reported interactions with @DRUG$: Fentanyl (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, @DRUG$, nicardipine, and nifedipine.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , @DRUG$ Methylthiadiazole (Cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Other cardiovascular agents: @DRUG$ and @DRUG$ Co-administered with beta-adrenergic blockers, methyldopa, nitrates, calcium blockers, hydralacin, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
There are no data for the concomitant use of INVIRASE/@DRUG$ or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
Multivalent Cation-Containing products: co-administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-false
Because @DRUG$ is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard @DRUG$.	DDI-false
Hypotension : Patients on Diuretic Therapy : Patients on @DRUG$ In particular, patients who have recently started diuretic therapy may occasionally experience an excessive reduction in blood pressure after initiation of therapy. @DRUG$ or enalaprilat .	DDI-effect
Administration of Betaseron to three cancer patients over a dose range of 0.025 mg to 2.2 mg resulted in dose-dependent inhibition of @DRUG$ 14 The effect of 0.25 mg @DRUG$ on drug metabolism in MS patients is unknown .	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
@DRUG$ ('@DRUG$') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Tolbutamide: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a @DRUG$ inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a @DRUG$ Inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Some drugs/substances are known to speed up metabolism @DRUG$ by stimulating the synthesis of @DRUG$ ( enzyme induction ) .	DDI-false
Sulindac : The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third .	DDI-mechanism
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , ritonavir , @DRUG$ , saquinavir , @DRUG$ A reduction in the dose of budesonide should be considered.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Also, phenobarbital, quinidine, and @DRUG$ , both at therapeutic concentrations in serum and with @DRUG$ At three different serum concentrations.	DDI-false
@DRUG$ : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or @DRUG$ antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV together with beta-adrenergic blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralacin, @DRUG$ and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
The effects of @DRUG$ ( @DRUG$ ) on inositol 1,4,5-trisphosphate ( InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, @DRUG$.	DDI-false
Acetaminophen/@DRUG$, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and valproic acid/phenobarbital.	DDI-false
In addition , @DRUG$ neither influenced the pharmacodynamics of warfarin , acetylsalicylic acid , piroxicam , and @DRUG$ The pharmacokinetics of digoxin in steady state.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , @DRUG$ , a CYP3A4 inhibitor) or calcium channel antagonists (e. g. @DRUG$ , a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Both @DRUG$ and @DRUG$ block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ may enhance the seizure risk in patients taking @DRUG$	DDI-effect
There have been case reports of increased steady-state levels of quinidine, @DRUG$, and @DRUG$ during concomitant therapy with amiodarone.	DDI-false
DIGOXIN: Plasma @DRUG$ levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
Therefore, interactions after concomitant use of @DRUG$ - narcotics, analgesics, antiemetics, @DRUG$ , sedatives).	DDI-false
Monoamine oxidase inhibitors and tricyclic antidepressants : @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents .	DDI-advise
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-effect
Coadministration with compounds that are potent inducers of CYP3A4 ( eg , phenobarbital , phenytoin , @DRUG$ , carbamazepine ) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Concomitant use of LEVSIN with other antimuscarinic agents may lead to additive side effects due to cholinergic blockade. @DRUG$ , haloperidol , @DRUG$ , monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Co-administration of @DRUG$ and @DRUG$ did not alter the pharmacokinetics of cerivastatin sodium.	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
@DRUG$      @DRUG$ antagonism	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other cardiovascular agents : enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , @DRUG$ , calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/@DRUG$.	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
Garlic capsules Garlic capsules should not be used during ingestion @DRUG$ ( @DRUG$ ) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Erythromycin : In healthy people, plasma concentrations of @DRUG$ The concomitant use of atorvastatin and @DRUG$ , a known inhibitor of cytochrome P450 3A4 .	DDI-false
Antiarrhythmics : @DRUG$ , bepridil , @DRUG$ , propafenone, quinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
Both @DRUG$ and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
@DRUG$ : @DRUG$ *, terfenadine * CONTRAINDICATED due to the potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
Suppression by @DRUG$ of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ By Wistar rats.	DDI-false
Theophylline : As with some other @DRUG$ , concurrent administration of ciprofloxacin with @DRUG$ It may lead to increased serum concentrations of theophylline and an extension of the elimination half-life.	DDI-mechanism
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and @DRUG$.	DDI-false
Concomitant @DRUG$, doxorubicin, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , calcium-blocking agents , @DRUG$ , @DRUG$ And digoxin without evidence of clinically significant adverse interactions.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and @DRUG$.	DDI-false
Acetaminophene, lidocaine, phenobarbital, @DRUG$ , @DRUG$ , and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
There is a significant increase in exposure to @DRUG$ when @DRUG$ is coadministered with ketoconazole (CYP3A4 inhibitor).	DDI-false
"Ergot derivatives: dihydroergotamine, @DRUG$ , ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
@DRUG$/Hypnotics: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin, phenobarbital or St.	DDI-false
Colestipol : plasma concentrations of @DRUG$ About 25% declined if: @DRUG$ and atorvastatin were coadministered .	DDI-false
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., @DRUG$, methyldopa, reserpine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , @DRUG$ , quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
Therefore, interactions may occur after concomitant administration of psychotropic medicinal products (e. g. @DRUG$ , analgesics , antiemetics , @DRUG$ , tranquilizers ) .	DDI-false
Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ D-Ala2-metenekephalinamide or its synthetic analogues; or @DRUG$ , on the antinonciceptive effect of these peptides in mice after intracisternal injection .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other CONCOMITANT THERAPY: Although specific interaction studies have not been performed, in clinical studies cerivastatin sodium was used together with angiotensin converting enzyme ( ACE) inhibitors, beta-blockers, @DRUG$ , diuretics , and nonsteroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ It had no significant effects on the Cmax and AUC of zidovudine, although it significantly reduced the Cmax and AUC of zidovudine. @DRUG$ Tmax increased by 44% and intracellular exposure to phosphorylated zidovudine by 110%.	DDI-mechanism
@DRUG$ may displace acidic drugs such as @DRUG$ - or tolbutamide from its bindings.	DDI-mechanism
BACKGROUND : The effects of combined administration of @DRUG$ and verapamil hydrochloride ( verapamil ) , a @DRUG$ , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
@DRUG$ (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of antacid.	DDI-false
This study demonstrates that concurrent administration of @DRUG$ permits at least a twofold increase in dose and total exposure to @DRUG$.	DDI-mechanism
unlike @DRUG$, @DRUG$ does not affect responding for a nondrug reinforcer (water).	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Acetaminophen : In normal volunteers , concomitant administration of @DRUG$ Acetaminophene and acetaminophene resulted in an approximately 50% increase in @DRUG$ plasma levels.	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with @DRUG$ ): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ The clearance decreased by 46%, the half-life decreased by 17% and the measured psychomotor performance decreased.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide, and @DRUG$ with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-int
Warfarin : Quinolones have been reported to enhance the effects of the oral @DRUG$ @DRUG$ ==References==<br>	DDI-false
In EM individuals treated with @DRUG$ or @DRUG$ , the AUC of atomoxetine is approximately 6- to 8-fold and Css , max is about 3- to 4-fold greater than atomoxetine alone .	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with @DRUG$ , methyldopa , @DRUG$ , calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and @DRUG$.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , @DRUG$ , nicardipine, and nifedipine.	DDI-int
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ 12 beta-blockers and other antihypertensive agents may increase the hypotension observed with @DRUG$.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Antiarrhythmics: Amiodarone, @DRUG$, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
The benzodiazepines are a family of @DRUG$ and @DRUG$.	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of @DRUG$ (7.4 mg/kg body weight) and subcutaneous injections of @DRUG$ (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
@DRUG$ should be administered with caution to patients receiving Antabuse (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-advise
In a clinical pharmacology study, @DRUG$ or @DRUG$ was administered to hypertensive patients receiving VASOTEC.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as @DRUG$ , intraconazole , ritonavir , indinavir , saquinavir , @DRUG$ , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
However, in the second study, administration of 12 g cholestyramine 1 hour before dinner and 0.3 mg @DRUG$ About 4 hours after the same evening meal, cerivastatin AUC decreased by less than 8% and Cmax decreased by about 30% compared to the dose. @DRUG$ alone .	DDI-false
@DRUG$ : As with some other @DRUG$ Concomitant administration of ciprofloxacin and theophylline may lead to increased serum concentrations of theophylline and an extension of the elimination half-life.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
WARFARIN: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
Fulminant rhabdomyolysis has already been administered three weeks after initiation of a combined therapy with another @DRUG$ and @DRUG$ but may be seen after several months .	DDI-effect
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as @DRUG$ or aluminum antacids , @DRUG$ , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
The availability of potent @DRUG$ NNRTI-based antiretroviral therapy regimens and concerns about protease inhibitor (@DRUG$)-related metabolic disorders have led to significant shifts in treatment practices in HIV infection.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, @DRUG$, and quinidine.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and @DRUG$ with vincristine plus bleomycin ) without receiving @DRUG$ therapy .	DDI-false
Other Cardiovascular Agents : Enalapril and @DRUG$ IV were co-administered with beta-adrenerg blockers, methyldopa, nitrates, calcium blockers, hydralazine, @DRUG$ And digoxin without evidence of clinically significant adverse interactions.	DDI-false
hypersensitivity reactions have been reported in patients receiving combination regimens with sequentially high-dose PROLEUKIN and @DRUG$ , specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-false
@DRUG$-@DRUG$ can antagonize the effect of warfarin	DDI-false
, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and valproic acid/phenobarbital.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Multivalent Cation-Containing Products : Simultaneous Application of a @DRUG$ , including ciprofloxacin, containing multivalent cation products such as magnesium or aluminium antazida, sucralfat, VIDEX chewable tablets/buffer tablets or paediatric powders or products which: @DRUG$ , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, @DRUG$, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with @DRUG$ , methyldopa, nitrates, calcium blockers, @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Because @DRUG$ is metabolized by CYP2C9 and CYP3A4 , patients who require anticoagulation should receive low-molecular weight or standard @DRUG$.	DDI-false
Other reported interactions with @DRUG$ : Fentanyl ( @DRUG$ substrate ) in combination with amiodarone may cause hypotension , bradycardia , and decreased cardiac output .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ In healthy subjects receiving the CYP3A4 inducer, carbamazepine, with 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) of @DRUG$ was decreased approximately 72 % .	DDI-false
Warfarin : @DRUG$ In patients receiving chronic prothrombin, this did not have a clinically significant effect on the prothrombin time. @DRUG$ treatment .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ (e. g., fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
Caution should be exercised when an HMG-CoA reductase inhibitor is administered concomitantly with medicinal products that may reduce the concentration or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$ , and @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ taken concomitantly with quinidine increases @DRUG$ serum concentration by 33% after two days.	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Beta-blocking Agents: The concomitant use of @DRUG$ and @DRUG$ has been well tolerated in patients with stable angina.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Potassium-sparing diuretics (e.g. spironolactone, @DRUG$ , or amilorid), @DRUG$ supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients who block -@DRUG$ (e.g. @DRUG$ , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Antimycobacterial Agents : @DRUG$ The plasma concentrations of @DRUG$ are reduced due to the concomitant use of this medicine with saquinavir in an antiretroviral regimen.	DDI-false
Antimycobacterial agents : rifampin, which has been used since the concomitant use of this medicinal product with @DRUG$ in an @DRUG$ regimen reduces the plasma concentrations of saquinavir .	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: @DRUG$ and paroxetine.	DDI-int
Since amiodarone is a substrate for @DRUG$ , there is the potential that the use of St. John s Wort in patients receiving @DRUG$ This could lead to reduced amiodarone levels.	DDI-false
Cardiovasculars : Cardiac glycosides : In patients receiving @DRUG$ therapy , administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity .	DDI-false
In EM individuals treated with @DRUG$ or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous opiate such as @DRUG$.	DDI-mechanism
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	DDI-false
It is concluded that chloral hydrate and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy .	DDI-false
hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high-dose PROLEUKIN and antineoplastic agents, in particular: @DRUG$ , cis-platinum , tamoxifen and @DRUG$.	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, @DRUG$, reserpine.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Medicines detected as CYP3A inhibitors of possible clinical significance based on clinical studies @DRUG$ Caution should be exercised when co-administering @DRUG$ ): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-false
@DRUG$: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
Tolbutamide: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
@DRUG$: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	DDI-false
• Amiodarone together with @DRUG$ Elevates plasma concentrations of procainamide and N-acetyl for less than seven days @DRUG$ 55% and 33% respectively.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ ( caution is recommended during coadministration with alprazolam ): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-false
Acetaminophen, lidocaine, @DRUG$, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
These results suggest that both dexamethasone and retinyl acetate , and possibly other @DRUG$ and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF .	DDI-effect
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
It is concluded that @DRUG$ and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with @DRUG$ and @DRUG$.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
@DRUG$ IV has been used concomitantly with @DRUG$ without evidence of clinically significant adverse reactions.	DDI-false
Warfarin : @DRUG$ enhances the effect of @DRUG$.	DDI-false
A dose adjustment of STRATTERA may be required when co-administered with CYP2D6 inhibitors, e.g. @DRUG$ , fluoxetine, and @DRUG$.	DDI-false
Treatment with CYP3A4 inhibitors (e.g. @DRUG$ , @DRUG$ , ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated and Budesonide dose reduction should be considered.	DDI-false
The effects of @DRUG$ and @DRUG$ upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice .	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ has been reported to increase the @DRUG$ requirements in human subjects ingesting these agents simultaneously.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ , @DRUG$ , quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
@DRUG$ increases enterohepatic elimination of amiodarone and may reduce its serum levels and @DRUG$/2.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.	DDI-false
Ergot Derivatives : Dihydroergotamine , ergonovine , @DRUG$ , methylergonovine CONTRAINDICATES due to the potential for serious and life-threatening reactions such as acute @DRUG$ Toxicity characterized by peripheral vasospasm and ischemia of extremities and other tissues.	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and @DRUG$ (INN, @DRUG$) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
The administration of local @DRUG$ Containing epinephrine or norepinephrine in patients who: @DRUG$ , tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Non-selective MAO inhibitors including @DRUG$, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
These results suggest that both dexamethasone and @DRUG$ , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF .	DDI-effect
Other Cardiovascular Agents : @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , @DRUG$ , hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Like @DRUG$ ( 40 mg/kg ) , 18-MC ( 40 mg/kg ) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats ;	DDI-false
In clinical studies with fondaparinux, the concomitant use of oral anticoagulants ( @DRUG$ , platelet inhibitors ( @DRUG$ ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Corticosteroids , @DRUG$ And diuretics: concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
@DRUG$ Rifampin CONTRAINDICATED since co-administration of this medicinal product with @DRUG$ In an antiretroviral regimen, this reduces the plasma concentrations of saquinavir.	DDI-false
The effects of @DRUG$ and L-CCG-1 upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice .	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family ( e.g. , @DRUG$ , itraconazole , erythromycin , clarithromycin ) .	DDI-advise
Warfarin: @DRUG$ have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-effect
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$ : @DRUG$ Toxicity has been reported in patients receiving lithium concomitantly with medicinal products that cause the excretion of sodium, including ACE inhibitors.	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-false
It differs structurally from the other HMGCoA reductase inhibitors currently available ( @DRUG$ , simvastatin and @DRUG$ This leads to unique biopharmaceutical properties compared to other active substances in this class.	DDI-false
Coadministration of phenytoin with 40 mg @DRUG$ tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
Other reported interactions with amiodarone: @DRUG$ ( @DRUG$ The substrate) in combination with amiodarone may cause hypotension, bradycardia, and reduced cardiac output.	DDI-false
@DRUG$: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime, cefoperazone), @DRUG$ , cefamandol, latamoxef) or methylthiadiazole ( @DRUG$ ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : @DRUG$ - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
Histamine H2-receptor antagonists : @DRUG$ appear to have no significant effect on the bioavailability of @DRUG$.	DDI-false
Haemodynamic effects of @DRUG$ and insulin were additive when @DRUG$ was co-administered but not under basal conditions.	DDI-false
The effect of @DRUG$ on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.	DDI-effect
Pre-treatment of megakaryocytes with extracellular @DRUG$ * ( 50 microM ) also inhibited @DRUG$-induced reactions.	DDI-effect
@DRUG$/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Warfarin: Quinolones have been reported to enhance the effects of the oral @DRUG$ @DRUG$ or its derivatives.	DDI-false
Interaction on the antinociceptive effect between @DRUG$ and @DRUG$ or tuftsin.	DDI-effect
Mineral Oil-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
@DRUG$ If multiple doses of atorvastatin and digoxin have been co-administered, steady-state plasma is @DRUG$ concentrations increased by approximately 20 % .	DDI-false
The use of local anaesthetics containing epinephrine or norepinephrine in patients who: @DRUG$ , @DRUG$ Or phenothiazines can cause severe, prolonged hypotension or hypertension.	DDI-false
@DRUG$-Orlistat may decrease the absorption of @DRUG$.	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when administering imatinib @DRUG$ with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , @DRUG$ ,,,,,,,,,,,	DDI-advise
The reported examples include: @DRUG$ : @DRUG$ It is known that CYP3A4 inhibits to varying degrees.	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Barbiturates and @DRUG$ should not be administered to patients receiving @DRUG$.	DDI-advise
Antihypertensives : Amiodarone should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and @DRUG$ , a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest, and AV block;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ • with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, @DRUG$, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
@DRUG$ : Amiodarone should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
Monitoring for @DRUG$ toxicity and serial measurement of @DRUG$ serum concentration during concomitant protease inhibitor therapy should be considered.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin ( 1 microgram/ml ) , @DRUG$ ( 10 ng/ ml ) and @DRUG$ [ 3.7 micrograms/ ml or 0.1 IU/ ml].	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ (e. g., quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem and triazolam) may increase plasma concentrations when co-administered with @DRUG$ ;	DDI-mechanism
Nephrotoxicity following concomitant administration of @DRUG$ and @DRUG$.	DDI-effect
Ergot Derivatives: @DRUG$, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when @DRUG$, @DRUG$, or azoles were administered concomitantly.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and @DRUG$ or erythromycin .	DDI-false
@DRUG$ may enhance the effects of alcohol, @DRUG$, and other CNS depressants.	DDI-effect
Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
@DRUG$ : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion .	DDI-false
@DRUG$ Influence of the warfarin type ( CYP2C9 and CYP3A4 substrate) @DRUG$ The response is almost always observed in patients receiving amiodarone and can lead to severe or fatal bleeding.	DDI-false
Acetaminophen/theophylline, @DRUG$/chinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
@DRUG$ • 150 mg twice daily did not significantly interact with @DRUG$ The AUC was reduced by 15 - 20 %.	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent @DRUG$ For example, furosemide.	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Similarly dialyzed were phenobarbital, @DRUG$, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
@DRUG$ Histamine H2 receptor antagonists do not appear to have a significant influence on the bioavailability of @DRUG$.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and @DRUG$/Phenobarbital.	DDI-false
@DRUG$ The extension of the QT interval observed with @DRUG$ could be exaggerated by tricyclic antidepressants.	DDI-effect
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , @DRUG$ , calcium-channel blockers , diuretics , and @DRUG$ NSAIDs without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ FORADIL should be used with extreme caution in patients treated with monoamine oxidase inhibitors or tricyclic antidepressants, as the effect of @DRUG$ on the cardiovascular system may be potentiated by these agents .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and @DRUG$.	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
Antihypertensives : @DRUG$ should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or @DRUG$ • antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Haemodynamic effects of @DRUG$ and @DRUG$ were additive when somatostatin was co-administered but not under basal conditions .	DDI-false
@DRUG$ : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a @DRUG$ inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Anticoagulants: @DRUG$ type potentiation ( CYP2C9 and CYP3A4 substrate ) @DRUG$ The response is almost always observed in patients receiving amiodarone and can lead to severe or fatal bleeding.	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or @DRUG$.	DDI-false
It is therefore necessary to be familiar with the clinical and paraclinical pattern @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ The intake, which requires only oral physiological supplement and magnesium deficiency, related to a dysregulation of the control mechanisms of magnesium status, which requires more or less specific regulation of its causal dysregulation.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing @DRUG$ , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ The Cmax and AUC had no significant effects on the Cmax and AUC. @DRUG$ , although it significantly decreased the zidovudine tmax by 44 % and increased the intracellular exposure to phosphorylated zidovudine by 110 % .	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine, and @DRUG$ chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or with a CHOP-like regimen (i.e. cyclophosphamide, doxorubicin, @DRUG$ , and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and @DRUG$ when administered concomitantly with an intravenous opiate such as morphine.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
This interaction should be considered in patients who: @DRUG$ concomitantly with @DRUG$.	DDI-advise
It is concluded that @DRUG$ and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
Other concomitant therapies : In clinical trials, the safety profile in patients with acamprosate concomitantly with @DRUG$ , hypnotics and sedatives ( including benzodiazepines ) , or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ Flupentixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupentixol increases the effect of tricyclic antidepressants	DDI-false
Drugs Interactions : Flupentixol may interact with some drugs, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	DDI-false
@DRUG$ have been reported to decrease the tubular secretion of @DRUG$ And to increase its toxicity.	DDI-mechanism
The monoamine oxidase inhibitory effects of @DRUG$ may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following @DRUG$.	DDI-false
Anticoagulant inhibition was observed during the administration of @DRUG$, @DRUG$ and glutethimide;	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, @DRUG$, tranquilizers).	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , amiodarone , quinidine , warfarin , @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( @DRUG$ , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( @DRUG$ ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
It is believed that increased interactions between 3H-spiroperidol and high affinity binding points for @DRUG$ The antipsychotic effect of dopamine2 and serotonin2 receptors @DRUG$ ==References====External links==	DDI-false
Co-administration of @DRUG$ with Acamprosate produced a 25 % increase in AUC and a 33 % increase in the Cmax of @DRUG$.	DDI-false
The data from in vitro studies with benzodiazepines other than alprazolam indicate a possible interaction of the following medicinal products: @DRUG$ , cyclosporine , @DRUG$ , nicardipine , and nifedipine .	DDI-false
@DRUG$ : @DRUG$ should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Physiological oral @DRUG$ supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with @DRUG$s, with practically only one contra-indication: overt renal failure.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Sine bradycardia was associated with oral amiodarone in combination with @DRUG$ ( @DRUG$ ==References====External links==	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
@DRUG$ may increase sensitivity to the @DRUG$.	DDI-effect
Here we show that a combination of @DRUG$ or 3,7-dihydroxyflavone with @DRUG$ may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains .	DDI-false
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ after their prolonged administration.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Response to @DRUG$ It can be extended by @DRUG$.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
@DRUG$-Vitamin K can antagonize the effect of @DRUG$	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
Dexamethasone and @DRUG$ Similarly, @DRUG$ or insulin-induced proliferation of prostate epithelium inhibits and stimulates.	DDI-effect
The hypoglycemic effect of @DRUG$ has been reported to increase when @DRUG$ It is given at the same time.	DDI-effect
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
@DRUG$-based regimens may have several advantages over @DRUG$-based therapy for initial or prolonged therapy , including more convenient administration regimens , lower tablet volume , fewer drug interactions , and central nervous system penetration .	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a @DRUG$ substrate , and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
@DRUG$, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Cardiovascular diseases : Cardiovascular glycoside disorders : In patients who have @DRUG$ Administration of oral amiodarone regularly leads to an increase in serum levels. @DRUG$ Concentration that can achieve toxic values with resulting clinical toxicity.	DDI-false
Anticoagulant inhibition was observed during the administration of @DRUG$ , secobarbital and @DRUG$ ;	DDI-false
@DRUG$ , lidocaine , phenobarbital , quinidine , theophylline , and @DRUG$ were added to pooled human serum at therapeutic concentrations .	DDI-false
Combinations of @DRUG$ and @DRUG$: effects on drug discrimination and behavioral inhibition in rats.	DDI-false
Drug-drug interactions have not been observed between Argatroban and @DRUG$ or @DRUG$.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other drugs : Drugs like @DRUG$ , disopyramide , procainamide , phenothiazines , @DRUG$ , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
Treatment with CYP3A4 inhibitors (e.g. @DRUG$ , intraconazole , @DRUG$ , indinavir , saquinavir , erythromycin , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
The intensity , uniformity and time course of @DRUG$ - influence by phenobarbital, secobarbital, glutethimide, chloralhydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( @DRUG$ ( acetylsalicylic acid), @DRUG$ ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
@DRUG$ : Amiodarone, Bepridil, Flecainide, @DRUG$ , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Aspirin : In normal volunteers , a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and @DRUG$ were administered concomitantly .	DDI-mechanism
Drugs Interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ Increases the effect of tricyclic antidepressants	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
Coingestion of @DRUG$ with @DRUG$ , phenobarbital with acetaminophen , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-effect
Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	DDI-false
There were no significant interactions between: @DRUG$ and @DRUG$ or digoxin .	DDI-false
@DRUG$ (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , @DRUG$ , a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ The concomitant use of fluoxetine and @DRUG$ The maximum plasma concentration of alprazoleam increased by 46%, clearance by 21%, half-life by 17% and measured psychomotor performance.	DDI-false
@DRUG$ has been shown to be antagonistic to @DRUG$, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Hypotension : patients receiving diuretic therapy: patients on diuretics and especially those in which diuretic therapy has been recently initiated may occasionally experience an excessive reduction in blood pressure after initiation of therapy with @DRUG$ or @DRUG$.	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$ , @DRUG$ , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
In clinical trials with: @DRUG$ Co-administration of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs ( @DRUG$ ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, indomethacin) is myelotoxic (e.g. @DRUG$ chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , @DRUG$ , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems .	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma ( HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , teniposide , and prednisone with @DRUG$ Bleomycin) without antiretroviral therapy.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , @DRUG$ , @DRUG$ Erythromycin, clarithromycin, erythromycin, erythromycin, erythromycin.	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate , @DRUG$ , and Pargylin HC1: Simultaneous use of L-tyrosine and non-selective @DRUG$ may cause hypertension .	DDI-false
@DRUG$ In hypercholesterolemic patients, the AUC and Cmax of cerivastatin at steady-state increased after 10 days with concomitant administration of @DRUG$ , a known inhibitor of cytochrome P450 3A4 .	DDI-false
Drug/Laboratory Test Interactions @DRUG$ , including @DRUG$ , are known to occasionally induce a positive direct Coombs test .	DDI-false
Accordingly , when @DRUG$ It is used with oral @DRUG$ Prothrombin time should be closely monitored during and for several days after co-administration of medicinal products.	DDI-advise
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$ , in particular, dacarbazine, @DRUG$ , tamoxifen and interferon alpha.	DDI-false
When LEVSIN is co-administered with others @DRUG$ , amantadine , @DRUG$ , phenothiazine, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Acetaminophene: Pharmacokinetic or pharmacodynamic drug-effect interactions between @DRUG$ 2 hours before starting the argatroban 1 g/kg/min. over 4 hours) or @DRUG$ ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of Argatroban 1.5   g/kg/min . over 18 hours ) .	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to @DRUG$ , including antiarrhythmic agents such as quinidine and @DRUG$ , cardiac glycosides and tricyclic anti-depressants .	DDI-false
@DRUG$ and glutethimide should not be administered to patients receiving @DRUG$.	DDI-advise
Myocardial injury , including myocardial infarction , myocarditis , ventricular hypokinesia , and severe rhabdomyolysis appear to be increased in patients receiving @DRUG$ and @DRUG$ concurrently .	DDI-effect
Concomitant use of LEVSIN with other antimuscarinic agents, amantadine, may lead to additive side effects due to cholinergic blockade. @DRUG$ , phenothiazines , @DRUG$ , tricyclic antidepressants or some antihistamines.	DDI-false
@DRUG$ It had no significant effect on the Cmax and AUC of zidovudine, although it significantly reduced Zidovudintmax by 44% and the intracellular exposure to phosphorylated @DRUG$ - 110%.	DDI-mechanism
Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
and (ii) the effects of @DRUG$ were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of @DRUG$ were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.	DDI-false
The effects of @DRUG$ and L-CCG-1 upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
@DRUG$ : Dihydroergotamine , @DRUG$ , ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasms and ischaemia of extremities and other tissues.	DDI-false
In clinical studies performed with @DRUG$ , the concomitant use of oral anticoagulants ( warfarin ) , @DRUG$ ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
On administration of oral @DRUG$ , the need for @DRUG$ Treatment should be reviewed and the dose reduced or discontinued by approximately 50%.	DDI-advise
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
There are no data on the concomitant use of INVIRASE/ritonavir or @DRUG$/@DRUG$ And garlic capsules.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, @DRUG$, and CYP3A4.	DDI-false
FLEXERIL may enhance the effects of @DRUG$, @DRUG$, and other CNS depressants.	DDI-false
Acid-catalyzed ethanolysis of @DRUG$ in anhydrous and aqueous @DRUG$ solutions.	DDI-mechanism
These results suggest that both @DRUG$ and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for @DRUG$ Treatment and concerns about metabolic disorders associated with protease inhibitors (PI) have led to significant shifts in treatment practices in HIV infection.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, VIDEX chewable tablets or pediatric powder or products which: @DRUG$ Iron or iron @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ ( 162.5 mg orally administered 26 and 2 hours before starting argatroban 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban). @DRUG$ 1.5 g/kg/min over 18 hours).	DDI-false
Additional drugs that are not recommended for coadministration with @DRUG$ and @DRUG$ are included below .	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
Antiarrhythmics : Other antiarrhythmic drugs , such as @DRUG$ , @DRUG$ , disopyramide , and phenytoin , have been used concurrently with amiodarone .	DDI-false
Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
Cholestyramine-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Potential differences in @DRUG$ Dosage and pharmacokinetics at different levels @DRUG$ The exposure was assessed by ANOVA.	DDI-false
@DRUG$ : Other antiarrhythmic drugs , such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with @DRUG$.	DDI-false
Antiarrhythmics: Amiodarone, @DRUG$, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
However, the absolute number of @DRUG$-related deaths is far greater than the number of deaths in @DRUG$ or heroin users.	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
Drug Interactions : @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide, and prednisone with vincristine plus). @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
Although neither @DRUG$ nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , @DRUG$ or methylthiadiazole ( @DRUG$ ) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ When co-administered with an intravenous opiate such as @DRUG$.	DDI-mechanism
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Sinus bradycardia has been reported with oral @DRUG$ in combination with @DRUG$ CYP3A4 substrate) for local anaesthesia.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
@DRUG$: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of @DRUG$.	DDI-false
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes @DRUG$ undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter @DRUG$ concentrations significantly.	DDI-false
Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
@DRUG$: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and @DRUG$ by approximately 30% and 20%.	DDI-false
@DRUG$ may block the antihypertensive action of @DRUG$ and similarly acting compounds.	DDI-effect
Anticoagulant inhibition was observed during the administration of phenobarbital, @DRUG$ and @DRUG$;	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-benzodiazepines , dihydropyridine calcium channel blockers , certain @DRUG$ ..............................................................................................................................................................................................................................................................................................................................................................................	DDI-mechanism
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	DDI-false
Sedatives/@DRUG$ : @DRUG$ , Midazolam CONTRAINDICATES due to the potential for serious and/ or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Drugs That Inhibit @DRUG$ Metabolism Via Cytochrome P450 3A : The initial step in @DRUG$ The metabolism is catalysed by cytochrome P450 3A ( CYP 3A ).	DDI-false
@DRUG$ : Dihydroergotamine , ergonovine , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ Toxicity characterized by peripheral vasospasm and ischemia of extremities and other tissues.	DDI-false
Other chemotherapeutic agents In a separate study, concomitant use of lapatinib with @DRUG$ The pharmacokinetics of an active substance (or metabolites of @DRUG$ ) .	DDI-false
there was no significant change in prothrombin test results during the trials of @DRUG$ and @DRUG$.	DDI-false
Although this effect was noted even when @DRUG$ was given 4 hours prior to @DRUG$ , this regimen did not result in diminished efficacy .	DDI-effect
Acetaminophen/theophylline, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
• Drug interactions: Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors ( @DRUG$ - Arecolin - eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupenthixol increases the effect of @DRUG$	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-@DRUG$ , dihydropyridine calcium channel blockers , certain @DRUG$ ..............................................................................................................................................................................................................................................................................................................................................................................	DDI-false
@DRUG$ inhibits @DRUG$.	DDI-false
• Lack of an effect of @DRUG$ On the disposition of @DRUG$ and dideoxyinosine in HIV-infected patients .	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-int
Both efavirenz and @DRUG$ Treatment with PI indinavir was compared with triple therapy for 48 weeks as an initial therapy, with similar response rates as in patients with PI indinavir. @DRUG$ Regimes and superiority observed with efavirenz.	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as @DRUG$ , procainamide , disopyramide , and @DRUG$ , were used simultaneously with amiodarone.	DDI-false
@DRUG$ including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Naproxen : The concomitant administration of @DRUG$ and @DRUG$ In normal subjects, this did not affect naproxene plasma levels, but significantly reduced renal excretion of naproxene and its glucuronide metabolite.	DDI-mechanism
Anticoagulants including coumarin derivatives , indandione derivatives , and platelet aggregation inhibitors such as @DRUG$ ( @DRUG$ ) , and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
@DRUG$ : In normal volunteers , concomitant administration of @DRUG$ Hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
@DRUG$: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.	DDI-false
@DRUG$: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.	DDI-false
The risk of myopathy during treatment with medicines in this class is increased with concomitant administration of cyclosporin, fibric acid derivatives, niacin ( @DRUG$ ) , erythromycin , @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Concurrent administration of oxyphenbutazone and @DRUG$ may result in elevated serum levels of @DRUG$.	DDI-false
Antiarrhythmics : Amiodarone , bepridil , @DRUG$ , propafenone , @DRUG$ CONTRAINDICATE because of the potential for serious and/or life-threatening reactions.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Since the concomitant administration of @DRUG$ with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
Antiarrhythmics : Other @DRUG$ medicines, such as quinidine, @DRUG$ ==References====External links==* Official website* Official website	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In addition to the above mentioned interactions, chronic ( 2 weeks ) oral @DRUG$ administration impairs metabolism of @DRUG$ ==References====External links==* Official website	DDI-false
Omeprazole : The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ It was given alone or if @DRUG$ 2 hours after administration of omeprazole at the dose that suppresses gastric acid secretion maximum.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of @DRUG$	DDI-false
Digoxin: When multiple doses of @DRUG$ and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-mechanism
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and @DRUG$ were administered concomitantly.	DDI-mechanism
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , @DRUG$ , a @DRUG$ inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
@DRUG$: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.	DDI-false
Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and @DRUG$ by approximately 30 % and 20 % .	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
Cefmenoxime, cefoperazone, cefotetan, cefamandol, latamoxef) or methylthiadiazole ( @DRUG$ ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , @DRUG$ , phenothiazine, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Co-medications that induce CYP3A4 ( e.g. , dexamethasone , phenytoin , @DRUG$ , rifampin , @DRUG$ or St.	DDI-false
Coadministration of @DRUG$ with 40 mg @DRUG$ tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.	DDI-mechanism
@DRUG$ may enhance the effects of alcohol , @DRUG$ And other CNS depressants.	DDI-effect
@DRUG$ and @DRUG$ should not be administered to patients receiving coumarin drugs.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous @DRUG$ such as morphine.	DDI-mechanism
@DRUG$/@DRUG$ Pharmacokinetic or pharmacodynamic drug interactions have not been established between argatroban and co-administered aspirin ( 162.5 mg orally 26 and 2 hours before the start of argatroban 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally 12, 6 and 0 hours before and 6 and 12 hours after the start of argatroban 1.5 g/kg/min for 18 hours).	DDI-false
ANTACID (@DRUG$): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	DDI-false
• Broadband spectrum antibiotics-@DRUG$ can sterilize the intestine and the @DRUG$ Contribution to the body through the intestinal microflora.	DDI-false
In clinical studies performed with @DRUG$ , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ Plasma digoxin levels and steady-state digoxin clearance were not affected by concomitant administration of 0.2 mg @DRUG$.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, @DRUG$ • Chewable/buffered tablets or pediatric powders, or products containing calcium, iron, or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-false
The risk of myopathy during treatment with medicines in this class is associated with the use of @DRUG$ , @DRUG$ Niacin (nicotinic acid), erythromycin, azole antimycotics.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
HMG-CoA reductase inhibitors: simvastatin ( @DRUG$ Substrate) in combination with @DRUG$ It has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$ As with some other quinolones, co-administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life .	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Nephrotoxicity following concomitant administration of @DRUG$ with @DRUG$ or potent diuretics such as furosemide .	DDI-effect
Digoxin : If multiple doses @DRUG$ and @DRUG$ Plasma digoxin concentrations at steady-state increased by about 20%.	DDI-mechanism
Concomitant cyclophosphamide , doxorubicin , @DRUG$ , and prednisone chemotherapy plus @DRUG$ Treatment in patients with human immunodeficiency virus-associated non-Hodgkin lymphoma.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (@DRUG$ substrate) given for local @DRUG$.	DDI-false
Other reported interactions with amiodarone : Fentanyl ( @DRUG$ substrate ) in combination with @DRUG$ For this reason, hypotension, bradycardia, and reduced cardiac output may occur.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , ritonavir , @DRUG$ , @DRUG$ , erythromycin , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ , amiodarone , quinidine , warfarin , @DRUG$ (e. g. cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , @DRUG$ , itraconazole , erythromycin , @DRUG$ ) .	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Both @DRUG$ and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens , but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens .	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , @DRUG$ chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with @DRUG$ may increase toxicity in these organ systems .	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium @DRUG$ , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , @DRUG$ , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
@DRUG$ , @DRUG$ and Diuretics : Concomitant treatment with xanthine derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
@DRUG$/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Dosage adjustment of @DRUG$ Paroxetine may be necessary when co-administered with CYP2D6 inhibitors, e.g. @DRUG$ , and quinidine .	DDI-advise
In clinical studies with fondaparinux, the concomitant use of oral anticoagulants ( @DRUG$ ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and @DRUG$ The pharmacokinetics/pharmacodynamics of fondaparinux sodium were not significantly affected.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	DDI-false
The concomitant use of warfarin and @DRUG$ The pharmacokinetics of @DRUG$ have not been altered.	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
The use of acetaminophene with acetaminophene @DRUG$ , phenobarbital with acetaminophene and @DRUG$ The binding of the target medication is reduced with phenobarbital at high to toxic concentrations.	DDI-false
Coadministration of @DRUG$ with 40 mg SULAR tablets in epileptic patients lowered the @DRUG$ Plasma concentrations up to undetectable concentrations.	DDI-false
• Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-effect interactions between argatroban and co-administered aspirin ( 162.5 mg orally 26 and 2 hours before starting argatroban 1 g/kg/min for 4 hours), or @DRUG$ ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of Argatroban 1.5   g/kg/min . over 18 hours ) .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, @DRUG$ , pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some @DRUG$.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - @DRUG$ Eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupenthixol increases the effect of tricyclic antidepressants	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a @DRUG$ inhibitor ) or @DRUG$ antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Lack of an effect of azithromycin on the disposition of @DRUG$ and @DRUG$ in HIV-infected patients.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma ( HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , @DRUG$ , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , @DRUG$ , diuretics, and @DRUG$ NSAIDs without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ is metabolized to @DRUG$ by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
Antipyrine : Because @DRUG$ does not affect the pharmacokinetics of @DRUG$ , interactions with other drugs metabolized via the same cytochrome isozymes are not expected .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Antiarrhythmics: Amiodarone, bepridil, @DRUG$, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Anticoagulants: potentiation of the warfarin type ( CYP2C9 and CYP3A4 substrate) @DRUG$ The response is almost always observed in patients who: @DRUG$ and can result in serious or fatal bleeding .	DDI-false
@DRUG$ : The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$ , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite .	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Combination of @DRUG$ with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.	DDI-false
The aim of this paper was to study the interaction between @DRUG$ Enkephaline as well as its synthetic analogues @DRUG$ , or tuftsin, the anti-non-ciceptive effect of these peptides in mice after intracistern injection.	DDI-false
Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Anticoagulants : Potentiation of warfarin-type ( @DRUG$ and @DRUG$ The substrate) Anticoagulant response is almost always seen in patients receiving amiodarone and can lead to severe or fatal bleeding.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: sertraline and @DRUG$.	DDI-int
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: @DRUG$ and paroxetine.	DDI-false
Other reported interactions with @DRUG$ : @DRUG$ CYP3A4 substrate in combination with amiodarone may lead to hypotension, bradycardia and decreased cardiac output.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, @DRUG$, rifampin, phenobarbital or St.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics , hypnotics and sedatives ( including benzodiazepines ) , or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/phenobarbital.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Co-administration of warfarin and @DRUG$ did not alter the pharmacokinetics of @DRUG$.	DDI-false
Coingestion of @DRUG$ with theophylline , @DRUG$ With acetaminophene and valproic acid with phenobarbital at high to toxic concentrations, binding of the target medication is reduced.	DDI-false
Data from in vitro studies of @DRUG$ Other than alprazolem propose a possible interaction for the following drugs: @DRUG$ , cyclosporin, amiodarone, nicardipine, and nifedipine.	DDI-int
@DRUG$  may interact with drugs known to interact with the conventional formulation of @DRUG$.	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
In general, these drugs have one or more pharmacological activities, similar to @DRUG$ , including antiarrhythmic agents such as quinidine and procainamide, @DRUG$ And tricyclic antidepressants.	DDI-false
The @DRUG$ Study-dose patients with 1200 mg/ day @DRUG$ ( n = 7 ) ( subsequently modified to 600 mg/day [ n = 5 ] ) for days 8 to 21 of a 21-day course of 100 mg, five times/day zidovudine.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ Ciprofloxacin when co-administered with an intravenous @DRUG$ Like morphine.	DDI-mechanism
Theophylline: As with some other @DRUG$, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat .	DDI-effect
@DRUG$ It has been reported that the blood pressure lowering effect of systemic @DRUG$ is dulled.It is not known whether concomitant use of these active substances with ALPHAGAN P in humans can result in a resulting interference with the IOP-lowering effect.	DDI-effect
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Some @DRUG$/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of amiodarone. @DRUG$ ( enzyme induction ) .	DDI-false
The effects of @DRUG$ and @DRUG$ upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ : Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity , possibly due to decreased synthesis of renal prostacyclin .	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Little has been studied of the adverse effects of the exposure of the liver to the interaction of @DRUG$ with its congeners and @DRUG$, coexisting in the contents of alcoholic beverages.	DDI-false
Pre-treatment of healthy volunteers with multiple doses @DRUG$ followed by a single dose of Gleevec, increased @DRUG$ Oral dose clearance was reduced by 3.8-fold, significantly reducing the mean cmax and AUC(0-8) (p 0.05).	DDI-false
ANTACID ( @DRUG$ ): @DRUG$ plasma concentrations were not affected by co-administration of antacid .	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as @DRUG$ , intraconazole , ritonavir , @DRUG$ , saquinavir, erythromycin, etc.) is indicated, reduction of budesonide dose should be considered.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (@DRUG$, nevirapine or @DRUG$).	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The steady state plasma concentrations of imipramine and @DRUG$ It has been reported that concomitant use of @DRUG$ Tablets at doses up to 4 mg/ day.	DDI-mechanism
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Antihypertensives : @DRUG$ should be used with caution in patients receiving   -receptor blocking agents ( e.g. , @DRUG$ , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or @DRUG$ ( 1000 mg orally administered 12, 6 and 0 hours before, and 6 and 12 hours after, start of argatroban 1.5 g/kg/min. over 18 hours).	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to @DRUG$ , including anti-arrhythmic agents such as @DRUG$ And procainamide, cardiac glycosides and tricyclic antidepressants.	DDI-false
In a clinical pharmacology study, indomethacin or @DRUG$ was administered to hypertensive patients receiving @DRUG$.	DDI-false
Although @DRUG$ administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by @DRUG$ Or in place, histological type, depth of involvement, labelling index, apoptotic index, or tumor vascularity of colon cancer, it significantly reduces the incidence of cancer metastases.	DDI-false
@DRUG$ : Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
Moreover , the mechanisms underlying the development of dependence may be similar for @DRUG$ and @DRUG$.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Antipyrine : Because @DRUG$ does not affect the pharmacokinetics of antipyrine , interactions with other @DRUG$ Metabolism via the same cytochrome isozymes is not expected.	DDI-false
The steady state plasma concentrations of @DRUG$ and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	DDI-mechanism
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
Both @DRUG$ and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite @DRUG$ were unaffected following co-administration with Acamprosate .	DDI-false
Atorvastatin plasma concentrations decreased approximately 25% if: @DRUG$ and @DRUG$ were coadministered .	DDI-mechanism
unlike @DRUG$ , @DRUG$ does not affect responding for a nondrug reinforcer ( water ) .	DDI-false
Corticosteroids , Methylxanthines and @DRUG$ ; Concomitant treatment with xanthine derivatives, steroids or @DRUG$ A potential hypokalemic effect of beta2-agonists may be increased.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-effect
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-false
Acetaminophene, lidocaine, @DRUG$ , @DRUG$ Theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$ : Simvastatin ( CYP3A4 substrate ) in combination with @DRUG$ It has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
• Amiodarone together with @DRUG$ • for less than seven days increases plasma concentrations of @DRUG$ n-acetylprocainamide by 55% and 33% respectively.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 ( eg , phenobarbital , @DRUG$ , @DRUG$ Carbamazepine) may lead to decreased plasma levels of saquinavir.	DDI-false
@DRUG$ is inhibited by @DRUG$.	DDI-mechanism
The @DRUG$ are a family of anxiolytic and @DRUG$.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , @DRUG$ , haloperidol , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some @DRUG$.	DDI-false
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, @DRUG$ ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , @DRUG$ ) effects with PROLEUKIN may increase toxicity in these organ systems .	DDI-false
Theophylline : As with some other @DRUG$ Co-administration of ciprofloxacin and theophylline may lead to increased serum concentrations. @DRUG$ and prolongation of its elimination half-life .	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, reserpine.	DDI-effect
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), @DRUG$ ( acetylsalicylic acid ) , @DRUG$ Piroxicam and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ Eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), @DRUG$ ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and @DRUG$ The pharmacokinetics/pharmacodynamics of fondaparinux sodium were not significantly affected.	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-false
@DRUG$: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
@DRUG$ ('Seroquel') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving @DRUG$ therapy .	DDI-false
Monitoring for @DRUG$ toxicity and serial measurement of amiodarone serum concentration during concomitant @DRUG$ therapy should be considered.	DDI-false
The risk of myopathy during treatment with medicines in this class is increased with concomitant administration of cyclosporin, fibric acid derivatives, niacin ( @DRUG$ ) , @DRUG$ Azol Antimycotics.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
• Concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, indomethacin), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. @DRUG$ ) or hepatotoxic (e.g. methotrexate, @DRUG$ ) effects with PROLEUKIN may increase toxicity in these organ systems .	DDI-false
@DRUG$ ( @DRUG$ ) produces psychotomimetic effects in humans that resemble schizophrenia symptoms .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: sertraline and @DRUG$.	DDI-false
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
It is concluded that chloral hydrate and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$ Although it significantly reduces zidovudine tmax by 44% and increased intracellular exposure to phosphorylated @DRUG$ by 110 % .	DDI-false
Antiarrhythmics: @DRUG$, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Concomitant use of LEVSIN with other antimuscarinic agents may lead to additive side effects due to cholinergic blockade. @DRUG$ , @DRUG$ , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, @DRUG$ , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
The effects of @DRUG$ ( RR ) on @DRUG$ ( InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
Naproxen : The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of @DRUG$ And his glucuronide metabolite.	DDI-false
Acetaminophen, lidocaine, phenobarbital, quinidine, @DRUG$, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Combination of @DRUG$ with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, procainamide, and phenytoin during concomitant therapy with @DRUG$.	DDI-false
Ergot Derivatives : Dihydroergotamine , @DRUG$ , ergotamine , @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
Antiarrhythmics : @DRUG$ , bepridil , flecainide , propafenone , @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Concomitantly given @DRUG$ did not interfere with the absorption of a tablet of @DRUG$.	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors , @DRUG$ Or phenothiazines can cause severe, prolonged hypotension or hypertension.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Acetaminophen : In normal volunteers , concomitant administration of @DRUG$ and @DRUG$ The plasma levels of acetaminophen increased by about 50%.	DDI-mechanism
@DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : @DRUG$ - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
The concomitant intake of @DRUG$ and @DRUG$ The pharmacokinetics of alcohol or acamprosate are not affected.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , @DRUG$ Acetylsalicylic acid, NSAIDs (piroxicam) and digoxin did not significantly affect @DRUG$ pharmacokinetics/pharmacodynamics.	DDI-false
Aspirin/@DRUG$ : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ 1 g/kg/min) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after the start of argatroban 1.5 g/kg/min. for 18 hours.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
However, if @DRUG$ is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , ritonavir , @DRUG$ , saquinavir , erythromycin , etc . ) is indicated , reduction of the @DRUG$ dose should be considered .	DDI-advise
@DRUG$ : In healthy individuals , plasma concentrations of @DRUG$ increased approximately 40 % with coadministration of atorvastatin and erythromycin , a known inhibitor of cytochrome P450 3A4 .	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
The intensity , uniformity and time course of @DRUG$ - influence by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and @DRUG$ The pharmacokinetics/pharmacodynamics of fondaparinux sodium were not significantly affected.	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, @DRUG$ , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and @DRUG$ • with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ Or potent diuretics like @DRUG$.	DDI-false
BACKGROUND : The effects of combined administration of bombesin and @DRUG$ ( @DRUG$ ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
@DRUG$ and @DRUG$ The prolongation of the QT interval observed with bepridil hydrochloride could exaggerate.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-effect
FLEXERIL may enhance the effects of @DRUG$ , @DRUG$ And other CNS depressants.	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective @DRUG$ may cause hypertension.	DDI-effect
@DRUG$ • decreased the binding of @DRUG$ 11.0 % for 662 micromol/L and 7.1% for 1324 micromol/L (percentage increase for FDF, 13.7%).	DDI-mechanism
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue @DRUG$, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Interaction on the antinociceptive effect between @DRUG$ And enkephaline or @DRUG$.	DDI-effect
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
The continuing need for the other @DRUG$ agent should be reviewed after the effects of @DRUG$ have been established , and discontinuation ordinarily should be attempted .	DDI-false
Coingestion of @DRUG$ with theophylline , phenobarbital with @DRUG$ Valproic acid with phenobarbital in high to toxic concentrations decreases the binding of the target drug.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with @DRUG$.	DDI-effect
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : @DRUG$ and @DRUG$ Cause additive CNS depression - Tricyclic antidepressants : flupenthixol increases the effect of tricyclic antidepressants	DDI-effect
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ For normal volunteers, simultaneous use of diflunisal and @DRUG$ This resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Other chemotherapy agents In a separate study, concomitant use of @DRUG$ with @DRUG$ The pharmacokinetics of an active substance (or metabolites of capecitabine) were not significantly altered.	DDI-false
There are 3 types of indications: specific (for the treatment of some forms of @DRUG$ deficit i.e. acute), pharmacological (i.e. without alterations of @DRUG$ status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients receiving antihypertensive agents (e.g. @DRUG$ , a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and @DRUG$ , a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest, and AV block;	DDI-false
Colestipol-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of tricyclic antidepressants	DDI-int
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Like @DRUG$ (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with @DRUG$ for the following: sertraline and paroxetine.	DDI-false
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered , a fixed 9.9-g/m2 dose of @DRUG$ It was administered intravenously for three hours concomitantly with escalating doses of @DRUG$.	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, @DRUG$, and @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with @DRUG$ Bleomycin) without antiretroviral therapy.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
In addition, additional interaction studies with: @DRUG$ Propranolol and propranolol have no effect on @DRUG$ plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data .	DDI-false
Moreover , additional interaction studies with @DRUG$ and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and @DRUG$.	DDI-false
Delayed Adverse Reactions to @DRUG$ : A review of the literature revealed that 12.6 % ( range 11 - 28 % ) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered @DRUG$ experienced acute , atypical adverse reactions .	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , @DRUG$ , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , @DRUG$/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
WARFARIN: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, @DRUG$, and cimetidine.	DDI-false
Other cardiovascular agents: @DRUG$ , methyldopa, nitrates, calcium blockers, hydralacin, prazosin and enalapril IV were co-administered with beta-adrenergic blockers, methyldopa, @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
Amiodarone taken concomitantly with @DRUG$ increases @DRUG$ serum concentration by 33% after two days.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
• The intake of acetaminophene with theophylline, phenobarbital with @DRUG$ , and valproic acid with @DRUG$ At high to toxic concentrations, binding of the target medication is reduced.	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8 % , and a decrease in Cmax of about 30 % when compared to dosing cerivastatin sodium alone .	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , fibric acid derivatives , @DRUG$ ( @DRUG$ Erythromycin, azole antifungals.	DDI-false
@DRUG$ , such as @DRUG$ Diltiazem and nifedipine inhibit platelet activation in vitro and reduce intravascular adhesion of platelets.	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-mechanism
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors , @DRUG$ or @DRUG$ For this reason, severe, prolonged hypotension or hypertension may occur.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , @DRUG$/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
Similarly dialyzed were phenobarbital , @DRUG$ , and theophylline , both alone at therapeutic concentrations in serum and with @DRUG$ At three different serum concentrations.	DDI-false
@DRUG$ : Because atorvastatin does not affect the pharmacokinetics of @DRUG$ , interactions with other drugs metabolized via the same cytochrome isozymes are not expected .	DDI-false
To assess the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide and prednisone). @DRUG$ plus bleomycin ) without receiving @DRUG$ therapy .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
therefore , the use of @DRUG$ Not required is an adjustment in @DRUG$ dose to maintain therapeutic digoxin levels .	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Coingestion of @DRUG$ Theophylline, phenobarbital with acetaminophene and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, @DRUG$).	DDI-false
This time window is different than for other oral formulations of @DRUG$ , which are usually administered 2 hours before or 6 hours after @DRUG$.	DDI-advise
The effects of @DRUG$ and L-CCG-1 upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$ , doxorubicin , teniposide , and @DRUG$ • with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Careful observation is required when @DRUG$ is administered concurrently with @DRUG$.	DDI-advise
Colestipol-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
To determine if the injection of thiosulfate is larger doses of thiosulfate @DRUG$ A fixed dose of 9.9 g/m2 @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin .	DDI-false
To determine if the injection of thiosulfate is larger doses of thiosulfate @DRUG$ to be administered , a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or @DRUG$ antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
@DRUG$ The simultaneous use of @DRUG$ Good tolerability was achieved in patients with stable angina pectoris and beta-blockers.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum antacids , @DRUG$ VIDEX chewable/buffer tablets or paediatric powders or products containing calcium, iron or zinc may significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
This effect is small with occasional doses of @DRUG$ However, it may be clinically significant if: @DRUG$ ==References====External links==	DDI-false
@DRUG$ , Methylxanthines and Diuretics : Concomitant treatment with xanthine derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of   @DRUG$	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , @DRUG$ ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with @DRUG$ may increase toxicity in these organ systems .	DDI-effect
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
These increases should be considered when selecting an oral dose. @DRUG$ For a woman taking @DRUG$.	DDI-advise
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Acetaminophen/@DRUG$, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/Phenobarbital.	DDI-false
Earlier studies showed a significant reduction in oral bioavailability of trovafloxacin and @DRUG$ If co-administered with an intravenous @DRUG$ such as morphine .	DDI-mechanism
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Fenfluramine may have the effect of @DRUG$ , e.g. , @DRUG$ , methyldopa, reserpine.	DDI-false
The risk of myopathy during treatment with medicines in this class is associated with the use of @DRUG$ , fibrous acid derivatives, niacin ( @DRUG$ Erythromycin, azole antifungals.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , @DRUG$ and @DRUG$ The use of placebo with these concomitant medications was similar to that of volunteers (including benzodiazepines), or non-opioid analgesics.	DDI-false
In order to determine whether the injection of @DRUG$ would permit larger doses of @DRUG$ A fixed dose of 9.9 g/m2 thiosulfate was administered intravenously for three hours at the same time as an escalating dose of cisplatin.	DDI-false
Oral Contraceptives : Coadministration of @DRUG$ and an oral contraceptive increased AUC values for @DRUG$ Ethinylestradiol by about 30% and 20%.	DDI-mechanism
Antiarrhythmics: Amiodarone, bepridil, @DRUG$, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Antimycobacterial agents : rifampin, which has been used with saquinavir since it was co-administered. @DRUG$ regimen reduces the plasma concentrations of @DRUG$.	DDI-false
@DRUG$ Atorvastatin had no clinically significant effect on the prothrombin time when administered to patients with chronic @DRUG$ treatment .	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-advise
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin, containing multivalent cationic products such as magnesium or aluminium antacids, sucralfat, VIDEX chewable/buffer tablets or pediatric powder or products containing calcium, @DRUG$ , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
@DRUG$ ( ' Seroquel ' ) is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ Before starting treatment with @DRUG$ or enalaprilat .	DDI-false
@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
These results suggest that both dexamethasone and @DRUG$ , and possibly other glucocorticoids and @DRUG$ Prostate epithelium proliferation can be controlled by dose-dependent changes in insulin and EGF activity.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Co-administration of @DRUG$ with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.	DDI-mechanism
Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	DDI-false
Agents Causing Renin Release : The antihypertensive effect of enalapril and enalapril IV is augmented by @DRUG$ that cause renin release ( e.g. , @DRUG$ ) .	DDI-false
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
How ibogain ( 40 mg/kg ) reduces intravenous self-injection of 18-MC ( 40 mg/kg ) @DRUG$ and @DRUG$ and the oral self-administration of ethanol and nicotine in rats ;	DDI-false
@DRUG$ and @DRUG$: a drug interaction.	DDI-int
Other medicines: medicines such as quinidine, disopyramide, procainamide, @DRUG$ , @DRUG$ , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime), @DRUG$ , cefotetan , @DRUG$ Methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , @DRUG$ , @DRUG$ Or some antihistamines.	DDI-false
Both @DRUG$ - and 18-MC blockmorphine-induced and @DRUG$-induced dopamine release in nucleus accumbens;	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and @DRUG$/phenobarbital.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
The data from in vitro studies with benzodiazepines other than alprazolam indicate a possible interaction of the following medicinal products: @DRUG$ , cyclosporin, amiodarone, nicardipine and @DRUG$.	DDI-false
The concomitant use of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission ( e.g. , @DRUG$ ) should only be performed with caution as the effect of the toxin may be potentiated .	DDI-false
Clinical implications of @DRUG$ # Interactions with five @DRUG$.	DDI-int
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , @DRUG$ Myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. @DRUG$ Hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
@DRUG$: @DRUG$*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
To assess the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide and prednisone). @DRUG$ plus @DRUG$ ) without antiretroviral therapy.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$ , fibric acid derivatives , @DRUG$ - (nicotinic acid), erythromycin, azole antifungals.	DDI-false
Warfarin : @DRUG$ have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin , tacrolimus , cyclosporine , @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Co-administration of @DRUG$ with @DRUG$ The AUC increased by 25% and the Cmax of acamprosate by 33%.	DDI-mechanism
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/@DRUG$.	DDI-false
@DRUG$: Concomitant administration of @DRUG$ may reduce plasma levels of diflunisal.	DDI-false
It has been shown that @DRUG$ antagonized evidently the antinociceptive effect of @DRUG$ And their analogy.	DDI-effect
@DRUG$ Concomitant administration of warfarin and cerivastatin to healthy subjects resulted in concomitant administration of warfarin and cerivastatin to healthy subjects. @DRUG$ and placebo .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecolin - eproxindine - ethanol : @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ inhibits @DRUG$.	DDI-false
However , in the second study , administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ About 4 hours after the same evening meal led to a decrease in the @DRUG$ The AUC of less than 8% and a decrease in Cmax of about 30% compared to the dose of cerivastatin sodium alone.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
There are no data for the concomitant use of @DRUG$/@DRUG$ or FORTOVASE/ritonavir and garlic capsules .	DDI-false
@DRUG$ : Plasma @DRUG$ The steady-state concentrations and digoxin clearance were not affected by concomitant administration of cerivastatin sodium 0.2 mg.	DDI-false
@DRUG$: @DRUG$, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Concurrent administration of @DRUG$ (used to treat hypotension associated with birth blocks) and @DRUG$ may cause severe , persistent hypertension or cerebrovascular accidents .	DDI-effect
Reported examples include the following: @DRUG$: @DRUG$ are known to inhibit CYP3A4 to varying degrees.	DDI-false
• Corticosteroids, methylxanthine and diuretics: concomitant treatment with @DRUG$ , steroids, or @DRUG$ A potential hypokalemic effect of beta2-agonists may be increased.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Dextromethorphan is a substrate for both @DRUG$ and @DRUG$.	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Other Cardiovascular Agents : Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , calcium-blocking agents , @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ and @DRUG$ Interaction pharmacologically with orally administered anticoagulants, but the effect is not clinically significant.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , @DRUG$ , glutethimide , @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the @DRUG$ Indinavir for 48 weeks as initial therapy, with similar response observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
In addition , Fondaparinux neither influenced the pharmacodynamics of warfarin , @DRUG$ , @DRUG$ The pharmacokinetics of digoxin in steady state.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitors (@DRUG$)-based therapies for @DRUG$ Treatment and concerns about metabolic disorders associated with protease inhibitors (PI) have led to significant shifts in treatment practices in HIV infection.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
In addition , @DRUG$ The pharmacodynamics of warfarin, acetylsalicylic acid, has neither influenced nor @DRUG$ , and digoxin , nor the pharmacokinetics of digoxin at steady state .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
No data are available for the coadministration of @DRUG$/ritonavir or @DRUG$/ritonavir and garlic capsules.	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal .	DDI-false
Combination of amiodarone with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
Drug interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupentixol and @DRUG$ Cause additive CNS depression - tricyclic antidepressants : flupenthixol increases the effect of @DRUG$	DDI-false
The @DRUG$ study dosed subjects with 1200 mg/day of azithromycin ( n = 7 ) ( later changed to 600 mg/day [ n = 5 ] ) for Days 8 to 21 of a 21-day course of 100 mg , five times/day of @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporine , @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The effects of DCG-IV and @DRUG$ upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
In addition, fondaparinux did not affect the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$ , the pharmacokinetics of @DRUG$ At Steady State.	DDI-false
This effect may be mediated by the ability of @DRUG$ to induce microsomal enzymes and, thus, the catabolism of @DRUG$.	DDI-mechanism
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ The effect of alternating use of 0.25 mg betaseron on drug metabolism in MS patients is unknown.	DDI-mechanism
@DRUG$, lidocaine, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$ Patients who: @DRUG$ ( disulfiram , Wyeth-Ayerst Laboratories ) .	DDI-advise
Concomitant use of LEVSIN with other antimuscarinic agents, amantadine, may lead to additive side effects due to cholinergic blockade. @DRUG$ , @DRUG$ , monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
@DRUG$ The concomitant use of aspirin may decrease @DRUG$ Plasma levels, possibly through competition for protein-binding sites.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Antihypertensives : @DRUG$ should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Acetaminophen , lidocaine , phenobarbital , @DRUG$ , theophylline , and @DRUG$ The pooled human serum was added at therapeutic concentrations.	DDI-false
Drug Interactions : @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
It is therefore necessary to be familiar with the clinical and paraclinical pattern @DRUG$ deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-int
@DRUG$ and @DRUG$ The effect of additive ocular and renal vasodilator on healthy people.	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
These results suggest that both @DRUG$ Prostate epithelium proliferation can be regulated by dose-dependent changes in insulin and @DRUG$ activity.	DDI-effect
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
Erythromycin: plasma concentrations of atorvastatin increased in healthy subjects when co-administered with @DRUG$ and @DRUG$ A known inhibitor of cytochrome P450 3A4.	DDI-mechanism
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Fenfluramine may slightly increase the effect of antihypertensive agents, e.g. @DRUG$ , @DRUG$ , reserpine .	DDI-false
Antiarrhythmics : @DRUG$ , @DRUG$ , flecainide , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ Antacids or aluminium antacids, sucralfat, VIDEX chewable/buffer tablets or pediatric powder or products containing calcium, @DRUG$ Zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite 6-beta-naltrexol were unaffected following co-administration with @DRUG$.	DDI-false
High-dose @DRUG$ with @DRUG$ protection.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of @DRUG$	DDI-false
Aspirin: Concurrent administration of @DRUG$ may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-mechanism
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The effect of the blood pressure of @DRUG$ In chronic renal failure patients, the @DRUG$ than in patients on no other antihypertensive therapy .	DDI-effect
@DRUG$ • may cause certain CYP450 enzymes, including: @DRUG$ CYP2C9, CYP2D6 and CYP3A4.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Barbiturates and @DRUG$ should not be administered to patients receiving @DRUG$.	DDI-advise
• Drug interactions: Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically influence @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Cholestyramine-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Cholestyramine increases enterohepatic elimination of @DRUG$ And can reduce its serum levels and @DRUG$/2.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Other reported interactions with amiodarone: Fentanyl (@DRUG$ substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered , a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipoid, and @DRUG$ with vincristine plus @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
There have been case reports of increased steady-state levels of quinidine, procainamide and @DRUG$ during concomitant therapy with @DRUG$.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/@DRUG$, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
These results suggest that both dexamethasone and dexamethasone @DRUG$ The proliferation of prostatic epithelium, and possibly other glucocorticoids and retinoids, may be controlled by dose-dependent changes in insulin and @DRUG$ activity.	DDI-effect
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
Chloral hydrate and @DRUG$ interact pharmacologically with orally administered @DRUG$ However, the effect is not clinically significant.	DDI-int
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$ The renal tubular transport of methotrexate may be caused by concomitant use of @DRUG$ , potentially leading to increased plasma levels of methotrexate .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/@DRUG$ , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
Slow-channel calcium blockers , such as @DRUG$ , diltiazem and @DRUG$ , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
In the first study, the co-administration of 0.2 mg @DRUG$ and 12 g cholestyramine resulted in decreases of more than 22 % for AUC and 40 % for Cmax when compared to dosing @DRUG$ alone .	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect @DRUG$ pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Like ibogain ( 40 mg/kg), @DRUG$ ( 40 mg/kg ) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats ;	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Aspirin : Simultaneous use of @DRUG$ may lower @DRUG$ plasma levels , possibly by competing for protein-binding sites .	DDI-mechanism
Two groups (SH/DA; SH/FA) were treated daily with synthetic hydroalcoholic solutions which: @DRUG$ , methanol , higher alcohols and @DRUG$ — in the same proportions as in the most frequently distilled and fermented alcoholic beverages;	DDI-false
@DRUG$ : The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
Apomorphine - before taking @DRUG$ may decrease the emetic response to @DRUG$ in the treatment of poisoning .	DDI-effect
- ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$ , @DRUG$ , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol , @DRUG$ , and @DRUG$.	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents , specifically , dacarbazine , @DRUG$ , tamoxifen and interferon alpha.	DDI-effect
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus @DRUG$/@DRUG$ regimens.	DDI-false
* Delayed side effects on @DRUG$ : A review of the literature revealed that 12.6 % ( range 11 - 28 % ) of 501 patients treated with various @DRUG$ The treatment regimens, which subsequently received radiographic iodised contrast agents, showed acute, atypical adverse reactions.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , @DRUG$/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
METHOD : This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg , 1 mg , or 2 mg twice daily with @DRUG$ and @DRUG$.	DDI-false
@DRUG$ has been reported to increase the @DRUG$ requirements in human subjects ingesting these agents simultaneously .	DDI-mechanism
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , analgesics , @DRUG$ , sedatives , @DRUG$ ) .	DDI-false
1 hour after starting the @DRUG$ or @DRUG$ 500 mg p.o.	DDI-false
In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of @DRUG$ by @DRUG$ (200 m m M i.e., 350 mg/L) was 17-28%.	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and valproic acid/phenobarbital.	DDI-false
Although @DRUG$ administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by @DRUG$ or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and CYP3A4.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, @DRUG$ or some antihistamines.	DDI-false
Both @DRUG$ and 18-MC block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , @DRUG$ , itraconazole , @DRUG$ , clarithromycin ) .	DDI-false
Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
• WARFARIN: @DRUG$ and @DRUG$ No changes in prothrombin time or coagulation factor VII occurred in healthy volunteers compared to co-administration of warfarin and placebo.	DDI-false
@DRUG$-@DRUG$ In large doses, vitamin K-epoxide reductase can inhibit, leading to vitamin K deficiency.	DDI-false
• Co-administration with compounds that are potent CYP3A4 inducers (e.g. phenobarbital, @DRUG$ , dexamethasone , carbamazepine ) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Cefmenoxime, cefoperazone, @DRUG$ , cefamandol, latamoxef) or methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Lack of an effect of azithromycin on the disposition of @DRUG$ and @DRUG$ in HIV-infected patients .	DDI-false
@DRUG$ ( Magnesium-Aluminum Hydroxide ): @DRUG$ plasma concentrations were not affected by co-administration of antacid .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drug interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Co-administration : Concomitant use of Argatroban with @DRUG$ , thrombolytics , and other @DRUG$ The risk of bleeding can be increased.	DDI-false
Although neither dexamethasone nor retinyl acetate proliferates in RPMI1640, @DRUG$ alone , they modify the mitogenic effect of EGF and @DRUG$.	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors , @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors , sodium channels , and the 5-HT transporter .	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin, containing multivalent cationic products such as magnesium or aluminium antacids, sucralfate, VIDEX chewable tablets or paediatric powders or products containing calcium, iron or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , @DRUG$ , antiemetics, sedatives, @DRUG$ ) .	DDI-false
@DRUG$ (e.g. spironolactone, triamterene or amilorid), @DRUG$ supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
@DRUG$ : In normal volunteers , concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50 % increase in plasma levels of acetaminophen .	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
* Drug interactions : Flupentixol may interact with some drugs, such as @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and @DRUG$ Cause additive CNS depression - Tricyclic antidepressants : flupenthixol increases the effect of tricyclic antidepressants	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of @DRUG$	DDI-effect
@DRUG$ : Co- administration of warfarin and @DRUG$ No changes in prothrombin time or coagulation factor VII occurred in healthy volunteers compared to co-administration of warfarin and placebo.	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , @DRUG$ And nifedipine.	DDI-int
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , @DRUG$ , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Anticoagulants : Potentiation of warfarin-type ( @DRUG$ Anticoagulant response is almost always observed in patients who: @DRUG$ and can result in serious or fatal bleeding .	DDI-false
Effects of @DRUG$ on Drug Metabolizing Enzymes and Drug Transport Systems @DRUG$ inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
In a clinical pharmacology study, @DRUG$ or sulindac was administered to hypertensive patients receiving @DRUG$.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients who block -@DRUG$ (e.g. propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
BACKGROUND : The effects of combined administration of bombesin and verapamil hydrochloride ( verapamil ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ ( @DRUG$ ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
Nephrotoxicity following concomitant administration of @DRUG$ With aminoglycoside antibiotics or potent diuretics such as @DRUG$.	DDI-effect
Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone , they modify the mitogenic effect of @DRUG$ and @DRUG$.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, @DRUG$ , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect @DRUG$ pharmacodynamics - Arecolin - eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
HMG-CoA Reductase Inhibitors: @DRUG$ (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
@DRUG$ may enhance the effects of @DRUG$, barbiturates, and other CNS depressants.	DDI-effect
Longitudinal assessment of @DRUG$ in de novo renal transplant recipients over the first post-transplant year : pharmacokinetics , exposure-response relationships , and influence on @DRUG$.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
@DRUG$ In diabetic patients receiving diflunisal and tolbutamide, no significant effects on @DRUG$ plasma levels or fasting blood glucose .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-int
Coingestion of @DRUG$ with theophylline, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ Antineoplastic agents, in particular dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
This time window is different than for other oral formulations of @DRUG$, which are usually administered 2 hours before or 6 hours after @DRUG$.	DDI-advise
In an in vitro study in human liver microsomes , inhibition of CYP2A6 hydroxylation of @DRUG$ by @DRUG$ 350 mg/L) was 17-28%.	DDI-mechanism
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine , the AUC of atomoxetine is approximately 6- to 8-fold and Css , max is about 3- to 4-fold greater than @DRUG$ alone .	DDI-false
@DRUG$ : Meclofenamate sodium enhances the effect of @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - @DRUG$ : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
Other reported interactions with amiodarone : @DRUG$ CYP3A4 substrate) in combination with @DRUG$ For this reason, hypotension, bradycardia, and reduced cardiac output may occur.	DDI-false
Ketoconazole : In healthy subjects receiving @DRUG$ , a CYP3A4 inhibitor , at 200 mg twice daily for 7 days , systemic exposure ( AUC ) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control .	DDI-mechanism
WARFARIN: Co- administration of @DRUG$ and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
The data from in vitro studies with benzodiazepines other than alprazolam indicate a possible interaction with the following medicinal products: ergotamine, @DRUG$ , amiodarone , @DRUG$ And nifedipine.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
WARFARIN : Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo .	DDI-false
@DRUG$     @DRUG$ antagonism	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, @DRUG$, and phenytoin during concomitant therapy with amiodarone.	DDI-false
@DRUG$ : Amiodarone , @DRUG$ , flecainide, propafenone, quinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
Acetaminophen/theophylline, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Other medicines: medicines such as quinidine, @DRUG$ , @DRUG$ , phenothiazines, antihistamines and tricyclic antidepressants may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Garlic capsules Garlic capsules should not be used during ingestion @DRUG$ Fortovase is the only @DRUG$ due to the risk of decreased saquinavir plasma concentrations .	DDI-false
In order to evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL ), the authors retrospectively compared a group of 24 patients with HIV-NHL who had been treated with the @DRUG$ , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide, and prednisone with vincristine plus bleomycin) without treatment @DRUG$ therapy .	DDI-false
@DRUG$ : In normal volunteers , a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly .	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or with a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide and prednisone). @DRUG$ plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Other substances: Grapefruit juice given to healthy volunteers increased @DRUG$ AUC by 50% and Cmax by 84%, resulting in increased plasma levels of @DRUG$.	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Co-medicines that induce CYP3A4 (e.g. @DRUG$ , phenytoin , carbamazepine , rifampin , @DRUG$ or St.	DDI-false
Antihypertensives : @DRUG$ should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , @DRUG$ , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Both ibogaine and @DRUG$ • Block @DRUG$-induced and nicotine-induced dopamine release in the core accumbens;	DDI-effect
The use of acetaminophene with acetaminophene @DRUG$ , phenobarbital with @DRUG$ , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
The zidovudine study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ , carbamazepine, fentanyl, @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Nitrates : The simultaneous use of @DRUG$ With long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris .	DDI-false
CONCLUSIONS/INTERPRETATION : @DRUG$ and @DRUG$ can exert additive vasodilator properties on renal and ocular circulation .	DDI-false
It has been reported that QTc prolongation with or without TdP has been reported in patients taking amiodarone, @DRUG$ , @DRUG$ , or azoles were administered concomitantly .	DDI-false
Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
Data from in vitro studies of @DRUG$ A possible interaction with alprazoleam is recommended for the following: sertraline and @DRUG$.	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ Elevated plasma concentrations may occur when co-administered with other medicinal products. @DRUG$ ;	DDI-mechanism
@DRUG$ and @DRUG$ interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.	DDI-false
Combination of @DRUG$ with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone .	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , dacarbazine , @DRUG$ , Tamoxifene and @DRUG$.	DDI-false
In the first therapy, efavirenz and nevirapine were compared with triple therapy with PI indinavir for 48 weeks. @DRUG$ regimens and superiority observed with @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
@DRUG$: Simvastatin (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ , ergotic derivatives, pimozide, @DRUG$ (e. g., fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
Concomitant cyclophosphamide, doxorubicin, vincristine, and @DRUG$ chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitors (@DRUG$)-based antiretroviral therapy regimens and concerns about protease inhibitors (@DRUG$)-related metabolic disorders have led to significant shifts in treatment practices in HIV infection.	DDI-false
@DRUG$/Hypnotics : triazolam , @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
@DRUG$: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, @DRUG$, and verapamil.	DDI-false
Apomorphine - before taking diphenidol, the @DRUG$ response to @DRUG$ In the treatment of poisoning.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some @DRUG$.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum @DRUG$ , Sucralfat, VIDEX chew/buffer tablets or paediatric powder, or products that can significantly reduce calcium, iron or zinc absorption of @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect @DRUG$ pharmacodynamics - Arecolin - eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - @DRUG$ Flupentixol increases the effect of tricyclic antidepressants	DDI-false
Data from in vitro studies with alprazolem suggest a potential interaction with: @DRUG$ For the following: @DRUG$ and paroxetine .	DDI-int
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ It had no effect on the plasma levels of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as morphine.	DDI-mechanism
Broad-Spectrum Antibiotics-@DRUG$ may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	DDI-false
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
DIGOXIN : Plasma digoxin levels and @DRUG$ The steady-state clearance was not affected by concomitant administration of 0.2 mg @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$ : @DRUG$ Treatment with prothrombin in patients receiving chronic warfarin treatment had no clinically significant effect on prothrombin time.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with @DRUG$.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
@DRUG$/@DRUG$: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
@DRUG$ may enhance the effects of @DRUG$ , barbiturates , and other CNS depressants .	DDI-effect
However, the absolute number of @DRUG$-related deaths is far greater than the number of deaths in amphetamine or @DRUG$ users.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$-Vitamin K can antagonize the effect of @DRUG$	DDI-false
CONCLUSIONS/INTERPRETATION: @DRUG$ and @DRUG$ can exert additive vasodilator properties on renal and ocular circulation.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as @DRUG$ Antacids or antacids of aluminium, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
However , the absolute number of alcohol-related deaths is far greater than the number of deaths in @DRUG$ or @DRUG$ users .	DDI-false
Therefore , interactions could occur following concomitant administration of @DRUG$ ( e.g. , narcotics , @DRUG$ , antiemetics , sedatives , tranquilizers ) .	DDI-false
FLEXERIL may enhance the effects of @DRUG$ , barbiturates , and other @DRUG$.	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite 6-beta-naltrexol were unaffected following co-administration with @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, dextromethorphan, and @DRUG$.	DDI-false
Acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and @DRUG$ ( including @DRUG$ The use of placebo with these concomitant drugs was similar to that of subjects who used placebo (e. g., non-opioid analgesics).	DDI-false
Anticoagulant inhibition was observed during the administration of @DRUG$ , @DRUG$ and glutethimide ;	DDI-false
Both @DRUG$ and @DRUG$ Treatment with PI indinavir was compared with triple therapy as early therapy for 48 weeks, with similar reactions observed with nevirapine therapies and superiority with efavirenz.	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Corticosteroids, @DRUG$ and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Similarly dialyzed were phenobarbital , @DRUG$ , and @DRUG$ , both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum .	DDI-false
Drug interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupentixol and @DRUG$ Cause of additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In some patients, the combined use of @DRUG$ and @DRUG$ It was associated with fatal gastrointestinal bleeding.	DDI-effect
Administering @DRUG$ together with @DRUG$ (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.	DDI-effect
@DRUG$ • may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$ , CYP2D6 , and CYP3A4 .	DDI-false
In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.	DDI-mechanism
• Co-administration with compounds that are potent CYP3A4 inducers (e. g. @DRUG$ , phenytoin , @DRUG$ , carbamazepine ) may result in decreased plasma levels of saquinavir .	DDI-false
Prostatic epithelial proliferate in a defined medium, consisting of basal medium RPMI1640, containing: @DRUG$ 1 micrograms/ ml), @DRUG$ 10 ng/ ml) and insulin (3.7 micrograms/ ml or 0.1 IU/ ml).	DDI-false
BACKGROUND : The effects of the combined administration of bombsin and verapamil hydrochloride (Verapamil ), a @DRUG$ , about the incidence of peritoneal metastases of intestinal adenocarcinoma induced by @DRUG$ ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antiarrhythmics : Other @DRUG$ drugs , such as quinidine , procainamide , disopyramide , and @DRUG$ , were used simultaneously with amiodarone.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-mechanism
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
For patients with monoamine oxidase inhibitors and tricyclic antidepressants: FORADIL should be used in patients with monoamine oxidase inhibitors or @DRUG$ because the action of @DRUG$ On the cardiovascular system can be potentiated by these active substances.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , @DRUG$ ) effects with @DRUG$ The toxicity in these organ systems can be increased.	DDI-effect
Since the concomitant administration of @DRUG$ with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ Antacids or aluminium antacids, sucralfate, VIDEX chewable/buffer tablets or pediatric powder or products containing calcium, iron or @DRUG$ may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
@DRUG$ ( ' @DRUG$ ' ) is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .	DDI-false
Moreover , additional interaction studies with niacin and @DRUG$ They have no effect on @DRUG$ plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data .	DDI-false
There have been case reports of increased steady-state levels of quinidine, procainamide, and @DRUG$ during concomitant therapy with @DRUG$.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, @DRUG$, CYP2D6, and CYP3A4.	DDI-false
These results suggest that both dexamethasone and retinyl acetate , and possibly other glucocorticoids and @DRUG$ , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF .	DDI-effect
@DRUG$-Orlistat may decrease the absorption of @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, @DRUG$, and methotrexate.	DDI-false
Amiodarone may suppress certain CYP450 enzymes , including @DRUG$ , @DRUG$ CYP2D6 and CYP3A4.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , @DRUG$ , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Probenecid: @DRUG$ interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	DDI-mechanism
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Since @DRUG$ - is a substrate for @DRUG$ There is the potential that the use of St. John's word in patients receiving amiodarone could lead to reduced amiodarone levels.	DDI-false
@DRUG$: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	DDI-false
Concomitant administration of @DRUG$ doubled the AUC for @DRUG$.	DDI-mechanism
It is concluded that @DRUG$ and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy .	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
Theophylline : As with some other quinolones , concurrent administration of @DRUG$ Theophylline may cause increased serum concentrations of @DRUG$ and prolongation of its elimination half-life .	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
Interaction on the antinociceptive effect between neurotensin and @DRUG$ or @DRUG$.	DDI-false
In the present study, the @DRUG$ @DRUG$ The study was tested in combination with an active dose of PCP in double drug discrimination and mixed signaled unsigned differential enhancement of low rates (DRL) procedures.	DDI-false
If cholinergic blockades occur, additive undesirable effects may occur if: @DRUG$ is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine oxidase ( MAO ) inhibitors , @DRUG$ or some antihistamines .	DDI-effect
@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-false
Oral anticoagulant agents : Pharmacokinetic drug-drug interactions between @DRUG$ and @DRUG$ ( 7.5 mg single oral dose ) have not been demonstrated .	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Moreover , additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , @DRUG$ , @DRUG$ Methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Coadministration of @DRUG$ with 40 mg @DRUG$ tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels .	DDI-mechanism
Cardiovasculars : @DRUG$ The oral administration of amiodarone regularly increases serum levels in patients receiving digoxin therapy. @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity .	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and cyclosporine (INN, @DRUG$) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
@DRUG$ - before taking @DRUG$ may decrease the emetic response to apomorphine in the treatment of poisoning .	DDI-false
HMG-CoA Reductase Inhibitors: Simvastatin (@DRUG$ substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
- medicinal products detected as CYP3A inhibitors of potential clinical importance based on clinical studies involving alprazoleam (precaution is recommended when co-administered with alprazoleam): co-administration of fluoxetine with @DRUG$ Elevated the maximum plasma concentration of @DRUG$ The clearance decreased by 46%, the half-life decreased by 17% and the measured psychomotor performance decreased.	DDI-false
In the present study, the @DRUG$ @DRUG$ was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors ( lovastatin , @DRUG$ , and @DRUG$ This leads to unique biopharmaceutical properties compared to other active substances in this class.	DDI-false
@DRUG$/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing @DRUG$ , iron , or zinc may substantially decrease the absorption of @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
@DRUG$ The plasma concentrations of atorvastatin decreased by about 25% if: @DRUG$ Atorvastatin and atorvastatin were co-administered.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$ , and phenytoin during concomitant therapy with @DRUG$.	DDI-false
In a clinical pharmacology study, @DRUG$ or @DRUG$ was administered to hypertensive patients receiving VASOTEC .	DDI-false
@DRUG$ is a substrate for both CYP2D6 and @DRUG$.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( @DRUG$ Cefoperazon, Cefotetan, Cefamandol, @DRUG$ Methylthiadiazole (Cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
These results suggest that both @DRUG$ and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Acute symptoms should be treated with a short-acting , inhaled   @DRUG$ such as @DRUG$ ( the physician should provide the patient with such medication and instruct the patient in how it should be used ) .	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to @DRUG$ , including @DRUG$ Like quinidine and procainamide, cardiac glycosides and tricyclic antidepressants.	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, procainamide, and @DRUG$ during concomitant therapy with amiodarone.	DDI-false
Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$ ,,,,,,,,,,, @DRUG$ , reserpine .	DDI-false
@DRUG$ : In normal volunteers , concomitant administration of diflunisal and acetaminophen resulted in an approximate 50 % increase in plasma levels of @DRUG$.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum @DRUG$ , Sucralfat, VIDEX chewable/buffer tablets or pediatric powder, or containing products @DRUG$ Iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-@DRUG$ , @DRUG$ , certain HMG-CoA reductase inhibitors , etc . ) .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by @DRUG$ , secobarbital, glutethimide, chloral hydrate and methaqualone have been systematically studied in 16 patients treated with coumarin.	DDI-false
@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	DDI-false
Limited comparative data in patients with high viral loads treated with @DRUG$- or @DRUG$-based regimens currently exist .	DDI-false
Ergot Derivatives : @DRUG$ Ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine, ergotamine @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with alprazolam ): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of @DRUG$ The clearance decreased by 46%, the half-life decreased by 17% and the measured psychomotor performance decreased.	DDI-false
Nitrates: The concomitant use of @DRUG$ with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients receiving receptor blockers (e.g. propranolol, CYP3A4 inhibitor), or @DRUG$ • antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, @DRUG$ Inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
Cimetidine : @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
Like ibogaine ( 40 mg/kg ) , @DRUG$ 40 mg/kg decreases intravenous self-administration of morphine and cocaine and oral self-administration of @DRUG$ and nicotine in rats ;	DDI-false
therefore, the use of @DRUG$ does not necessitate an adjustment in @DRUG$ dose to maintain therapeutic digoxin levels.	DDI-false
The following eight target drug/added drug combinations were studied: @DRUG$/@DRUG$.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Monoamine Oxidase Inhibitors and @DRUG$ : FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ On the cardiovascular system can be potentiated by these active substances.	DDI-false
@DRUG$-Broad-spectrum antibiotics may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora .	DDI-false
- ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$ , erythromycin , etc . ) is indicated , reduction of the @DRUG$ dose should be considered .	DDI-advise
Tolbutamide : In diabetic patients who @DRUG$ and tolbutamide , no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose .	DDI-false
Sulindac: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-mechanism
The possibility of hypotensive effects with @DRUG$ or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-false
Cephalosporine-@DRUG$ containing side chains of N-methylthiotetrazole (Cefmenoxime), @DRUG$ Cefotetan, cefamandol, latamoxef) or methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
@DRUG$: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-false
Amiodarone may suppress certain CYP450 enzymes , including CYP1A2 , CYP2C9 , @DRUG$ , and @DRUG$.	DDI-false
Concomitant @DRUG$ , @DRUG$ , vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients associated with human immunodeficiency virus, non-Hodgkin lymphoma.	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-mechanism
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum @DRUG$ , Sucralfat, VIDEX chew/buffer tablets or children's powder, or products that contain calcium, iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
A dose adjustment of STRATTERA may be required when co-administered with CYP2D6 inhibitors, e.g. paroxetine, @DRUG$ , and @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide and prednisone with vincristine plus bleomycin) without treatment @DRUG$ therapy .	DDI-false
No significant interactions were found between @DRUG$ and warfarin or @DRUG$.	DDI-false
The superiority of @DRUG$ About @DRUG$-based regimens were observed in comparison data in a subset of patients with high viral load.	DDI-false
• Corticosteroids, methylxanthine and diuretics: concomitant treatment with xanthine derivatives, @DRUG$ Diuretics may potentiate a possible hypokalemic effect @DRUG$	DDI-effect
In the first study, co-administration of 0.2 mg cerivastatin sodium and 12 g @DRUG$ resulted in decreases of more than 22 % for AUC and 40 % for Cmax when compared to dosing @DRUG$ alone .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with @DRUG$ , methyldopa , nitrates , calcium-blocking agents , hydralazine , @DRUG$ and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by @DRUG$.	DDI-effect
Antihypertensives : Amiodarone should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a @DRUG$ Inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Although @DRUG$ It has been shown that PROLEUKIN-induced adverse reactions such as fever, renal insufficiency, hyperbilirubinaemia, confusion and dyspnoea are reduced, concomitant administration of these active substances with PROLEUKIN may reduce the efficacy of antitumours. @DRUG$ and thus should be avoided . 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as @DRUG$ and @DRUG$ , cardiac glycosides and tricyclic antidepressants.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
@DRUG$ , such as verapamil, diltiazem and @DRUG$ , inhibit platelet activation in vitro, and reduce platelet adhesion intravascularly.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : @DRUG$ - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
@DRUG$ The substrate is for both CYP2D6 and @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ ( 162.5 mg orally administered 26 and 2 hours before the start of argatroban 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after the start of argatroban 1.5 g/kg/min for 18 hours).	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ The absorption of @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : @DRUG$ , cyclosporine , amiodarone , @DRUG$ And nifedipine.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ , Methylxanthines and @DRUG$ Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a potential hypokalemic effect of beta2-agonists.	DDI-false
@DRUG$ may displace acidic drugs such as phenytoin or @DRUG$ From their binding sites.	DDI-mechanism
HMG-CoA reductase inhibitors: @DRUG$ ( @DRUG$ The substrate) in combination with amiodarone has been associated with myopathy/rhabdomyolysis reports.	DDI-false
• Drug interactions: Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - @DRUG$ Flupentixol increases the effect of tricyclic antidepressants	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, @DRUG$ and tricyclic anti-depressants.	DDI-false
DIGOXIN: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Both ibogaine and @DRUG$ block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
@DRUG$ has been shown to be antagonistic to @DRUG$ , including ceftazidime , based on in vitro studies and time kill curves with enteric gram-negative bacilli .	DDI-effect
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
This may occur because @DRUG$ competitively displaces @DRUG$ from protein binding sites.	DDI-mechanism
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , @DRUG$ , calcium-channel blockers , @DRUG$ , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
During the transition to oral @DRUG$ The dose of previously administered active substances should be reduced by 30 to 50% for several days after the addition of oral @DRUG$.	DDI-false
ERYTHROMYCIN: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-mechanism
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	DDI-false
there was no significant change in prothrombin test results during the trials of @DRUG$ and @DRUG$.	DDI-false
Acetaminophen , lidocaine , @DRUG$ , quinidine , @DRUG$ , and valproic acid were added to pooled human serum at therapeutic concentrations .	DDI-false
Therefore , patients under @DRUG$ therapy should be carefully monitored when concomitant @DRUG$ The therapy is indicated.	DDI-advise
Antimycobacterial Agents : @DRUG$ Treated since co-administration of this medicine with saquinavir in a @DRUG$ regimen reduces the plasma concentrations of saquinavir .	DDI-false
Administering @DRUG$ together with @DRUG$ ( 100 - 500 microM ) inhibited InsP(3)-induced responses ( both Ca(2 + ) and current responses ) in a dose-dependent fashion .	DDI-effect
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
• The intake of acetaminophene with theophylline, phenobarbital with acetaminophene and @DRUG$ with @DRUG$ at high to toxic concentrations decreases the binding of the target drug .	DDI-effect
Efavirenz and nevirapine were treated with @DRUG$ Indinavir was observed for 48 weeks as initial therapy, with similar response with nevirapine therapies and superiority with @DRUG$.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, @DRUG$, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Co-administration of @DRUG$ Aminoglycosides or other substances that affect neuromuscular transmission (e.g. @DRUG$ Caution should be exercised as the effect of the toxin may be increased.	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with @DRUG$ , betablockers , @DRUG$ , diuretics , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
In vitro studies have shown that precipitation occurs when eye drops containing @DRUG$ are mixed with @DRUG$.	DDI-false
These results suggest that an acute @DRUG$ would not affect behaviors most closely associated with @DRUG$ intoxication .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Both ibogaine and @DRUG$ Block-morphine-induced and @DRUG$-induced dopamine release in nucleus accumbens;	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and @DRUG$ , a @DRUG$ Inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
@DRUG$: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the @DRUG$ response to apomorphine in the treatment of poisoning .	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-int
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, @DRUG$ or St.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for @DRUG$ versus @DRUG$/oxycodone regimens.	DDI-false
Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and @DRUG$.	DDI-false
@DRUG$ taken concomitantly with @DRUG$ increases quinidine serum concentration by 33 % after two days .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by @DRUG$ , secobarbital, glutethimide, chloral hydrate and methaqualone have been systematically studied in 16 patients who: @DRUG$ therapy .	DDI-false
Naproxen : The concomitant administration of diflunisal and @DRUG$ In normal subjects, this did not affect plasma levels of @DRUG$ However, urinary excretion of naproxene and its glucuronide metabolite was significantly reduced.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients who block -@DRUG$ (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, @DRUG$ Substrate, and diltiazem, an inhibitor of CYP3A4) due to the potential for bradycardia, sinus arrest, and AV block;	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Anticoagulants : Potentiation of @DRUG$-type ( CYP2C9 and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding .	DDI-false
